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ABSTRACT 
 
The insulin-like growth factor-1 (IGF-1) is a polypeptide growth factor that is essential 
for normal body growth and development of several tissues. IGF-1 is implicated in the 
progression and risk of several malignancies, including breast cancer (BC). Alternative 
splicing of terminal exon 5 of the igf-1 gene results in multiple isoforms possessing 
distinct carboxy-terminal extensions, called the Ea-, Eb- and Ec-domains. 
The first chapter of the Thesis provides evidence for an evolutionary mechanism 
generating the diversity of igf-1 splicing and expression across species. Our study 
highlights how the igf-1 exon 5 originates from exonization of a Mammalian interspersed 
repetitive-b (MIR-b) element in mammals. The acquisition of exon 5 alters the splicing 
pattern of igf-1 in mammals by generating two new isoforms: IGF-1Eb and IGF-1Ec. The 
evolutionary analysis of mammalian IGF-1 domains showed that E-domains are 
subjected to a strong evolutionary constraint on the synonymous sites, and they are 
enriched in disorder-promoting amino acids (i.e. intrinsically disordered), suggesting an 
important and novel regulatory role for these domains, not previously described. 
In the second chapter, we highlighted that IGF-1 pro-hormones are not a simple inactive 
precursor of mature IGF-1, but are stable intermediates of their posttranslational 
processing. The IGF-1 pro-hormones can induce BC cell proliferation via the IGF-1 
receptor, independently from the mature IGF-1 form. These results underline the 
importance of an accurate assessment of the presence of IGF-1 pro-hormones within the 
BC microenvironment. 
The third chapter describes the mechanisms, which control the IGF-1 pro-hormones 
biosynthesis. We demonstrated that N-linked glycosylation regulates the stability and 
secretion of IGF-1Ea pro-hormone, probably ensuring proper pro-hormone folding and 
favoring its passage through the secretory pathway. The alternative Eb- and Ec-domains 
lack N-terminal glycosylation sites hence IGF-1Eb and IGF-1Ec pro-hormones were 
insensitive to glycosylation status of the cells. Moreover, the Eb- and Ec-domains 
regulate the subcellular localizations of IGF-1Eb and IGF-1Ec pro-hormones, promoting 
their nuclear accumulation. Thus, disordered E-domains play an important role in the 
structure, regulation and functioning of IGF-1. 
 
 
The final chapter of the Thesis describes the data deriving from DIANA-5, and focuses 
on the effectiveness of modification in dietary change-associated with moderate physical 
activity in the prevention of BC recurrence, highlighting the importance of the lifestyle 
modification in the modulation of the circulating levels of IGF-1. 
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THE COMPLEXITY OF THE IGF-1 POOL: GENE 
SPLICING, REGULATION AND FUNCTION 
 
The insulin-like growth factor 1 (IGF-1), also called somatomedin C, is a polypeptide 
growth factor, which is essential for normal body growth and development [1]. A variety 
of cellular responses are induced by IGF-1, including cell proliferation, differentiation 
and survival [2].  
Initially, in the early 1970s, the ―somatomedin hypothesis‖ was proposed as a model for 
the actions of IGF-1 on the skeleton [3]. This hypothesis postulated that the growth 
hormone (GH), secreted by the pituitary gland, stimulated IGF-1 synthesis in the liver 
and its release into the blood stream to target organs acting in an endocrine manner. This 
hypothesis was later challenged by subsequent findings, including a seminal study 
examining skeletal development in mice with liver-specific deletion of the Igf-1 gene 
(LiverIGF-1−/−) [4]. In this experiment, the circulating IGF-1 level was reduced to less 
than 25% of normal. Despite this severe reduction, the knockout mice developed and grew 
normally, and their skeletal changes were minimal, indicating that local IGF-1 production 
is enough to guarantee general growth and skeletal development. The local IGF-1 
production extended this hypothesis and included the autocrine-paracrine manner of IGF-
1 action. Investigators have recognized that the physio-pathologic mechanisms, through 
which IGF-1 is regulated and secreted, are more complicated than originally believed. In 
most of the cellular-animal models, it was proposed that GH stabilized serum IGF-1 by 
promoting the formation of the ternary complex composed of IGF-1, IGF binding protein 
(IGFBP) 3 (IGFBP-3) and the acid-labile subunit (ALS) [3]. The bioavailability of 
circulating IGF-1 modulated by the IGFBPs is further described in the paragraph ―IGF-1 
and binding proteins (IGFBPs)‖. 
In physiological conditions, circulating IGF-1 is mostly synthesized in the liver and acts 
as an endocrine factor. IGF-1 levels are relatively low at birth, increase during childhood, 
reaching peak levels in adolescence and begin to decline during the third decade of life 
[5]. It plays an important role in the first decades of life in normal development and 
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growth as a key regulator of cell proliferation and differentiation and as an apoptosis and 
necrosis inhibitor. 
Several factors may affect the hepatic synthesis of IGF-1, including insulin, GH, age and 
nutrition. The growth hormone, produced by the pituitary gland, is the most important 
hormone involved in regulating body growth and development as well as carbohydrate 
and lipid metabolism, and its action can be directed to target tissues that possess specific 
receptors or indirectly through other factors that enhance and complement its effects. The 
most important mediator of GH effects is IGF-1 [6]. The production and concentration of 
the two hormones are positively related to each other. The connective tissue cell types 
that synthesize IGF-1 contain GH receptors and an increase in GH secretion stimulates 
IGF-1 synthesis. At the same time, an increase in IGF-1 blood concentration suppresses 
GH synthesis in the pituitary gland though a negative-feedback regulation that represents 
an important homeostatic mechanism for the maintenance of normal plasma IGF-1 
concentration [3].  
Other hormones participate with GH in regulating hepatic IGF-1 synthesis, including 
thyroxin, cortisol, estradiol and testosterone. Thyroxin enhances sensitivity to GH and 
can increase IGF-1 concentration in hyperthyroidism. Cortisol acts to inhibit IGF-1 
synthesis, and high cortisol concentrations can lead to growth attenuation. Etradiol 
inhibits IGF-1 secretion in the liver by constraining GH stimulated signal transduction 
[7]. Testosterone enhances hepatic IGF-1 synthesis, but also alters the sensitivity of the 
pituitary gland to negative-feedback regulation of GH secretion, leading to an increase in 
GH synthesis and thus an increment in IGF-1 secretion.  
Nutrient intake is another variable regulating plasma IGF-1 concentrations. The IGF-1 
plasma concentrations are markedly reduced in low protein or calorie-restricted diets [8]. 
In adults, total caloric intake is more important than protein intake. In fact, in the 
presence of an adequate caloric intake, even with a low protein intake regime, there can 
be an increase in IGF-1 levels. Conversely, there is a threshold of caloric intake below 
which protein intake cannot increase the levels of IGF-1 after fasting. When caloric 
intake is severely reduced, the dietary content of carbohydrates and essential amino acids 
is critical for an optimal recovery of IGF-1 levels after fasting [9]. These conditions are 
associated with a marked decrease in the number of somatotropic receptors supporting 
the role of a receptor deficiency in the decline of the circulating IGF-1. 
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In the last decade, many in vitro and in vivo studies have investigated the igf-1 gene 
conservative structure. Different mRNA transcripts are produced as a result of the 
alternative splicing of the igf-1 gene, encoding for several IGF-1 precursor proteins also 
called isoforms. These IGF-1 protein isoforms can be distinguished by the structure of 
their extension peptides, or E-peptides, on the carboxy-terminal end and by the length of 
their amino-terminal signal peptides. Interestingly, it has been proposed that these pro-
hormones might possess bioactivities that are distinct from those of mature IGF-1 [10]. 
 
 
THE GENE STRUCTURE OF IGF-1 AND ALTERNATIVE SPLICE 
VARIANTS 
 
The igf-1 gene is highly conserved among mammals and primates [11]. It is located on 
the long arm of chromosome 12 in humans and consists of six exons and five introns that 
cover about 90 kb of DNA with different promoter regions. It is widely believed that all 
IGF-1 biological actions are mediated by mature IGF-1, but the igf-1 gene encodes 
multiple mRNA variants that differ in terms of the presence of an alternative leader 
sequence and polyadenylation signal [2, 12]. The gene transcription of igf-1 is very 
complex due to many transcriptional and post-transcriptional modifications that give rise 
to several isoforms, of which six are known in the literature.  
In particular, exons 1 and 2 encode for the sequence that determines the class of the 
protein deriving from different splicing of these two exons to the common exon 3. 
Transcripts starting with exon 1 are referred to as class 1, whereas class 2 transcripts use 
exon 2 as their leader exon. These exons form two different non-coding 5 'UTR 
sequences and a sequence that contains the information for a portion of the signal peptide. 
The expression of these two exons seems to be dependent on two different promoters that 
are regulated in a tissue specific manner [13]. In particular, class 2 transcripts are 
expressed mainly in the liver and represent the circulating IGF-1 forms. It has been 
shown that these forms are dispensable for fetal and postnatal growth [14], which are 
thought to be more GH dependent [15], whereas transcripts initiating at promoter 1 are 
widely expressed in many tissues representing local tissue forms [16].  
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The alternative splicing at the 3' end of the gene involving exons 4, 5 and 6 forms three 
different extension peptides in humans, called E-peptides, at the carboxy-teminal end 
(Fig. 1). However, all of them contain exon 3 and exon 4, which encode the mature IGF-1 
peptide sequence. This sequence is composed of a total of 70 amino acids, 25 of which 
derive from exon 3 and 45 from exon 4, forming four domains named for their homology 
to insulin as B amino-terminal domain, C and A domain and D carboxy-terminal domain. 
This sequence represents the mature invariant peptide present in all transcripts [17].  
The final part of exon 4 encodes for the first 16 amino acids of the amino-terminal 
portion of the IGF-1 E-peptide domain, which are common to all the three different E-
peptides. The alternative splicing involving exons 4, 5 and 6, producing three different 
IGF-1 E-peptides in humans, produces the remaining portion of the E-peptide.  
The IGF-1Ea transcripts from the splicing of exon 4 and exon 6 excluding exon 5, which 
represents the main isoform for the formation of mature IGF-1 produced by the liver and 
also in most other tissues and the most conserved isoform across species [11]. This 
mRNA splicing produces the Ea-peptide, which is composed of 35 amino acids. The first 
16 are common peptides deriving from exon 4, whereas the remaining 19 amino acids are 
encoded by exon 6.  
The variant, called IGF-1Eb isoform, contains exon 4 and splices with exon 5, whereas 
exon 6 is excluded. This transcript is rarely expressed in other species, so this isoform is 
often considered a human-specific splice variant [12]. It was first detected in human liver 
[18] and then found in other tissues such as lung carcinoma cells [10], skeletal muscle 
[19], prostate [20] and endometrium [21]. This variant yields the Eb-peptide, which 
contain 16 common peptides and 61 additional amino acids deriving from exon 5, 
resulting in a total of 77 amino acids.  
Finally, the alternative spicing of the igf-1 gene also generates a third transcript, human 
IGF-1Ec, which corresponds to IGF-1Eb in rodents. In this variant, exon 4 is joined to a 
partial sequence of exon 5, which in turn is joined to exon 6. It was first detected in the 
liver and its expression accounts for about 10% of the IGF-1 transcripts. This transcript 
differs from IGF-1Ea for the presence of the first 49 base pairs from exon 5 and a 
premature stop codon within exon 6. IGF-1Ec is generated through a cryptic IGF633 donor 
splice site located 49 bp downstream from the 5' end of exon 5, which in turn splices with 
the acceptor site in the intron preceding exon 6. When this cryptic IGF633 donor splice 
site is not used, the alternative splicing of exon 4 and 5 occurs and the IGF-1Eb peptide is 
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produced [22]. It results in a different C-terminal peptide sequence due to a read frame 
shift leading to an Ec-peptide composed of 16 common amino acids, 16 encoded by exon 
5 and 8 by exon 6. This splice variant is also referred to as mechano-growth factor (MGF) 
because it has been shown to be up-regulated in response to muscle exercise and damage 
[23].  
 
 
 
 
Figure 1. Schematic representation of the igf-1 gene (A) and its splice variants (B-C). (A) Map of the 
igf-1 gene showing exons (boxes), introns (solid lines), splicing options (dashed lines), cryptic 5' splice site 
(c5'ss) in exon 5 and poly(A) sites (pA). (B) Splice variants of the igf-1 gene. Exons 1 and 2 encode for the 
sequence that determines the class of the protein. The mature IGF-1 is encoded by exons 3 and 4, and the 
three different E-peptides in humans constitute the carboxy-teminal end, and the three different E-peptides 
Human 
Ea 
1   mgkisslptq lfkccfcdfl kvkmhtmsss hlfylalcll tftssatagp etlcgaelvd 
61  alqfvcgdrg fyfnkptgyg sssrrapqtg ivdeccfrsc dlrrlemyca plkpaksars 
121 vraqrhtdmp ktqkevhlkn asrgsagnkn yrm 
 
Eb 
1   mgkisslptq lfkccfcdfl kvkmhtmsss hlfylalcll tftssatagp etlcgaelvd 
61  alqfvcgdrg fyfnkptgyg sssrrapqtg ivdeccfrsc dlrrlemyca plkpaksars 
121 vraqrhtdmp ktqkyqppst nkntksqrrk gwpkthpgge qkegteaslq irgkkkeqrr 
181 eigsrnaecr gkkgk 
 
Ec 
1   mgkisslptq lfkccfcdfl kvkmhtmsss hlfylalcll tftssatagp etlcgaelvd 
61  alqfvcgdrg fyfnkptgyg sssrrapqtg ivdeccfrsc dlrrlemyca plkpaksars 
121 vraqrhtdmp ktqkyqppst nkntksqrrk gstfeerk 
+19AA
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121 vraqrhtdmp ktqkevhlkn asrgsagnkn yrm 
 
Eb 
1   mgkisslptq lfkccfcdfl kvkmhtmsss hlfylalcll tftssatagp etlcgaelvd 
61  alqfvcgdrg fyfnkptgyg sssrrapqtg ivdeccfrsc dlrrlemyca plkpaksars 
121 vraqrhtdmp ktqkyqppst nkntksqrrk gwpkthpgge qkegteaslq irgkkkeqrr 
181 eigsrnaecr gkkgk 
 
Ec 
1   mgkisslptq lfkccfcdfl kvkmhtmsss hlfylalcll tftssatagp etlcgaelvd 
61  alqfvcgdrg fyfnkptgyg sssrrapqtg ivdeccfrsc dlrrlemyca plkpaksars 
121 vraqrhtdmp ktqkyqppst nkntksqrrk gstfeerk 
+ 61 AA
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Ea 
1   mgkisslptq lfkccfcdfl kvkmhtmsss hlfylalcll tftssatagp etlcgaelvd 
61  alqfvcgdrg fyfnkptgyg sssrrapqtg ivdeccfrsc dlrrlemyca plkpaksars 
121 vraqrhtdmp ktqkevhlkn asrgsagnkn yrm 
 
Eb 
1   mgkisslptq lfkccfcdfl kvkmhtmsss hlfylalcll tftssatagp etlcgaelvd 
61  alqfvcgdrg fyfnkptgyg sssrrapqtg ivdeccfrsc dlrrlemyca plkpaksars 
121 vraqrhtdmp ktqkyqppst nkntksqrrk gwpkthpgge qkegteaslq irgkkkeqrr 
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61  alqfvcgdrg fyfnkptgyg sssrrapqtg ivdeccfrsc dlrrlemyca plkpaksars 
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C
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are produced by the alternative splicing at the 3' end of the gene involving exons 4, 5 and 6. (C) Of the 
amino acid sequences of the three E-peptides, the first 16 common peptides deriving from exon 4 are in 
green and the different Ea, Eb and Ec amino acids are in red. 
 
 
THE PROCESSING OF THE IGF-1 PRE-PRO-HORMONE  
 
The translation of the igf-1 gene gives rise to an immature IGF-1 peptide, the pre-pro-
IGF-1. This precursor of the mature IGF-1, contains a signal peptide at the 5‘ end of the 
gene, the mature IGF-1 and a C-terminal E-peptide extension at the 3‘ end. Pre-pro-IGF-1 
is subject to numerous post-translational modifications leading to mature peptide 
production composed of four domains and 70 amino acids. The mature sequence is highly 
conserved among primate species, whereas it has been shown that the sequences of both 
the signal peptides and the E-peptides are less strongly conserved compared to the mature 
IGF-1 peptide [11]. 
The first cleavage leads to N-terminal signal peptide removal by intracellular serine 
proteases facilitating the passage of the polypeptide into the endoplasmic reticulum. The 
resulting molecule is the pro-IGF-1 composed of the mature IGF-1 plus the E-peptide.  
The pro-IGF-1 can be subject to additional processing prior to secretion, including the 
cleavage of the carboxy-terminal E domain resulting in the release of free mature IGF-1 
and E-peptide [24] (Fig. 2). All the classes of pro-IGF-1 contain a highly conserved and 
unique pentabasic motif K
65
-X-X-K
68
-X-X-R
71
-XX-R
74
-X-X-R
77
. All the E-peptides 
begin with amino acid 71; thus, cleavage occurs at Arg
71
 [17]. Proproteins can be 
processed at this specific motif by serine protease from the subtilisin-related proprotein 
convertase family (SPCs), a major family of endoproteolytic processing enzymes of the 
secretory pathway in mammals. Seven mammalian PCs have been identified, namely, 
PC1, PC2, furin, PC4, PC5, PACE4 and PC7, and they have been proposed as predictors 
of general cleavage sites. Furin appears to have a more rigorous specificity recognizing 
sites that contain the sequence motif R-X-[R/K]-R, whereas R-X-X-R is its minimal 
cleavage sequence [25]. 
Because SPCs are located in the secretory pathway, the process that leads to the 
formation of mature IGF-1 by the cleavage of the E-peptides has been shown to occur 
intracellularly, as expected for intracellular convertases, such as furin [24]. However, the 
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unprocessed pro-IGF-1 can be secreted and has been detected in conditioned media and 
in vivo serum [26]. This finding shows that the E domains are not cleaved intracellularly 
and suggests the presence of potential proprotein convertases that could process pro-IGF-
1 extracellularly [27].  
There is evidence of possible candidate proteases that could release the mature peptide 
outside of the cell when needed. The proprotein convertase subtilisin/kexin type 6, 
commonly known as PACE4, is expressed constitutively in muscle cells [28] and can be 
found in the Golgi as well as extracellularly; hence, it is a likely candidate to cleave pro-
IGF-1 in both areas performing the same intracellular reaction [24].  
 
 
Figure 2. Processing of IGF-1 leading to the mature peptide. The igf-1 gene is translated into the pre-
pro-IGF-1, which contains a signal peptide, mature IGF-1 and a C-terminal E-peptide extension. During 
translation the N-terminal signal peptide is removed and the resulting molecule is the Pro-IGF-1. An 
additional protease cleavage separates the mature IGF-1 from the E-peptides. The Y represents the 
glycosylation site present within the Ea-peptide.  
 
IGF-1Ea
IGF-1Eb
IGF-1Ec/MGF
1 or 2 3 4 6
51 or 2 3 4
61 or 2 3 4
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mature IGF-1 
Signal peptide
Translation
E-peptide
Mature
70 aa
Ea-peptide (35 aa)
Eb-peptide (77 aa)
Ec-peptide (40 aa)
Class  I (48 aa) 
Class  II (32 aa)
Mature
70 aa
Ea-peptide (35 aa)
Eb-peptide (77 aa)
Ec-peptide (40 aa)
Mature
70 aa
Ea-peptide (35 aa)
Eb-peptide (77 aa)
Ec-peptide (40 aa)
E-peptides
Y
Y
Y
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In addition, the secretion of unprocessed pro-IGF-1Ea isoform, both glycosylated and 
nonglycosylated, has been reported [27, 29]. 
In rodents there are two potential N-glycosylation sites at Asn
92
 and Asn
100
, whereas the 
human Ea domain contains one N-linked glycosylation site at Asn
92
 [30] based on the 
consensus sequence Asn-X-Ser/Thr, where X represents any encoded amino acid except 
proline [31]. This glycosylation site is not present in the human Eb- and Ec-peptides 
because of the reading frame shift caused by the insertion of exon 5 in these two IGF-1 
isoforms.  
Considering the unique role of glycosylation in the protein biosynthesis process [31], it is 
possible that Ea-peptide glycosylation might play a role in interactions regarding the 
regulation of the bioavailability of the different species of this IGF-1 isoform (i.e., pro-
IGF-1Ea, mature IGF-1 or Ea-peptide). Although glycosylation has been shown to be a 
critical step in the protein biosynthesis process, its significance to IGF-1 function has yet 
to be determined. The presence of a human N-linked glycosylation site only in Ea-peptide 
and not in the Ec and Eb domains might play a role in the regulation of the bioavailability 
of this isoform relating to its secretion and stability and possibly reflecting a different 
biological role of the IGF-1Ea isoform [27].  
It is traditionally believed that IGF-1 post-transcriptional processing leads to the 
formation of the mature protein, which is the main mediator of IGF-1 actions binding 
IGF-1R. On the contrary, the complexity introduced by the post-transcriptional regulation 
and post-translational modification of the igf-1 gene leads to the production of different 
IGF-1 forms that can be secreted. In particular, three forms of the IGF-1 protein could 
exist in the extracellular environment: mature IGF-1, non-glycosylated pro-IGF-1, and 
glycosylated pro-IGF-1 [27]. To date, however, it remains to be determined whether pro-
IGF-1 is bioactive or simply an inactive precursor of mature IGF-1 and/or E-peptide [32]. 
 
 
THE BIOLOGICAL ACTIVITY OF PRO-IGF-1 AND E-PEPTIDES  
 
The biological significance of each IGF-1 splice variant is currently unknown, and the 
physiological and molecular mechanisms that regulate their expression and their 
circulating levels are unclear [2]. It is generally assumed that the biological actions of 
10 
 
IGF-1 are inferred through the mature peptide, whereas different biological effects have 
been reported for the different IGF-1 pro-forms or for their E-peptides exogenously 
administrated or over-expressed in various model systems. In particular, recent studies in 
humans have shown a differential expression profile of the splice variants in response to 
various conditions and pathologies, such as skeletal muscle damage [19], endometriosis 
[21], prostate [20], cervix [33] and colorectal cancer [34]. Therefore, it is not just the 
mature IGF-1 that possesses bioactivity, and differential expression of igf-1 gene could 
indicate distinct regulatory mechanisms and biological roles of the different pro-IGF-1 
forms, implying that the E-peptides may promote biological effects.  
A divergent action of the IGF-1 isoforms has been reported after viral-mediated 
expression in mouse skeletal muscle of the two different rodent pro-IGF-1 forms, IGF-
1Ea and IGF-1Eb, as well as the mature IGF-1 without the E-peptides. Interestingly, it 
has been shown that overexpression of mature IGF-1 in skeletal muscle does not promote 
muscle hypertrophy in young mice, whereas both the pro-IGF-1 forms caused 
hypertrophy. These results suggest that the pro-IGF-1 forms are required for IGF-1 action 
leading to muscle hypertrophy, and the presence of E-peptides is necessary for IGF-1 
action in muscle [35]. Although the two splice variants increased phosphorylation of IGF-
1R, the murine IGF-1Ea overexpression resulted in increased Akt phosphorylation only, 
whereas the overexpression of murine IGF-1Eb in skeletal muscle activated both the 
PI3K/Akt and MAPK pathways [36]. These results suggest variable IGF-1 isoform–
specific actions on the signaling pathways involved after IGF-1R phosphorylation.  
Considering that IGF-1 isoforms differ only in terms of E-peptides, it has been suggested 
that E-peptides of human IGF-1 precursors may act as independent growth factors with 
their own biological activity [37]. Curiously, few studies have explored the activity of the 
Ea-peptide, whereas many investigations have focused on the other two peptides. Since it 
is more highly expressed than other isoforms, the Ea-peptide probably has an essential 
biological function also because its sequence is highly conserved in many species, while 
the other splice variants diverge within primates [11]. 
Initial studies focused on the role of human Eb-peptides and reported mitogenic activity 
in human bronchial epithelial cells as a result of exposure to a specific region of the 
human Eb domain. Furthermore, it was observed that this peptide could still induce 
proliferation even after IGF-1R neutralization with a specific antibody [10]. It was first 
suggested that the Eb-peptide mediates its effect through a specific receptor. Conversely, 
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it was found that the Eb-peptide was not cleaved and the pro-IGF-1Eb was not secreted 
but was accumulated in the nucleolus [38]. Thus, this human IGF-1Eb pro-peptide may 
have biological roles that are independent of the mature IGF-1 effects. 
Interestingly, the role of the Ec-peptide has been the focus of several studies, mainly 
because of its action in skeletal muscle. Studies began at the end of the 1990s in the 
Goldspink Laboratory and revealed that IGF-1Ea was the only isoform expressed in 
resting rabbit muscles, whereas exon 5 inclusive transcripts were found to increase in 
rabbit muscles subjected to stretch and electrical stimulation. [39]. It was suggested that 
the IGF-1Eb splice variant, corresponding to the human IGF-1Ec, was responsible for the 
stretch induced hypertrophy. It was named Mechano-Growth Factor (MGF) because it 
was identified in muscle tissue in response to mechanical damage and to distinguish it 
from the liver forms of IGF-1 [40].  
Numerous studies have investigated the role of MGF in muscle repair and survival, 
leading to the so-called ―MGF hypothesis‖ (Fig. 3). The theory is based on the following 
findings. After skeletal muscle injury, it was found that both IGF-1Ea and MGF were 
produced with differential expression regulation and different time course. In particular, 
there was a transient increase in the splice variant containing the exon 5, which 
corresponds to IGF-1Eb in rodents and IGF-1Ec in humans. After some days, levels of 
this transcript decreased, and an up-regulation of the IGF-1Ea splice variant associated 
with the decline of the IGF-1Ec/MGF mRNA levels was found [23, 41]. Because of this 
varied expression regulation, distinct roles of these isoforms in muscle remodelling were 
suggested. The temporal expression of IGF-1Ec/MGF was postulated to be responsible 
for activating quiescent satellite cells after muscle damage and promoting myoblast 
proliferation. In contrast, the increase in IGF-1Ea expression appeared to correlate with 
myoblast differentiation and to promote the fusion of myogenic cells leading to tissue 
repair [23, 41]. However, it should be noted that the expression levels of MGF are 
normally vastly lower than those of IGF-1Ea mRNA in skeletal muscle and in other 
extra-hepatic tissues and the absolute mRNA levels of IGF-1Ea were always 10-fold 
greater than the MGF transcript levels, even when those transcript levels were elevated. 
In addition, there is no evidence that the mature IGF-1 and IGF-1Ea are not present in 
elevated amounts even during the early phase of muscle repair, when MGF is predicted to 
be up-regulated. Taking all these data into account, the MGF hypothesis should be 
viewed with extreme caution [42, 43].  
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Figure 3. Schematic representation of the MGF hypothesis. The MGF hypothesis suggests that after 
muscle injury or exercise, the igf-1 gene transient increases the IGF-1Eb splice variant in rabbit muscles, 
the so-called MGF. This specific isoform is postulated to be responsible for activating quiescent satellite 
cells to enter the cell cycle and become mononucleated myoblasts. Thus, MGF promotes myoblast 
proliferation. On the contrary, during the myoblast proliferative stage, splicing is increasingly shifted 
towards the IGF-1Ea splice variant, which promotes myoblast proliferation and differentiation into 
multinucleated fibers called myotubes. The MGF hypothesis therefore suggests that MGF is responsible for 
satellite cell activation and myoblast proliferation, whereas IGF-1Ea is responsible for myoblast 
differentiation. Although the graph shows cellular repair events that coincide with the postulated IGF-1 
splice variant mRNA levels, it does not reflect the absolute mRNA levels of the two isoforms. In particular, 
it is essential to note that levels of IGF-1Eb transcripts are far lower than those of IGF-1Ea mRNA. All the 
mRNA data extrapolated should be examined with extreme caution [42].  
 
 
Recently, actions regarding the bioactivity of E-peptides have been established. In 
particular, the biological actions of synthetic E-peptides, corresponding to the rodent Ea 
and Eb sequences, were compared to test the effects of these E-peptides on IGF-1R 
signaling. To determine whether E-peptides activate IGF-1R directly, the treatment of E-
peptides alone or with mature IGF-1 in the activation of IGF-1R was tested. It was shown 
that E-peptides do not induce IGF-1R phosphorylation directly, but they amplify IGF-1R 
activation in an IGF-1-dependent manner but not when IGF-1R was inhibited. In 
addition, when myoblasts were treated with both mature IGF-1 and E-peptides, there was 
an increase in the phosphorylation of ERK1/2, but not of phospho-AKT. It was therefore 
proposed that E-peptides might modulate IGF-1 signaling by modulating IGF-1R 
downstream signaling [44].  
 
 
 
   -           -    
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The biological activity of pro-IGF-1 has been investigated in a recent study on murine 
skeletal muscle cells, particularly focused on the IGF-1Ea isoform. It was shown that the 
untreated cells secreted IGF-1 predominantly in the form of pro-IGF-1Ea. Moreover, both 
the glycosylated and non-glycosylated forms were present at high levels, but only a small 
portion of mature IGF-1 was present. It was shown that pro-IGF-1Ea could activate IGF-
1R as well as mature IGF-1, and pro-IGF-1Ea was more potent than the mature peptide 
by about 20% of receptor phosphorylation when compared in an IGF-1R activation assay. 
On the contrary, glycosylated pro-IGF-1Ea was less efficient at receptor activation than 
pro-IGF-1Ea and mature IGF-1 was about 2-fold less potent than mature IGF-1. Because 
of its differential ability to activate IGF-1R, it was suggested that glycosylated pro-IGF-
1Ea might serve as a reservoir for IGF-1, which can be stored until needed [27].  
In this regard, it is known that the extracellular matrix (ECM) interacts with a range of 
growth factors and cytokines likely mediated by positively charged amino acid sequence 
motifs present in these peptides [45]. The E-peptides contain a high proportion of basic 
amino acids conferring a high positive charge at physiological pH and therefore pro-IGF-
1 might bind to negatively charged molecules in the ECM. It has been shown that both 
mouse pro-IGF-1Ea and pro-IGF-1Eb bind ECM with significantly higher affinity than 
does mature IGF-1. Therefore, the C-terminal IGF-1 E-peptides could function by 
tethering pro-IGF-1 to the ECM, which presumably plays a biological role in retaining 
high local concentrations of IGF-1 in tissues for subsequent cleavage and receptor 
activation [46]. 
It is generally accepted that the post-translational processing of IGF-1 leads to the 
formation of mature protein, which is the main mediator of the IGF-1 action activating 
the IGF-1R. In contrast, collectively these studies suggest that E-peptides are actually 
translated and secreted and exist as part of pro-IGF-1. To date, however, the biological 
significance of the IGF-1 isoforms remains unclear.  
Although much research has aimed to distinguish the E-peptides activity from that of 
mature peptides, it has been suggested that the E-peptides possess IGF-1 dependent 
activity. Recent evidence supports this hypothesis, suggesting that the E-peptides may 
modulate IGF-1 activity through multiple mechanisms. Thus, the retention of these 
sequences could control the bioavailability of IGF-1 by altering the IGF-1secretion or its 
association with IGFBs, modulating its power in receptor activation and improving its 
stabilization and localization in tissues.  
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IGF-1 AND BINDING PROTEINS (IGFBPS) 
 
A family of specific proteins modulates the bioavailability and the biological activity of 
circulating IGF-1: the binding proteins (IGFBPs) (Fig. 4). At least six IGFBPs have been 
identified and well characterized [47, 48] as well as nine IGFBP-related proteins (IGFBP-
rPs) [49]. These proteins belong to a family that shares the same cysteine pattern in the 
amino-terminal and carboxy-terminal, which is indispensable in the binding affinity of 
the IGF-1. Most of the circulating IGF-1 is in the form of a ternary complex of 150 KDa 
composed of IGFBP-3, the most abundant IGFBPs in blood, and the ALS subunit, a 
glycoprotein acid-labile [50]. This complex does not pass through the endothelium and 
acts as an inactive IGF-1 reserve, accounting for 75-80% of the total carrying capacity. It 
is hypothesized that binding with IGFBPs increases the half-life of IGF-1. In fact, the 
half-life of free IGF-1 is less than 15 minutes, whereas the ternary complex persists in 
circulation for a half-life of about 12-14 hours protecting the growth factor from 
proteolytic degradation and modulating peptide interaction with its receptor, increasing or 
decreasing the binding affinity [51]. The formation of this ternary complex results in 
most of the IGF-1 in the blood representing a stable IGF-1 reserve, while the free IGF-1 
concentration in normal subjects is less than 1% compared to that of total IGF-1. The GH 
stimulates the secretion of IGFBP-3 and ALS and this helps to stabilize IGF-1 levels. 
IGFBP-3 goes through proteolysis during various catabolic processes or dysmetabolic 
conditions such as diabetes, and as a result, with a lower concentration of this binding 
protein, IGF-1 will tend to be more degraded [52]. Additionally, IGFBPs compete with 
receptor binding and normally have higher binding affinity to IGF-1 than the receptor 
does. Consequently, the binding of IGFBPs to IGF-1 prevents the ligand from interacting 
with the receptor and suppresses the growth factor actions [51]. The exact mechanism 
through which IGF-1 is released from the ternary complex into the tissue is not 
completely known; however, it seems that an important role is played by proteases that 
degrade IGFBPs by allowing the release of IGF-1 and the binding to its receptor.  
It is known that IGFBP-2 is the second most abundant IGFBP. This IGFBP is not linked 
to ALS, and the IGF-1/IGFBP-2 complex has a rather short half-life of about 90 minutes. 
The serum IGFBP-2 is unsaturated and represents a reservoir capable of binding and thus 
carrying IGF-1. In contrast, IGFBP-1 carries only a small percentage of IGF-1. Like 
IGFBP-2, IGFBP-1 is generally unsaturated, it represents a potential regulator of free 
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IGF-1 level. The expression of this IGFBP is inhibited by insulin, whereas in fasting 
conditions there is a four- to five-fold increase in their expression. Following eating, the 
levels of these binding proteins decrease rapidly resulting in increased availability of free 
IGF-1 in peripheral tissues [52].  
The last three binding proteins, IGFBP 4-5-6, are present in low concentrations and 
appear to be less important in controlling free IGF-1 blood concentration. The IGFBPs 
are mainly produced in the liver, and their concentrations are modulated in response to 
GH and by changes in nutrition, but peripheral tissues and interstitial fluids also 
synthesize them, which often involve additional IGF-1 transport.  
Although the IGFBP family was recently expanded to include nine IGFBP-rPs that can 
bind IGF-1 and IGF2 [49], some investigators have challenged their inclusion due to the 
absence of clear phylogenetic relationships between the IGFBP-rPs and the IGFBPs [53] 
and the limited understanding of IGFBP-rP function [54]. 
 
 
Figure 4. Regulation of circulating IGF-1 levels. Circulating IGF-1 is mostly produced by the liver acting 
as an endocrine factor and by extra hepatic tissues acting as autocrine and paracrine mechanisms. Growth 
hormone, which is produced in the pituitary gland under the control of hypothalamic factors, is the main 
hormone that regulates IGF-1 and IGFBPs production in the liver. The bioavailability of IGF-1 is 
influenced by the presence of IGFBPs, which are found in circulation and in extravascular fluid, and 
modulate the interactions between IGF-1 and the receptors present on the cell surfaces [55].  
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THE IGF-1 RECEPTOR (IGF-1R) AND SIGNALING PATHWAYS 
 
IGF-1 mediates its biological actions on cell proliferation, differentiation and survival by 
binding to specific receptors present on cell surfaces. IGF-1 can interact with different 
receptors such as IGF-1R (or type 1 IGF receptor) and IGF-2R (or type 2 IGF receptor), 
insulin receptor (IR), and some atypical receptors such as the hybrid IR/IGF-1R [56]. 
Mature IGF-1, which is responsible for binding to the receptors, binds with high affinity 
to IGF-1R, which has a high degree of homology to the insulin receptor [57]. It is also 
able to interact with lower affinity IGF-2R, which has been shown to be identical to the 
cation–independent mannose 6-phosphate receptor and to IR. The IGF-1 receptor 
pathway shares multiple intracellular mediators with the insulin-signaling cascade 
stimulating glucose intake and protein synthesis in skeletal muscle. Many tissues, 
including skeletal muscle, express hybrid receptors, but the functional importance of 
these receptors remains poorly understood.  
The tyrosine-kinase receptor IGF-1R is expressed in many types of cells and is a key 
mediator of cell growth and proliferation. The IGF-1R is a hetero-tetramic protein 
composed of two extracellular -subunits specific for binding to the hormone and two 
transmembrane β-subunits containing the tyrosine kinase domain activity with a cluster 
presenting three tyrosine residues at positions 1131, 1135, and 1136 [1]. 
The binding of circulating IGF-1 to the cysteine-rich domain contained in the -subunits 
of the receptor causes a structural rearrangement in the transmembrane β-subunits. This, 
in turn, induces the activation of tyrosine kinase activity and leads to the 
autophosphorylation of the cytoplasmic tyrosine kinase domain of the receptor, as one 
kinase domain phosphorylates the other.  
These autophosphorylation events and conformational changes permit unrestricted access 
for a variety of protein substrates, including members of the insulin receptor substrate 
(IRS) proteins, whose function is to activate a complex signal transduction network. 
Transduction involves the PI3K and AKT pathways, leading to protein synthesis, cell 
survival and inhibition of apoptosis, as well as the pathway of MAP kinases that 
stimulates cell proliferation and differentiation (Fig. 5). 
Following phosphorylation, the IRS interacts with the SH2 domains of the PI3K 
(phosphoinositide 3-kinase) cytoplasmic protein, which actively catalyzes the 
phosphorylation of PIP2 (phosphatidylinositol 4,5-bisphosphate) leading to the synthesis 
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of PIP3 (phosphatidylinositol 3,4,5-triphosphate). The PIP3 accumulates at high 
concentrations and can recruit and activate PDK-1 (phosphoinositide-dependent kinases). 
Then PDK-1 phosphorylates another protein kinase: the AKT at Thr308 residue [58]. 
The activated AKT has a variety of substrates that are important to bone and muscle. It 
increases protein synthesis, promoting the activation of mTOR, which phosphorylates 
other protein substrates: p70S6K and 4E-BP (eukaryotic initiation factor 4E-binding 
protein) [6].  
An additional pathway activated by AKT is the inhibition of GSK3 (glycogen synthase 
kinase-3), which results from its phosphorylation in an N-terminal serine residue. In 
response to IGF-1, GSK3 inhibition promotes dephosphorylation and activation of 
glycogen synthase, contributing to the stimulation of glycogen synthesis. Activated AKT 
also phosphorylates PKC (kinase-C protein). The PKC, together with AKT, increase the 
cell‘s glucose intake by facilitating the translocation of GLUT4, glucose transporters, 
from the intracellular vesicle to the membrane. 
The AKT pathways plays a critical role in apoptosis by inhibiting BAD, which is a 
protein involved in the apoptosis process. When BAD proteins are not phosphorylated, 
they remain on the mitochondrial membrane and interact with BCL2 (B-Cell Lymphoma-
2) preventing its anti-apoptotic action. When, on the other hand, BAD is phosphorylated 
by AKT, it is associated with a cytoplasmic protein, and is unable to interfere with the 
action of BCL2. In addition, AKT phosphorylates FOXO family members, promoting the 
export from nucleus to cytoplasm, thus reducing the induction of genes such as atrogin-1 
and MuRF1, which are ubiquitin ligases involved in protein degradation [59]. 
Activated AKT also phosphorylates several pro-apoptotic members of the forkhead 
family (transcription factor), FKHRL1, FKHR, and prevents their activity. The actions of 
AKT diminish the expression of FasL (Fas Ligand), thus decreasing Fas-mediated 
apoptosis. In addition to inhibition of pro-apoptotic transcription factors, AKT activity 
also increases levels of anti-apoptotic proteins, including BCL2 and BCL-X and various 
adhesion molecules of the extracellular matrix. Activity induced by AKT also involves 
the expression of the anti-apoptotic transcription factor NF-kB, which enters into the 
nucleus and activates the transcription of anti-apoptotic genes. 
The activation of the PI3K/AKT pathway leads to the transduction of multiple IGF-1 
effects, such as increased glucose transport and inhibition of apoptosis through the 
activation of different proteins. 
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Another pathway activated by IGF-1R/IRS1 is the MAP kinase pathway, which is more 
involved in cell proliferation and migration. In this signaling, the activated IRS interacts 
with Shc that binds to the SH2 domain of Grb2, which in turn forms a complex with Sos, 
a guanine nucleotide exchange factor. This leads to activation of the small G-protein Ras 
and continues with a sequence of cascade phosphorylation. Subsequently, Ras activates 
the protein serine kinase Raf, which phosphorylates and activates MEK, leading to the 
phosphorylation and activation of ERK1/2 (MAPK). This complex results in the 
translocation of ERK1/2 to the nucleus, which phosphorylates and activates transcription 
factors such as elk-1 and c-jun, stimulating cell proliferation and cell cycle progression. 
These nuclear transcriptional factors lead to increase cyclin D1 and reduced p21 and p27 
expression, stimulating cell cycle progression from G1 to S and promoting proliferation. 
 
 
Figure 5. IGF-1 intracellular signaling. The IGF-1R comprises two extracellular -subunits and two 
transmembrane β-subunits containing the tyrosine kinase domain. The binding of circulating IGF-1 induces 
the activation of tyrosine kinase activity of the cytoplasmic portion of the β subunits, forming binding sites 
for a number of signaling molecules. Transduction involves the activation of the PI3K and AKT pathway. 
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This leads to protein synthesis through the activation of mTOR, which stimulates p70sk6, cell survival and 
inhibition of apoptosis phosphorylating BAD and FOXO. When phosphorylated, FOXO is prevented from 
entering the nucleus and stimulating various ubiquitin ligases such as atrogin-1/MAFbx. The 
Shc/Grb2/SOS complex activates the MAP kinase pathway leading to cell proliferation by activating 
ERK1/2, which enter the nucleus to activate various transcription factors. 
 
 
The signaling of IGF-1R plays an important role in both physiological and 
pathophysiological conditions. Under normal physiological conditions, IGF-1 increases 
the synthesis of DNA and proteins in cardiomyocytes, promotes myofibrenia 
development, and is necessary for cellular entry into the S phase. An important role is 
played by IGF-1 in the development of the hypertrophic response, when the expression of 
contractile proteins such as actin, myosin and troponin increases. Through its tyrosine 
kinase, with PI3K and MAPK signaling pathways, IGF-1R can also reduce the risk of 
heart failure by preventing apoptosis. In addition, IGF protects cells from apoptosis 
induced by a variety of conditions, including chemotherapy and the expression of 
oncogenes. 
The ability to regulate apoptosis may have an impact on various types of serious illnesses 
in humans, including several human cancers. Hence, it is of crucial importance to gain a 
fuller understanding of the different activity of the pro-IGF-1s on the IGF-1R 
intracellular pathways and subsequently to develop strategies for cancer prevention. 
Chapter 2 will focus on the results of our study indicating how IGF-1 pro-hormones can 
activate the IGF-1R independently of the mature IGF-1 form. These results underline the 
importance of an accurate assessment of the presence of IGF-1 pro-forms within the 
physio-pathologic context under study.  
 
 
IGF-1 AND CANCER 
 
IGF-1 is a cell growth factor that stimulates proliferation, differentiation and inhibits 
cellular apoptosis, all key factors associated with tumor. The circulating levels of IGF-1 
were evaluated in different pathological conditions. Growth factor is the main regulator 
of IGF-1 plasma levels, whereas transport proteins, IGFBPs, which bind most of the 
circulating IGF-1, regulate bioavailability. Studies have revealed that high level of IGF-1 
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or altered levels of IGFBPs are associated with an increased risk of cancers such as lung 
[60], colon [61], prostate and breast [62]. A prospective study has shown the association 
with high circulation IGF-1 and lower plasma IGFBP3 concentrations and an increased 
risk of colorectal adenoma [63]. The cleavage from IGFBPs can results in and increased 
released of free IGF-1, which can then bind the receptor and promote cell proliferation. 
Moreover, the overexpression of the IGF-1R is evaluated in different cancer cells [64] 
and can be implicated in the acquisition of the transformed phenotype [65]. The 
concentrations of IGF-1 and its transport proteins are extremely variable between 
individuals and this could affect the distribution of cancer risk in the population. 
The IGF-1R can regulate cell-cycle progression that may be important for acquisition of 
the malignant phenotype. It can promote G1-S transition by increasing cyclin D1 and 
cyclin-dependent kinase 4 (CDK4) leading to retinoblastoma (RB) phosphorylation and 
releasing the transcription factor E2F [66]. In addition, it down regulates the 
transcriptional inhibitor p27 and phosphatases the tumor suppressor PTEN, that has been 
deregulated in cancer [67]. Studies have shown an increasing expression of IGF-1 or of 
IGF-1R in different cancer such as breast, lung, thyroid, prostate, glioblastoma, 
neuroblastoma, meningioma and rhabdomyosarcoma. IGF-1 is also implicated in the 
development and progression of angiogenesis and can modulate the expression of the 
vascular endothelial growth factor (VEGF), a potent angiogenic factor [68]. Another IGF-
1 action that is implicated in the development of tumor is the inhibition of apoptosis by 
inhibiting pro-apoptotic proteins such as BAD and inducing the expression of anti-
apoptotic proteins such as BCL2. Multiple mechanisms have been shown to modulate 
tumor cell sensitivity to IGF-1 including increase in IGF-1 synthesis, increased IGF-1R 
expression, release of proteases that cleave IGFBPs.  
Recent studies have investigated the biological action induced by IGF-1 isoforms in 
tumor tissues. In particular, a differential expression profile of IGF-1 isoforms has been 
documented in the development and progression of human prostate cancer (PCa). It was 
shown that the IGF-1Ec isoform is overexpressed in human prostate cancer tissues and in 
human cancer PC-3 and LNCaP cell lines not only at expression level, but also at protein 
level. In addition, the transcription of this specific isoform was significantly higher in 
PCa and in prostatic intraepithelial neoplasia (PIN) than in normal prostate tissues, 
whereas the normal prostate epithelial cells (HPrEC) did not express IGF-1Ec [20].  
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A differential expression profile of IGF-1 transcript variants between normal and tumor 
tissues has also been observed in other in vivo human cancers, such as endometriosis 
[21], cervix [33], colorectal cancer [34] and in osteosarcoma cells in vitro [69].  
The expression analysis of IGF-1 isoforms in eutopic and ectopic endometrium suggest 
that the IGF-1Ec splice variant may be involved in the pathophysiology of endometriosis. 
In particular, it was revealed that all the three splice variants were expressed in both 
eutopic and ectopic endometrium, though it is significantly lower in endometriotic cysts 
both at the transcript and protein level. Different expression level was also analysed 
between the glandular cells of the eutopic and the ectopic endometrium, where the first 
not express any IGF-1 isoforms whereas the second express the IGF-1Ec isoform [21].  
In addiction the analysis of the expression profile during human papillomavirus (HPV) 
dependent cervical carcinogenesis revealed that all the IGF-1 splice variant were up-
regulated in pre-cancerous cells and in particular the IGF-1Eb expression was very high 
in the cancer samples [33]. Furthermore, testing the exogenous administration of the 
synthetic E-peptide of the pro-IGF-1Ec, consisting on the C-terminal 24 amino acids 
sequence of the human Ec-peptide, has been revealed in an increase in proliferation not 
only in PCa, PC-3 and LNCaP cells [20], in endometrial KLE cells [21] and in MG-63 
osteosarcoma cells [69]. The stimulation of PCa and LNCaP cells with the synthetic 
MGF led to a differential activation of intracellular signaling, with greater 
phosphorylation of ERK 1/2 without affecting the AKT activation, suggesting, suggesting 
its independent mode of action of this E-peptice [20]. 
These data suggest the potentially different roles of different pro-IGF-1 in the 
pathophysiology of all those conditions. Interestingly, IGF-1 splice profile appears to be 
different between tumors and the state of the disease, showing a differential regulation of 
its splice variants. The functional meaning of IGF-1 different splice patter and how the 
pro-peptides are connected to different autocrine, paracrine and endocrine roles in tumor 
genesis remains to be clarified. 
 
 
IGF-1 AND BREAST CANCER 
 
The IGF-1 plays a significant role in human physiology, particularly in the development 
of many tissues, including the mammary gland. In particular IGF-1 is a key mediator of 
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mammary gland terminal end bud formation and ductal morphogenesis during 
development [70]. In contrast, many studies have been associated to the aberrant 
expression of the IGF-1 system in the development of several malignancies including 
breast cancer (BC). This is the most common malignant neoplasm in women. BC 
recurrences and survival are influenced by the presence of many prognostic factors, 
including hormone factors. IGF-1 is mainly expressed by stromal and only rarely by 
epithelial cells both in normal and BC tissues but its mitogenic actions are mainly 
expressed in the epithelium [71]. Various studies have been conducted to evaluate 
whether mature IGF-1 blood levels are associated with the development of BC or 
recurrence. Many epidemiological and prospective studies have tried to confirm the 
positive correlation between plasma IGF-1 levels and BC risk. A pooled data analysis of 
seventeen prospective studies from twelve countries by the Endogenous Hormones and 
BC Collaborative Group showed a positively association between circulating IGF-1 and 
BC risk independently by IGFBP3 levels and menopausal status in estrogen-receptor 
(ER+) positive tumors [72]. This result is also supported by the data analysis from the 
European Prospective Investigation into Cancer and Nutrition cohort [73]. Furthermore in 
an Italian cohort study, serum IGF-1 levels have been positively associated with 
increased disease risk among BRCA gene mutation (hereditary BC) [74]. 
Numerous studies have investigated the role of IGF-1 levels and altered circulating 
IGFBPs levels, in particular IGFBP3, in association with BC risk and prognosis. It has 
been shown that low levels of IGF-1 are associated with improved survival in BC patients 
[75, 76]. In addition, it has been shown that low levels of IGFBP3 increase the amount of 
free IGF-1 that is associated with increased mortality. This study also confirmed a better 
prognosis in low-level IGF-1 BC patients [76]. 
IGF-1R mediates the mitotic and anti-apoptotic effects of IGF-1 and has been indicated a 
correlation between IGF-1R expression and disease development [77]. Another study 
revealed that IGF-1 receptor is over-expressed in about 90% of BC cases and its level are 
higher in malignant cells than in normal tissue [78]. Moreover, this over-expression has 
been related with poor prognosis in patients with early BC [79].  
In addition, IGF-1R has been involved in the metastatic progression in BC [80] and 
another study indicated the relation between IGF-1 and tumor progression. It favors the 
expression of angiogenic factors in synergy with other growth factors such as vascular 
endothelial growth factor (VEGF) and platelet-derived factor (PDGF). In particular, IGF-
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1 promotes tumor growth and lymphatic metastases by inducing VEGF and it has been 
indicated a relation between high levels of IGF-1, IGFBP3 and VEGF and lymph node 
metastasis in patients affected by BC [81]. 
Although much has been investigated regarding serum IGF-1 expression, it was recently 
revealed by microarray analysis that the increase of IGF-1 mRNA levels within tissue 
samples was associated with better prognosis [82]. This finding suggests a contradictory 
role of circulating and tissue IGF-1 and it can be explained by the lack correlation 
between circulating and tissue IGF-1 levels, thus local IGF-1 expression may be a better 
marker of tumor compared to circulating IGF-1 levels.  
Despite the large amount of studies that have investigated the role of mature IGF-1 in the 
BC development and recurrences, only few studies have considered the biological action 
of each IGF-1 isoforms involved in this tumor. Many tissues such as muscle, liver and 
adipose tissue synthesize IGF-1 specific isoforms, which act locally with 
autocrine/paracrine mechanisms and play a key role in repairing cellular damage. Not 
completely clear is the local contribution to the systemic IGF-1 and the potential 
environmental stimuli that might be involved to favour their local or systemic release. 
Data on survival of patients with BC indicate that subjects with a high tissue expression 
of one of the transcripts of IGF-1, IGF-1Ea, have a lower risk of recurrence and mortality 
than patients with a lower expression of the same transcript [83].  
The biological role of different IGF-1 isoforms and how they are related to different 
autocrine, paracrine and endocrine roles in tumor genesis is not entirely explained. 
Indeed, the different isoforms correlate with numerous cellular responses, thus knowing 
which IGF-1 transcriptional variant is involved in BC could help to elucidate the effect of 
the IGF-1 pool in the BC development and recurrence. 
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AIMS OF THE THESIS 
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The primary aim of this Thesis was to investigate the regulation of IGF-1 alternative 
splicing and the biological role of IGF-1 pro-hormones in human breast cancer (BC).  
The study objectives include: 
a) The evaluation of the evolutionary pressure within the different coding regions of 
the mammalian igf-1 gene. 
b) The comparison of the mechanisms regulating the IGF-1 exon 5 transcription and 
splicing between human and mouse. 
c) The characterization of the IGF-1 pool and their biological activity on BC cell lines. 
d) The investigation of the cellular mechanisms controlling IGF-1 pro-hormones 
production and secretion. 
e) The determination of the effects of lifestyle modification program on circulating 
IGF-1 level in BC patients. 
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MIR RETROPOSON EXONIZATION PROMOTES 
EVOLUTIONARY VARIABILITY AND GENERATES 
SPECIES-SPECIFIC EXPRESSION OF IGF-1 SPLICE 
VARIANTS 
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MIR retroposon exonization promotes evolutionary variability and 
generates species-specific expression of IGF-1 splice variants 
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Abstract 
Insulin-like growth factor (IGF-1) -1 is a pleiotropic hormone exerting mitogenic and 
anti-apoptotic effects. Inclusion or exclusion of exon 5 into the IGF-1 mRNA gives rise 
to three transcripts, IGF-1Ea, IGF-1Eb and IGF-1Ec, which yield three different C-
terminal extensions called Ea, Eb and Ec peptides. The biological significance of the 
IGF-1 splice variants and how the E-peptides affect the actions of mature IGF-1 are 
largely unknown. In this study we investigated the origin and conservation of the IGF-1 
E-peptides and we compared the pattern of expression of the IGF-1 isoforms in vivo, in 
nine mammalian species, and in vitro using human and mouse IGF-1 minigenes.  
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Our analysis showed that only IGF-1Ea is conserved among all vertebrates, whereas IGF-
1Eb and IGF-1Ec are an evolutionary novelty originated from the exonization of a 
mammalian interspersed repetitive-b (MIR-b) element. Both IGF-1Eb and IGF-1Ec 
mRNAs were constitutively expressed in all mammalian species analyzed but their 
expression ratio varies greatly among species. Using IGF-1 minigenes we demonstrated 
that divergence in cis-acting regulatory elements between human and mouse conferred 
species-specific features to the exon 5 region. Finally, the protein-coding sequences of 
exon 5 showed low rate of synonymous mutations and contain disorder-promoting amino 
acids, suggesting a regulatory role for these domains. 
In conclusion, exonization of a MIR-b element in the IGF-1 gene determined gain of 
exon 5 during mammalian evolution. Alternative splicing of this novel exon added new 
regulatory elements at the mRNA and protein level potentially able to regulate the mature 
IGF-1 across tissues and species. 
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1. Introduction 
The mammalian insulin-like growth factor (IGF) -1 gene is a single copy gene composed 
of six exons and five introns, which gives rise to an immature IGF-1 peptide (IGF-1 pro-
peptide) containing a signal peptide at the 5' end of the gene, a core region and an E-
peptide at the 3' end (Figs. 1A and 1B). Both signal peptide and E-peptide are then 
removed by protease cleavage to form the 70 amino acid-long mature IGF-1 peptide 
(IGF-1 core), which displays growth-promoting and metabolic functions. 
Four of the six IGF-1 exons are subjected to alternative splicing (Figs. 1A and 1B) [1]. 
Exon 1 and exon 2 are mutually exclusive first exons and generate different signal 
peptides. Transcripts containing exon 1 are referred to as Class I transcripts whereas 
those containing exon 2 are referred to as Class II transcripts. The Class II IGF-1 
knockout mice indicated that class II isoforms are dispensable for fetal and postnatal 
growth, and the significance of the alternate signal peptides encoded by the first two IGF-
1 exons was discussed in [2-3]. At the 3‘ end of the gene, alternative splicing yields three 
different mRNA transcripts, each encoding distinct carboxyl-terminal portions of E-
peptide followed by the 3'-untranslated region (3'UTR) (Figs. 1A and 1B). Thus, although 
alternative splicing generates different precursor peptides, it does not alter the sequence 
of the mature IGF-1 peptide. 
Splicing of exon 4 with exon 6 yields the most common IGF-1Ea variant, which encodes 
the 35 amino acids-long Ea peptide. The first 16 amino acids of the Ea peptide are 
encoded by exon 4 and are common in all E-peptides, whereas the remaining 19 amino 
acids are encoded by exon 6 and are unique to this isoform. The IGF-1Eb variant is 
produced when exon 4 is spliced with exon 5 and encodes the Eb peptide, which contains 
the 16 common amino acids and 61 additional amino acids encoded by exon 5. IGF-1Eb 
transcript terminates in exon 5 and excludes exon 6 from the mRNA, hence it has a 
completely different 3‘UTR compared to IGF-1Ea and IGF-1Ec. The third variant, named 
IGF-1Ec in humans, is generated by usage of a cryptic 5' splice site (c5‘ss) (named 
IGF633) [4] present in exon 5, which is in turn spliced with exon 6. The c5‘ss of IGF-1 
exon 5 deviates from the vertebrate consensus and is commonly used in rodents and 
rabbits [5-7] but rarely and in a tissue-specific manner in human [1, 4]. Notably, although 
this variant is named IGF-1Eb in rodents, for clarity we will use the human IGF-1Ec 
nomenclature throughout this manuscript, regardless of the species. The human Ec 
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peptide has a predicted length of 40 amino acids, with the common 16 amino acids 
deriving from the exon 4, 16 from exon 5 and the last 8 amino acids from exon 6. Since 
expression of IGF-1Ec was linked to mechanical stimuli in muscle and other 
mechanosensitive cells, this variant is sometime referred to as Mechano Growth Factor 
(MGF) [1]. 
Few studies have addressed the regulation of IGF-1 alternative splicing. In human cells, 
splicing of exon 5 is regulated by the antagonistic activities of the serine-arginine protein 
splicing factor-1 (SRSF1) and heterogeneous nuclear ribonucleoproteins A1 (hnRNPA1) 
[8-9]. SRSF1 was proposed to increase splicing of the IGF-1Eb variant by binding to a 
purine-rich exonic splicing enhancer (ESE) in exon 5 and preventing the recruitment of 
hnRNPA1, which functions as a splicing repressor [8-9]. Notably, neither splicing factor 
was capable of regulating the IGF-1Ec variant in human IGF-1 minigenes [8-9]. The 
reason of the lack of usage of the c5‘ss, and hence for the lack of IGF-1Ec isoform 
production, reported in these studies has yet to be clarified. Similarly, whether or not the 
mouse c5‘ss, which is closer to the canonical splicing donor consensus, can be recognized 
in these experimental settings has not been tested. Furthermore, it is currently unknown 
whether SRSF1 and hnRNP A1 function specifically with the human IGF-1 pre-mRNA 
or whether they also play a role in IGF-1 alternative splicing in other species. 
To date, the fate and the biological functions of E-peptides are not entirely clear [1, 10-
12]. Interestingly, gene structure comparison showed that IGF-1 exon 6 is conserved in 
all vertebrates, whereas exon 5 is conserved only among mammals [13-15]. In addition, 
comparative studies on mammalian IGF-1 show that both the IGF-1 core and Ea peptide 
are subjected to strong purifying selection, whereas sequences of the Eb and Ec peptides 
are more variable [16-17]. In particular it was shown that the ratio of non-synonymous 
(dN; amino-acid altering) to synonymous (dS; silent) substitutions is about 10-fold higher 
for Eb and Ec peptides compared to Ea peptide, suggesting that they have no specific 
roles or, at most, species-specific functions [17]. Indeed, it is usual to view poor protein 
sequence conservation, i.e. evolving under neutral or nearly neutral conditions, as 
evidence of reduced functional importance [17-18]. However, Lin and colleagues [19] 
recently demonstrated that the ―dual-coding‖ DNA sequences of IGF-1 exon 6, which is 
translated in two alternative reading frame to give rise to Ea and Ec peptides, showed a 
very low dS rate suggesting additional sequence constraints beyond those dictated by the 
amino acid sequence of the Ea and Ec peptides. Notably, the picture of largely neutral 
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evolution of synonymous substitutions in mammals has been recently challenged [20], 
showing that selection may constrain not only dN to preserve amino acid sequence, but 
also dS to preserve regulatory elements in nucleotide sequences, such as ESE, RNA 
secondary structures and microRNA target sites [19-21]. However, whether the dS drop 
of the dual-coding exon 6 has contributed to the observed local increase in dN/dS ratio of 
E-peptides and hence to an inaccurate estimate of evolutionary rate is still unclear. 
In this study, we have analyzed the conservation and the mRNA expression pattern of 
IGF-1 isoforms in different mammalian species and evaluated the evolutionary pressure 
within the different coding regions of the mammalian IGF-1 gene. Moreover, we have 
used human and mouse minigene systems to compare the mechanisms regulating the 
IGF-1 exon 5 splicing between these two species.  
 
 
2. Materials and Methods 
 
2.1 Sequences and databases 
Orthologous of the human IGF-1 gene were obtained from the UCSC Genome Browser 
Database (http://genome.ucsc.edu; Feb. 2009 GRCh37/hg19) and Ensembl website 
(http://www.ensembl.org). The ―CDS FASTA alignment from multiple alignments‖ data, 
derived from the ―multiz100way‖ alignment data prepared from 100 vertebrate genomes 
[22], were downloaded using the Table Browser tool of the UCSC Genome Browser. 
Sequences were subsequently realigned using MUSCLE [23] and protein coding 
sequences from 27 mammalian species were extracted from these alignment datasets. 
Supplementary file S1 contains the IGF-1 sequence of 27 mammalian species in FASTA 
format and the neighbor-joining tree used in the present study. Percent nucleotide and 
amino acid identities between sequences were computed using the CLUSTALW 
procedure [24]. The splice site scores were obtained for each 5' and 3' ss sequence using 
the Maximum Entropy scores [25]. For Transposable elements analysis, we used 
RepeatMasker (http://www.repeatmasker.org) and Repbase annotations [26-28]. 
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2.2 Human and animal tissues 
Freshly frozen normal human liver (2 males, mean age 54 +/- 9 years), adipose (2 males 
and 2 females, mean age 52 +/- 12 years) and muscle (3 males, mean age 25 +/- 6 years) 
samples were provided by the complex structure of biomarkers (DOSMM) of National 
Cancer Institute of Milan. The macaque (Macaca mulatta) autoptic specimens were 
kindly provided by Elena Borra (Department of Neuroscience, University of Parma, 
Parma, Italy). Three 4-year olds macaques were tested in this study (2 female and 1 
male). One-month old CD1 female mice (n=3) (Mus Musculus), 2-month old Young 
Sprague Dawley male rat (n=3) (Rattus norvegicus) and three 8 month-old New Zealand 
male rabbits (Oryctolagus cuniculus) (Charles River Laboratories, Milan, Italy) were 
housed with a 12-h light/dark cycle and free access to standard laboratory chow and 
water. Care and handling were in accordance with the Guide for the Care and Use of 
Laboratory Animals by Ministero della Sanità D.L. 116 (1992) and approved by the 
university committee for animal experiments. Animals were sacrificed with an overdose 
of anaesthetics (ketamine in combination with xylazine). Other tissues used in this study 
were collected at local slaughter during routine meat inspection: pig (Sus scrofa) (3 
males), cow (Bos taurus) (3 females), sheep (Ovis aries) (3 female) and goat (Capra 
hircus) (2 males and 1 female) were tested in this study. The age of the animals ranged 
from 2 to 5 years. All tissues (about 30 mg) were immediately submerged in RNAlater 
stabilization solution (Qiagen, Milan, Italy) and left at least 10 min at room temperature. 
Then, tissues were stored at -80°C until RNA extraction. 
 
2.3 RNA extraction and cDNA synthesis 
The tissues were removed from RNAlater and transferred into a clean Eppendorf tube 
where the total RNA was extracted and purified using the Omega Bio-Tek E.Z.N.A.TM 
Total RNA kit (VWR International s.r.l., Milan, Italy) according to the manufacturer‘s 
instructions. The amount and quality of RNA were assessed with DU-640 UV 
Spectrophotometer (Beckman Coulter). After DNA digestion with DNase I enzyme 
(Qiagen, Milan, Italy) complementary DNA was synthesized from 1 μg of total RNA 
using Omniscript RT (Qiagen, Milan, Italy) and random hexamers or anchored oligo-dT 
primers where specified.  
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2.4 Real time PCR quantification of human, macaque and mouse IGF-1 isoforms 
Serial dilution (1:4) of three recombinant plasmids containing the IGF-1Ea, IGF-1Eb and 
IGF-1Ec sequences of human and mouse were prepared in order to generate standard 
curves for plotting CT values against number of molecules. Molecules of each plasmid 
were calculated using the concentration of each plasmid, Avogadro‘s constant, the 
molecular weight of double-stranded DNA and the size of the target amplicon [29]. The 
copy number of genes was calculated in individual samples using a corresponding 
reference plasmid cDNA clone at known concentration. The amount of target transcripts 
was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Percentage of 
IGF-1 isoforms was calculated as [(mRNA copy number of single isoform/(mRNA copy 
numbers of IGF1Ea+IGF1Eb+IGF1Ec)*100]. Expression of IGF-1 isoforms was 
compared using 2-ways analysis of variance with interactions: species and IGF-1 
isoforms were used as predictive factors. In order to meet assumption of 
homoscedasticity percentage were arcsin radq transformed. Post-hoc analysis was 
performed using Bonferroni correction. 
Real-time quantitative PCR was performed with two microliters of cDNA and 300 nM of 
of each primer in an Applied Biosystems StepOnePlus
TM
 Real Time PCR System using 
SYBR Select Master Mix (Applied Biosystems, Monza, Italy). The real-time PCR 
conditions were: 50°C for 2 min, 95°C for 2 min followed by 40 cycles of three-steps at 
95°C for 15 sec, 60°C for 15 sec and 72°C for 30 sec. The specificity of the amplification 
products was confirmed by examining thermal denaturation plots and by sample 
separation in a 4% DNA agarose gel. The sequences and the annealing positions of the 
primers used to quantify the IGF-1 isoforms were shown in Supplementary Table S1. 
 
2.5 3' RACE-PCR 
The mRNA splicing pattern of IGF-1 was assayed by 3-RACE-PCR using an anchored 
oligo-dT primer (5'-AAGCAGTGGTATCAACGCAGAGTACT(30)NV-3') as reverse 
transcription primer. 1 μg of total liver RNA was reverse transcribed into cDNA. To 
amplify the 3'-end IGF-1 variants a reverse primer corresponding to the anchor sequence 
of the RT primers was used in combination with the following forward primers: human, 
macaque, rabbit, (5'-CCTCCTCGCATCTCTTCTACCTG-3'); mouse and rat (5'-
GCTATGGCTCCAGCATTCG-3'); and pig (5'-CGTGGATGAGTGCTGCTTC-3'). The 
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PCR reaction were as follows: 95° for 10 min; 35 cycles of three-steps at 95°C for 30 sec, 
60°C for 30 sec, 72°C for 1 min and 30 sec followed by a final elongation cycle (72°C for 
5 min). The PCR products were loaded on 4.0% agarose gel and DNA fragments were 
eluted from gel, subcloned and sequenced. 
 
2.6 Conventional RT-PCR 
RT-PCR was performed in 50 μl of reaction volume with 4 μl of cDNA, 800 nM of 
primers and 25 μl of 2X HotStartTaq mix (Qiagen, Milan, Italy). The sequences and the 
annealing positions of the primers used for RT-PCR were shown in Supplementary Table 
S1. RT-PCR conditions involved an initial denaturation step at 95°C for 10 min, followed 
by 35 cycles with denaturation step at 95°C for 30 sec, annealing at 60°C for 30 sec and 
extension at 72°C for 30 sec. PCR products were size-fractionated by electrophoresis on 
4.0% agarose gels and visualized by ethidium bromide staining under UV light. 
Amplification products were purified with QIAquick gel extraction kit (Qiagen), cloned 
and sequenced. 
 
2.7 Plasmid constructs 
The 5' and 3'end of IGF-1 mouse minigene were amplified using primers #(1,2) and 
#(3,4), respectively, from C57 mice genomic DNA. After enzymatic digestion, the PCR 
products were cloned in KpnI/SalI and SalI/NotI restriction sites of pCI vector 
(Promega). The 5' and 3'end of the IGF-1 human minigene were amplified using primers 
#(5,6) and #(7,8), respectively, from HeLa cell genomic DNA and cloned in EcoRI/SalI 
and SalI/NotI restriction sites of pCI vector. The mGAvsTG and hTGvsGA IGF-1 mutant 
minigenes were constructed using the mega-primer strategy [30]. The mouse and human 
IGF-1 5' mutant ends were generated using primers #(1,9,2) or #(5,10,6) respectively. All 
oligonucleotide sequences are listed in Supplementary Table S1. After enzymatic 
digestion, the PCR products were subcloned in the corresponding wild-type minigene. 
PCR reactions were performed using Phusion Hot Start High-Fidelity DNA polymerase 
(Thermo Scientific) according to manufacturer‘s instruction. All plasmids were 
sequenced and validated. 
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2.8 Cell cultures, transfections and protein extract preparation  
Cell cultures, transfections and sample preparation were carried out by standard methods 
as previously described [31]. Briefly, human and mouse cell lines were transfected with 
various combination of vectors as indicated using Lipofectamine 2000 (Invitrogen). 
Twenty-four hours after transfection, cells were collected for RNA and protein isolation, 
as previously described [31]. For RNAi experiments cell were transfected twice with 
60nM siRNAs using Lipofectamine RNAi Max according to manufacturer‘s instruction 
(Invitrogen). Sequences of siRNAs are listed in the Supplemental Table 1. 
 
2.9 Splicing assay and PCR analyses 
Twenty-four hours after transfection, cells were collected for RNA extraction using 
TRIzol (Ambion, Life Technologies) according to the manufacturer‘s instructions. After 
DNase digestion (Roche), 1 μg of total RNA was retrotranscribed using M-MLV reverse 
transcriptase (Promega). cDNA was used as template for conventional PCR reactions 
(GoTaq G2, Promega) in presence of specific primers and PCR products were analyzed 
on agarose gel. A minigene-specific forward primer #(11) was used to amplify minigene-
derived IGF-1 isoforms. In details, primers #(11,13) were used to amplify mIGF-1Eb 
isoform; primers #(11,12) to amplify mouse and human IGF-1Ea and IGF-1Ec isoforms; 
primers #(11,14) to amplify hIGF-1Eb; primers #(11,15) and #(11,16) to amplify total 
mouse and human IGF-1, respectively. In splicing assay human IGF-1Ea and IGF-1Eb 
were amplified using primers #(11,12,14) in the same PCR reaction. Amplification of 
mouse and human endogenous IGF-1 isoforms were performed as above, using primer 
#(1) or #(5), respectively, in substitution of primer #(11). The sequences and the 
annealing positions of the primers are showed in Supplementary Table S1. 
 
2.10 IGF-1 evolutionary analysis 
The MG94xREV_3x4 codon model with transition/transversion bias correction and nine 
base frequency parameters was fitted to sequence alignments by using the HyPhy 2.2.3 
package [32]. A neighbor-joining tree was built using the IGF-1 core alignment of 27 
mammalian species and the tree topology along with the alignment were used as input for 
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IGF-1Ea, IGF-1Eb and IGF-1Ec sequence analysis (Supplementary file S1). For every 
branch in a phylogenetic tree, the expected number of synonymous substitutions per 
synonymous site (dS) and its counterpart for nonsynonymous substitutions (dN) were 
estimated by using maximum likelihood [33] allowing for independent dN and dS values 
for each branch (the local parameters option). Mean and 95% confidence interval for each 
dS, dN and dN-dS values are calculated using bootstrap approach with n=1000 
resampling [34]. 
The web application of DisCons [35] was used to predict the protein disorder on the 
amino acid level, using IUPred long disorder prediction parameter [36].  
 
 
3. Results 
 
3.1 IGF-1 exon 5 is conserved in Mammalia but not in other vertebrates 
Previous studies demonstrated that the IGF-1Ea splice variant, which skips exon 5, is the 
most common E-peptide isoform expressed among vertebrates and is the predominant 
form in amphibians and birds [13-15]. To trace the evolutionary history of the IGF-1 
isoforms that include exon 5 (i.e. IGF-1Eb and IGF-1Ec), we performed BLAST searches 
in mammalian and non-mammalian draft genomes using the Ensembl database and the 
UCSC vertebrate genome alignment provided at the UCSC Genome Browser site (Fe. 
2009 GRCh37/hg19). ClustalX alignment of IGF-1 sequences was performed along the 
exon 5 and exon 6 regions among 23 representative amniota vertebrates (Supplementary 
Fig. S1). We retrieved orthologs of the exon 5 sequence from all placental mammals 
(Eutheria), except Guinea pig (Cavia aperea porcellus), probably because of insufficient 
sequencing coverage. In addition, we identified exon 5 sequences from the marsupial 
short-tailed opossums (Didelphidae) as well as from the monotremata egg-laying 
platypus (Prototheria). By contrast, we failed to identify exon 5 orthologs in all examined 
non-mammalian vertebrates (fish, amphibians, reptiles and birds), including turkey 
(Meleagris gallopavo), chicken (Gallus gallus), zebra finch (Taeniopygia guttata) and 
green anole lizard (Anolis carolinensis) (Supplementary Fig. S1). These data show that 
only exon 6 is conserved in all vertebrates and suggest that the Ea peptide represents the 
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ancestral IGF-1 E-peptide, whereas the exon 5-encoded Eb and Ec peptides have been 
acquired during evolution in the mammalian lineage. 
 
3.2 MIR-b retroposon exonization in the IGF-1 gene explains the origin of the 
alternatively spliced exon 5 in Mammalia  
Transposon exonization is a major source of new exons in higher eukaryotes [37]. This 
process occurs when transposon-derived intronic sequences are recognized by the 
spliceosome and are exonized. Using the RepeatMasker web server, we searched for 
transposon elements in the genomic region encompassing IGF-1 exon 5. No repetitive 
sequences were detected using the search tools ―abblast‖, ―rmblast‖ or ―cross-match‖ 
whereas the recently introduced ―nhmmer‖ search engine, which uses the Dfam database, 
[27-28], highlighted a transposon belonging to the Mammalian Interspersed Repetitive-b 
(MIR-b) element (bit score 13.6; E-value 0.0031). The IGF-1 exon 5 displays about 60% 
nucleotide identity to 103 nt of MIR-b consensus sequence from Repbase (Fig. 1C). The 
exonized MIR-b element is inserted in the antisense orientation relative to the IGF-1 
gene. Both the polypyrimidine tract and the IGF-1 exon 5 splice sites are embedded 
within the MIR-b sequence (Fig. 1C). The 3'ss of IGF-1 exon 5 is in close proximity to 
the 65 nt that form the highly conserved core region of MIR-b while the c5'ss lies within 
this region (Fig. 1C). This configuration is similar to those described for others antisense 
MIR-b exons [35-36] and for disease-linked genes containing MIR pseudoexons [38]. 
 
 
Figure 1. Schematic representation of the IGF-1 gene (A), its splice variants (B) and the exonization 
of MIR-b in the IGF-1 gene (C). (A) Map of the IGF-1 gene showing exons (boxes), introns (solid lines), 
splicing options (dashed lines), cryptic 5' splice site (c5'ss) in exon 5 and poly(A) sites (pA). The graph is 
not drawn to scale. (B) Splice variants of the IGF-1 gene; human IGF-1 NCBI RefSeq transcripts: class I 
IGF-1Ea (NM_000618), class I IGF-1Eb (NM_001111285), class I IGF-1Ec (NM_001111283) and class II 
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IGF-1Ea (NM_001111284). (C) Pairwise alignment of the human IGF-1 gene sequence and the MIR-b 
inverse consensus sequence created by RepeatMasker using ―nhmmer‖ search engine (intronic nucleotides 
in lower-case letters, exonic nucleotides in upper-case letters). The polypyrimidine tract and exon 5 splice 
sites are shown in bold in IGF-1 sequence; the bold region of MIR-b sequence corresponds to the 65-nt 
conserved central domain of MIR-b sequence. The middle line shows exact matches (spaces), gaps (dashes) 
and mismatches (i=transition; v=transversion).  
 
 
3.3 Comparison of the MIR-derived IGF-1 exon 5 sequence within mammalian 
species 
Alignment of the IGF-1 exon 5 sequence originated from exonization of MIR-b element 
among mammalian orthologous showed a level of nucleotide identity ranging from 56 to 
62% between MIR-b consensus sequence and IGF-1 exon 5 coding for Ec peptide (49 bp 
in human and 52 bp in other species) (Fig. 2A). This analysis indicates that, after 
exonization, the exon 5 sequence coding for the Ec peptides has been fairly well 
conserved among species, even though the percent of identity of nucleotide sequence was 
lower in rodents and logomorpha than in others species (Fig. 2A). Notably, the 3'ss of 
exon 5 is conserved and relatively strong, whereas the c5‘ss has only a limited match to 
the consensus, except in mouse and rat (Figs. 2A and 2B). Interestingly, humans and 
murids showed a marked difference in c5‘ss strength. This splice site is very weak in 
humans; by contrast it appears strong in mouse and rat (Fig. 2B). Further analysis of the 
IGF-1 c5‘ss strength among 58 mammalian genomic sequence datasets available at the 
UCSC genome browser showed that most mammals (79%) display medium strength, 
while 16% have high strength, including all members of the two rodent families 
Cricetidae: prairie vole (Microtus ochrogaster), chinese hamster (Cricetulus barabensis 
griseus), golden hamster (Mesocricetus auratus) and Muridae: mouse (Mus musculus) 
and rat (Rattus norvegicus) (Supplementary Fig. S2). These analyses suggest that 
processing of both IGF-1Eb and IGF-1Ec mRNA variants are expected in most 
mammals, whereas the weak nature of the c5‘ss of human exon 5 will likely prevent its 
recognition by the spliceosome, yielding predominantly the IGF-1Eb isoform. By 
contrast, the relatively strong c5'ss of exon 5 in the Muridae Family will favour 
processing of the IGF-1Ec. Therefore, our analyses suggest that, under normal conditions, 
the IGF-1 alternative splice variants are likely expressed in a species-specific manner.  
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Figure 2. Comparative analyses of exon 5 splice sites among mammals. (A) Multiple alignment of 
MIR-derived exon 5 of IGF-1 gene among mammals. Partial intron 4 and exon 5 sequences is shown 
(intronic nucleotides in lower-case letters, exonic nucleotides in upper-case letters). The nucleotides that 
did not match the 3'ss and 5'ss consensus sequences are highlighted in grey (y=purine; r=pyrimidine). 
Nucleotides conservation is marked at the lower edge with asterisks indicating full conservation relative to 
the MIR-b consensus sequence (lower row). The percentage of nucleotide identity between mammalian 
sequences and MIR-b consensus sequence is indicated under ―MIR-b identity‖. (B) Splice site score of the 
3'ss and c5'ss of IGF-1 exon 5 was calculated using the MaxEntScan algorithm [25]. 
 
 
3.4 Expression pattern of IGF-1 mRNA isoforms in mammals 
To test this hypothesis, we quantified by real-time PCR the IGF-1Ea, IGF-1Eb and IGF-
1Ec mRNA variants in skeletal muscle, adipose tissues and liver of human (Homo 
sapiens), macaque (Macaca mulatta) and mouse (Mus musculus). These species represent 
examples of weak, intermediate and strong exon 5 c5‘ss, respectively (Fig. 2B). As 
predicted by our analysis, the expression profile of these IGF-1 mRNA variants varies 
among species (Anova test; p<0.01) (Fig. 3A). In particular the IGF-1Ea and IGF-1Eb 
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isoforms are predominant in human skeletal muscle, adipose tissue and liver, whereas the 
IGF-1Ec isoform accounts only for 1-5% of total IGF-1 mRNAs (Fig. 3A). Conversely, 
IGF-1Ea and IGF-1Ec isoforms predominate in mouse tissues, whereas the IGF-1Eb 
isoform was barely detectable (≤1% of total IGF-1 mRNAs) (Fig. 3A), as also reported 
previously [39]. In macaque (Macaca mulatta), the expression of IGF-1Eb was higher 
compared to IGF-1Ec in skeletal muscle and adipose tissue, whereas these splice variants 
were expressed at approximately equivalent level in the liver (Fig. 3A). Noteworthy, the 
same PCR primers have been used to amplify human and macaque IGF-1 mRNA 
variants, ruling out differences in amplification efficiencies between species.  
To confirm the species-specific expression pattern of IGF-1 isoforms, we performed 3' 
RACE-PCRs using liver-derived cDNA from human, macaque or mouse. In addition, we 
analyzed liver tissues from rat (Rattus norvegicus; strong c5'ss), rabbit (Oryctolagus 
cuniculus; intermediate c5'ss strength) and pig (Sus scrofa; intermediate c5'ss strength). 
IGF-1Ea, IGF-1Eb and IGF-1Ec mRNA products were amplified in macaque, rabbit and 
pig liver, which represent examples of intermediate c5'ss (Fig. 3B and Supplementary 
Figs. S3A, S3B and S3C for the complete nucleotide sequences and putative termination 
sites). On the contrary, the IGF-1Ec and IGF-1Eb splice variants were not detected in 
human and Muridae liver, respectively, probably because their expression level is too low 
for the sensitivity of the 3' RACE-PCR analysis. Notably, human, mouse, rabbit and pig 
IGF-1 isoforms show multiple termination sites (Fig. 3B and Supplementary Figs. S3A, 
S3B and S3C). Isoform-specific PCR analysis showed that both IGF-1Eb and IGF-1Ec 
mRNA variants were expressed in other species characterized by an intermediate c5'ss, 
such as cow (Bos taurus), sheep (Ovis aries) and goat (Capra hircus) (Supplementary 
Fig. S3D).  
Collectively, these results document that IGF-1Eb is more widely expressed than 
previously reported and point out a sharp difference in the expression of IGF-1 isoforms 
between human and mouse.  
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Figure 3. Expression pattern of IGF-1 mRNA isoforms within mammalian species. (A) Quantification 
of IGF-1Ea, IGF-1Eb and IGF-1Ec isoforms by real time RT-PCR on skeletal muscle, adipose tissue and 
liver of Human, Macaque and Mouse. Percentage mean (+/-SD) of IGF-1 isoforms was calculated as: 
[(mRNA of single isoform/(mRNAs of IGF1Ea + IGF1Eb + IGF1Ec)*100]. n=2-4. (B) Agarose gel of 3‘ 
RACE-PCR analysis performed in liver tissues from different mammalian species. PCR products were 
eluted from gel, subcloned and sequenced (See Supplementary Figs. S3A, S3B and S3C). A schematic 
representation of IGF-1 gene and the relative position of forward primers used in the 3‘RACE-PCR are also 
shown. See Materials and Methods section for universal reverse primer information. Diagrammatic 
representation of splice variants is given on the left of the gel; their sizes (bp) are indicated on the right. 
 
 
3.5 The mouse- and human-specific IGF-1 isoforms pattern is not dependent on the 
cell context  
In order to analyze the species-specific splicing of exon 5 in human and mouse, we 
constructed minigene systems consisting of exon 4, intron 4, exon 5, part of intron 5 and 
exon 6 of the corresponding IGF-1 genes (Fig. 4A). Minigene splicing assay performed 
in four human and three mouse cell lines showed that alternative splicing of the human 
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minigene (hIGF-1) did not generate the IGF-1Ec variant (Fig. 4B, left panel and 
Supplementary Fig. S4). These results are in line with the barely detectable amounts of 
this mRNA found by quantitative real-time PCR in human tissues (Fig. 3A). By contrast, 
the mouse minigene (mIGF-1) yielded mainly the IGF-1Ea and IGF-1Ec variants in all 
cell types analyzed (Fig. 4B, right panel and Supplementary Fig. S4), similarly to what 
observed in mouse tissues (Fig. 3A), with mostly shifted toward the IGF-1Ec isoform in 
mouse cell types. We suppose that these little differences might be due to the lack of part 
of intron 5 and/or of chromatin context, or to the presence of a different promoter in the 
minigene [40-41]. Collectively, these results indicate that the mouse and human IGF-1 
minigenes mostly recapitulate the splicing pattern observed in tissues. 
 
 
Figure 4. The expression pattern of human and mouse IGF-1 minigenes. (A) Schematic representation 
of IGF-1 minigenes. Exons (boxes), introns (lines), and cryptic 5' splice site (c5'ss) in exon 5 are indicated 
(left panel). A diagram of primers position used for RT-PCR analysis and the expected PCR products are 
also shown (right panel). A minigene-specific forward primer (P1) was used to amplify minigene-derived 
IGF-1 isoforms. Primers P1-P4 were used to amplify a constant region of minigene-derived IGF-1 mRNA; 
primers P1-P3 were used to amplify IGF-1Ea and IGF-1Ec isoforms; primers P1-P2 were used to amplify 
IGF-1Eb isoform. All oligonucleotide sequences are listed in Supplementary Table S1. (B) RT-PCR 
analysis of splicing assay performed in human HEK293T cells (left panel) and primary mouse hepatocytes 
(right panel) in presence of human (hIGF-1) or mouse (mIGF-1) minigenes. Untransfected cells (-) or cells 
transfected with the empty vector (vect.) were used as a PCR control. L34 was used as loading control. 
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Since the hIGF-1 and mIGF-1 splicing patterns were mostly preserved regardless of the 
cell context, it is likely that splicing of exon 5 is not regulated by a specific human or 
mouse trans-acting environment. To validate this hypothesis, we forced the expression of 
selected splicing factors to determine their effect on the mouse and human IGF-1 
minigenes. Human IGF-1 exon 5 splicing is regulated by competition between SRSF1 
and hnRNPA1 [8-9]. Thus, we tested whether or not the differences in human and mouse 
exon 5 splicing could be influenced by modulation of the expression of SRSF1, hnRNP 
A1 and other similar splicing factors (Fig. 5 and Supplementary Fig. S5). As expected [8-
9], overexpression of hnRNP A1 promoted splicing of the IGF-1Ea variant by the hIGF-1 
minigene, whereas overexpression of SRSF1 favored splicing of the IGF-1Eb variant 
(Fig. 5B, left panel). However, overexpression of neither splicing factor was capable of 
inducing the IGF-1Ec variant from the hIGF-1 minigene (Fig. 5B, left panel). Moreover, 
splicing assays in presence of several other hnRNPs (A2, F, G, H, I and K), SR (SRSF3 
and 7) and SR-like (TRA2α and 2β) proteins showed that none of them was capable of 
inducing the IGF-1Ec variant from the hIGF-1 minigene in HEK293T cells (Fig. 5B, left 
panel), even though most of these splicing factors influenced the IGF-1Eb/IGF-1Ea ratio 
(Fig. 5B, left panel). Similarly, depletion of hnRNPA1, SRSF1 or TRA2β did not 
promote splicing of IGF-1Ec isoform by the endogenous human gene (Fig. 5D, left panel 
and Supplementary Fig. S5B) and hIGF-1 minigene (Supplementary Fig. S5C). Since, 
splicing of IGF-1Ec is promoted by local muscle tissues damage in rodent [7], we tested 
whether oxidative stress condition in a human cell line (LNCaP) may promote splicing of 
this isoform. Notably, we observed modulation of IGF-1Eb/IGF-1Ea ratio but not 
splicing of IGF-1Ec (Supplementary Fig. S5D). These results strongly suggest that lack 
or low expression of the IGF-1Ec variant is unlikely due to deficient expression of trans-
acting factors in human cells. In the case of the mIGF-1 minigene, overexpression (Fig. 
5B, right panel) or depletion (Supplementary Fig. S5C) of most splicing factors 
modulated the IGF-1Ec/IGF-1Ea ratio between the two canonical variants, but none of 
them affected the low levels of basal expression of the IGF-1Eb variant produced by the 
mIGF-1 minigene. Accordingly, depletion of hnRNPA1, SRSF1 or TRA2β did not 
promote splicing of IGF-1Eb isoform from the endogenous mouse gene (Fig. 5D, right 
panel and Supplementary Fig. S5B). These results argue against a key role played by 
trans-acting factors in the alternative processing of IGF-1 exon 5 observed in both human 
and mouse. 
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Figure 5. Modulation of splicing factors expression regulates mouse and human IGF-1 alternative 
splicing. (A) Diagram of primers position used to amplify minigene-derived IGF-1 isoforms. (B) RT-PCR 
analysis of splicing assay performed in HEK293T cell line in presence of human (left panel) or mouse 
(right panel) IGF-1 minigenes and the indicated splicing factors. The bar graph shows the ratio of 
densitometric analysis between IGF-1Eb and IGF-1Ea (left panel) or IGF-1Ec and IGF-1Ea (right panel) 
isoforms (mean ± SD, n=3). C) Diagram of primers position used to amplify endogenous IGF-1 isoforms. 
(D) RT-PCR analysis of splicing assay of endogenous IGF-1 gene performed in human LNCaP cells (left 
panel) and in mouse NIH/3T3 cells (left panel) depleted with the indicated splicing factors.  
 
 
3.6 The relative strength of the c5'ss of IGF-1 exon 5 contributes to the species-
specific production of the IGF-1Ec isoform in human and mouse 
Given the marked difference in strength between the mouse and human c5'ss (Fig. 2B), 
we hypothesized that evolutionary modifications of this splice site explains its different 
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usage in the two species. To verify this possibility, we replaced by site-directed 
mutagenesis the weak human c5'ss with the strong mouse splice site (hMUT: TGvsGA) 
(Fig. 6A). Notably, strengthening of human c5'ss partially recovered splicing of IGF-1Ec 
(Fig. 6B). By contrast, weakening of the mouse c5'ss by reverting it to the human 
sequence (mMUT: GAvsTG) (Fig. 6A) prevented its usage and favored selection of 
another cryptic 5'ss located downstream the canonical one (IGF-1Ec* in Figs. 6A and 
6C). These results strongly suggest that the strength of the c5'ss in exon 5 is a crucial 
factor in determining the species-specific expression of the IGF-1Ec splice variant. 
We noticed that humanization of the mouse c5'ss (mMUT: GAvsTG) was not sufficient 
to enhance splicing of the IGF-1Eb variant from the mouse minigene (Fig. 6C). 
Moreover, splicing was not affected by overexpression of SRSF1, which promotes the 
IGF-1Eb variant from the human minigene (Supplementary Fig. S6A). Similarly, unlike 
with the mouse minigene, overexpression of SRSF1 did not decrease the IGF-1Ec/IGF-
1Ea ratio in presence of hMUT (TGvsGA) minigene (Supplementary Fig. S6A). 
Altogether, these results suggest that other sequence elements, in addition to the c5'ss, 
contribute to species-specific variations of IGF-1 alternative splicing, possibly by 
conferring sensitivity to trans-acting factors. 
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3.7 Molecular evolution of mammalian IGF-1 isoforms and prediction of IGF-1 
domain structural properties 
The selective pressure acting on IGF-1 domains is currently largely unknown [17, 19]. 
The higher variability of E-peptide sequences compared to core region sequences among 
mammals might reflect a less stringent functional requirement for this portion of the IGF-
1 protein [17]. On the other hand, the extremely low synonymous mutation rates found on 
the dual-coding exon 6 across 29 mammalian species [19] suggests an enrichment of 
conserved regulatory elements in this region of the gene [18]. 
To better estimate the evolutionary pressure acting on IGF-1 domains we compared the 
non-synonymous (dN) and synonymous (dS) substitutions among 27 mammalian protein-
coding sequences of IGF-1 [32]. As shown in Table 1, there was substantial variation in 
the substitution rate within the gene regions encoding the different domains. Specifically, 
the Ea, Eb and Ec peptides showed a marked reduction of dS and only a slight increase of 
dN (significant only for Eb peptide) compared to the core region. Thus, the increase of 
the E-peptides dN/dS ratio was only marginally caused by an increase of dN, rather, it is 
likely due to a significantly smaller dS.  
Figure 6. Comparative analysis of 
human and mouse IGF-1 alternative 
splicing on wild-type and mutated 
minigenes. (A) Scheme of human 
(hMUT: TGvsGA) and mouse 
(mMUT: GAvsTG) mutant minigenes. 
The mutated bases are underlined. 
Position of the canonical (c5'ss) and 
non-canonical (*5'ss) cryptic 5' splice 
site used in mMUT minigene are also 
shown. (B and C) RT-PCR analysis of 
splicing assay performed in human 
HEK293T cells in presence of human 
(B) and mouse (C) IGF-1 mutant 
minigenes. RT-PCR was performed 
using primers as indicated in Fig. 4.  
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Table 1. All rates are estimated bymaximum likelihood using theMG94xREV_3x4 (local) codon 
substitution model. Mean (95% confidence intervals) and P values for the neutrality tests (dN–dS expected 
value = 0) are estimated by using parametric bootstrap based on 1000 replicates. Multiple comparisons 
among IGF-1 domains were performed with Analysis of variance boostrap based. Values in the same 
column bearing the same letter are not significantly different. The difference dN–dS was used in place of a 
more common ratio dN/dS, to avoid numerical issues when dS is zero, which is possible because HyPhy 
permits synonymous substitution rates to vary from site to site. * P < 0.05. 
 
 
This result confirms and extends previous findings [19], as we demonstrated strong 
reduction in the rate of on synonymous substitution both in the dual-coding region of 
exon 6 and in the single-coding region of exon 5. The strong evolutionary constraint on 
these exons is consistent with previous observations on alternatively spliced exons and is 
a signature of enrichment of functional elements, such as splicing enhancer or silencer 
elements [18, 21]. Accordingly, exon 5 contains binding sites for SRSF1 and hnRNP A1 
[8-9] and exon 5 alternative splicing is regulated by multiple splicing factors (Fig. 5). 
Intriguingly, recent studies demonstrated that protein-coding regions with low 
synonymous mutation rate are significantly enriched in Intrinsically Disordered Regions 
(IDRs) [42-43]. IDRs are polypeptide chains lacking a stable tertiary structure and the 
relaxed protein structural constraint provide an advantage when a protein-coding region 
simultaneously contains additional regulatory sites such as splicing enhancer and 
repressor sequences [43]. In order to analyze the structural properties of IGF-1 domains, 
we used DisCons [35], a sequence analysis tool able to identify protein disorder segments 
in an evolutionary context. As expected, among 27 mammalian species analyzed, the 
IGF-1 core region was predicted to be structured for the most part (Fig. 7). Conversely all 
the E-peptides were predicted to be almost completely ―constrained disorder‖ (Fig. 7). 
Namely, they were enriched in disorder-promoting residues and there was conservation 
of the property of disorder across mammals. These results do not depend on the disorder 
predictor algorithm because core results were qualitatively replicated using PONDR® 
VSL2 instead of IUPred (data not shown). Thus, during the course of mammalian 
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evolution, the structure of IGF-1 protein has been strongly conserved to maintain both the 
folded structure of IGF-1 core and its intrinsically disordered E-peptide tails. 
 
 
Figure 7. The sliding-window plot of the disorder conservation score of IGF-1 domains. The x axis 
represents the codon positions and the y axis shows disorder conservation profiles for IGF-1 core (black 
line), Ea (dashed line), Eb (dotted line) and Ec (gray line) peptides. The disorder conservation score for 
IGF-1 domains was calculated using the Disorder Conservation (DisCons) software with default parameters 
[35]. Low values correspond to order, high values to disorder. 
 
 
4. Discussion 
In the present work we provided evolutionary evidence supporting the emergence of a 
functional alternative exon 5 by exonization of a MIR-b element in mammalian IGF-1 
intron 4 (Fig. 1C). The exon 5 gain leads to the generation of two new IGF-1 E-peptides 
in the mammalian lineage: Eb and Ec. Our work indicates that the Ea peptide represents 
the ancestral E-peptide, common to all vertebrates, whereas Eb and Ec peptides are an 
evolutionary novelty appeared in Mammalia after the exonization of MIR-b transposon 
by exaptation [44]. The MIR element belongs to a family of transposable elements, which 
were actively propagating prior to mammalian radiation [45]. The MIR family, with a 
conservation rate between 60 and 70%, is one of the most diverged transposable element 
families identifiable in the human genome and only recent molecular approaches have 
improved their chances to be identified [27, 46]. For example, MIRs have a 95% chance 
of being missed by RepeatMasker if they are 50 bp in length, and 50% chance of being 
missed if 100 bp long [46]. In our study, we successfully identified and aligned the MIR-
b element to 103 nucleotides of the human IGF-1 exon 5 sequence only by using the 
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recently introduced ―hmmer‖ search engine of RepeatMasker, which uses the hidden 
Markov model search tool nhmmer and the Dfam library [27-28]. 
Several genome-wide studies have focused on the exaptation and exonization of MIR 
elements and found over 100 exonized MIR elements in the human genome, located both 
in the UTRs and the CDSs of annotated genes [47-48]. These studies showed that 
exonization of retroposed sequences can occur at any time following their insertion [49-
50]. Notably, both DNA sequence analyses performed in our study and mRNA analyses 
conducted in birds [13], fish [15] and reptiles [14] showed that IGF-1 exon 5 is absent in 
these vertebrates. Therefore, the emergence of IGF-1 exon 5 may have taken place 
around the mammalian diversification, which coincides with the timing of integration of 
the MIR elements [51]. 
The fact that MIR-b integrated in the IGF-1 exon 5 in its antisense orientation and 
contributed the splice sites and the oligopyrimidine tract may have facilitated its 
exonization immediately after integration [50]. Moreover, the 3'ss of IGF-1 exon 5 is 
located near the highly conserved core region of MIR-b, a feature that is present in many 
of the exonized-MIR described so far [38, 50] and that may have also contributed to its 
early exonization [50]. The conservation and the relative strength of the 3'ss of IGF-1 
exon 5, together with the maintenance of open reading frame in all main mammalian 
branches, suggest that during evolution the creation of a functional 3'ss inside the MIR-b 
integrated in the IGF-1 intron 4 was essential for successful exonization of this element 
[52]. 
Exonization of MIR-b in the mammalian IGF-1 gene also created a c5'ss that allows 
splicing of the IGF-1Ec variant in some species. Our analyses highlighted that, in contrast 
to the 3'ss, the mammalian c5'ss shows a considerable variation in term of the number of 
matching nucleotides to the vertebrate 5'ss consensus, with the most marked difference 
observed between humans and Muridae (Figs. 2A, and 2B and Supplementary Fig. S2). 
This led us to hypothesize that the spliceosome ability to recognize the c5'ss present in 
exon 5 may vary among mammalian species. Hence, the relative quantity of the IGF-1Eb 
and IGF-1Ec isoforms might also differ among mammals. Accordingly, we observed a 
differential expression pattern of IGF-1 isoforms across 9 different mammalian species 
analyzed (Fig. 3 and Supplementary Fig. S3). In particular, we found a marked difference 
in IGF-1 splicing between humans and Muridae, with a prevalence of IGF-1Eb in humans 
and IGF-1Ec in Muridae. In other mammalian species, including the primate macaque, 
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expression of the IGF-1Eb isoform was slightly higher or equal to the IGF-1Ec. Hence, 
the expression of IGF-1Eb is not restricted to humans, and this splice variant should no 
longer be considered human-specific [1, 39]. 
Divergence of alternative splicing represents one of the major driving forces to shape 
phenotypic differences across species [53-57]. Such changes could arise from divergence 
in cis-regulatory elements and/or trans-acting splicing factors [58]. Therefore, we next 
focused on the mechanism underlying the diversification of IGF-1 alternative splicing 
between human and mouse. For this purpose we constructed minigene-based systems of 
the alternatively spliced regions. Both minigenes recapitulated the splicing pattern 
observed in tissues, as the human and mouse minigenes produced very low levels of IGF-
1Ec and IGF-1Eb isoforms, respectively (Fig. 4 and Supplementary Fig. S4). 
Nevertheless, our minigene splicing assays also showed some small differences with 
respect to mouse tissues. In particular, mouse minigene produces a small amount of the 
IGF-1Eb variant, whereas this isoform is minimally expressed in mouse tissues (Figs. 3A 
and 4B and Supplementary Fig. S4). Moreover, alternative splicing in the mouse cell 
lines is mostly shifted toward the IGF-1Ec isoform (Fig. 4B and Supplementary Fig. S4). 
We suppose that these differences might be due to alterations of the genomic and 
epigenetic structure of the IGF-1 gene with respect to the minigene and/or to the different 
promoter present in the minigenes, as all these features have been shown to modulate the 
outcome of pre-mRNA splicing [40-41]. Nevertheless, our splicing assays indicate that 
the IGF-1 minigenes are reliable tools for the analysis of the splicing regulation of the 
corresponding endogenous genes. By using these minigenes, we tested whether cis-acting 
elements and/or trans-acting factors were responsible for the different splicing patterns 
observed in vivo between mouse and human IGF-1 mRNA. Alternative splicing outcome 
is determined by competition between splice sites in different exons and is influenced by 
trans-acting splicing factors, which in turn influence splice site recognition by the 
spliceosome [59]. As a consequence, both changes in the sequence of cis-acting elements 
and in the expression levels of splicing factors can modulate usage of specific exons [58, 
60]. Our results argue against changes in expression of specific splicing factors as a key 
determinant between the splicing differences across species. Indeed, we found that 
splicing of the mouse and human IGF-1 minigenes is mostly preserved across different 
cell type contexts (Fig. 4B and Supplementary Figure S4). Moreover, by modulating the 
expression of specific splicing factors it was not possible to promote splicing of the IGF-
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1Ec variant from the human minigene (Fig. 5B, left panel and Supplementary Fig. S5C) 
or endogenous human gene (Fig. 5D, left panel and Supplementary Fig. S5B). Similarly, 
neither the overexpression (Fig. 5B, right panel) nor the siRNA-mediated depletion (Fig. 
5D, right panel and Supplementary Figs. S5B and S5C) of splicing factors affected the 
expression of mouse IGF-1Eb isoform. We tested several hnRNPs and SR proteins, 
including SRSF1 and hnRNP A1 that were previously shown to regulate splicing of 
human IGF-1 [8-9]. Most of these trans-acting factors modulated the human IGF-
1Eb/IGF-1Ea and mouse IGF-1Ec/IGF-1Ea ratio, but none of them promoted the variant 
typical of the other species. Thus, our results suggest that the mechanism regulating this 
process does not rely on differential expression of species-specific trans-acting factors. 
An alternative possibility is the presence of cis-acting elements conferring species-
specific features to the exon 5 region. This hypothesis is in line with a recent study 
showing that most vertebrate specie-specific splicing patterns are primarily cis-directed 
[54, 58]. Accordingly, our analysis revealed that the consensus bases within the c5'ss are 
highly divergent among mammalian species (Fig. 2A and Supplementary Fig. S2). This 
observation led us to hypothesize that variation in the c5'ss strength might represent a 
potential source of species-specific splicing pattern. In support of this hypothesis, 
strengthening the human c5'ss by replacing it with the mouse one (hMUT: TGvsGA) was 
sufficient to promote usage of this splice site and to yield IGF-1Ec variant (Figs. 6A and 
6B). On the other hand, weakening the mouse c5'ss by swapping it with the human 
sequence (mMUT: GAvsTG) completely prevented its usage (Figs. 6A and 6C). 
Nevertheless, our results also indicate that other cis-acting elements likely contribute to 
the splicing pattern typically observed in tissues. First, we found that ―murinization‖ of 
the human c5‘ss only partially promoted splicing of the IGF-1Ec variant, but did not 
restore the IGF-1Ec/IGF-1Ea ratio observed with the mouse minigene and in mouse 
tissues (Figs. 3A and 6B). Furthermore, ―humanization‖ of the mouse c5'ss (mMUT: 
GAvsTG) prevented splicing of the IGF-1Ec variant, but did not promote IGF-1Eb 
variant (Figs. 6A and 6C). By contrast, we observed the selection of another cryptic 
splice site (*5'ss) located 38 nt downstream of the canonical one (Figs. 6A and 6C). 
Notably, this cryptic splice site is not conserved in the human gene, thus explaining the 
generation of the unusual IGF-1 mRNA variant instead of IGF-1Eb from the mMUT 
(GAvsTG) minigene. Moreover, overexpression of SRSF1 did not promote splicing of 
the IGF-1Eb variant from the mMUT (GAvsTG) minigene (Supplementary Fig. S6A). 
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SRSF1-dependent splicing of human IGF-1Eb requires its binding to a purine-rich 
enhancer located in exon 5 [8-9]. Sequence alignment of human and mouse exon 5 
revealed that the SRSF1 binding site is not conserved in the mouse (Supplementary Fig. 
S6B), possibly explaining the different behavior of SRSF1 in presence of the mouse 
minigene. These results strongly indicate that the strength of the c5'ss in exon 5 is a 
prerequisite for IGF-1 alternative splicing diversification between species, but also 
highlight that the co-evolution of additional exonic and intronic cis-regulatory elements 
contribute to such diversification [40-41]. Notably, our phylogenetic analysis of the c5'ss 
indicates that this splice site is relative strong not only in mouse but also in rat and all 
members of Cricetidae family (Fig. 2B and Supplementary Fig. S2). It is possible that 
strengthening of this c5'ss in a common ancestor of Muridae and Cricetidae, as well as 
the emergence of other splicing regulatory motifs, have determined the marked shift 
toward production of the IGF-1Ec isoform in these species and possibly a rodent-specific 
gain of functional properties. Interestingly, a recent study comparing the IGF-1 isoform 
expression in both mouse and human muscle samples at different ages, showed that the 
age-related change of IGF-1 splice variants is species-dependent and, unlike the mouse, 
only the human IGF-1Eb isoform was regulated during ageing in skeletal muscles [61]. 
Thus, the results obtained with murine models on IGF-1Ec/mechano growth factor 
regulation must be interpreted with caution and additional studies comparing IGF-1 
expression levels across species are needed to clarify the functional role of the IGF-1 
isoforms.  
Compared with mature IGF-1 relatively little is known about the mechanism of action of 
the different E peptides [1, 10-12]. From an evolutionary point of view the unchanged 
persistence over long evolutionary periods of MIRb-derived IGF-1 exon 5 implies its 
functional relevance [52, 62]. Moreover, E-peptides are protein-coding regions in which 
synonymous mutation rates are extremely low compared to IGF-1 core (Table 1), 
indicating additional sequence constraints beyond those dictated by the structure and 
function of the proteins. These additional constraints probably stem from the demands of 
regulatory sites involved in transcript splicing (Fig. 5) and [8-9, 18], nevertheless the 
presence of other regulatory sites such as specific RNA secondary structures and 
microRNA targets [20-21] cannot be excluded. The systematic analysis of the role of 
synonymous variants and the comparative splicing evaluation of mammalian sequence 
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divergences [63-64] will help to characterize the functional roles of these regulatory 
elements. 
Analysis of structural properties of IGF-1 domains adds a new layer of complexity to the 
function of E-peptides. Indeed, our work represents the first evidence that E-peptides 
contain disorder-promoting amino acids and that there is substantial evolutionary 
pressure to keep the different E-peptides as intrinsically disordered regions (IDRs) (Fig. 
7). There is a growing interest on IDRs since they are usually enriched in 
posttranslational modification sites and may exert a number of regulatory functions on 
their ―host‖ protein [65-66]. Intriguingly, we and others recently demonstrated that the 
IGF-1 protein retaining C-terminal E peptides are the predominant forms produced 
intracellularly, instead of mature IGF-1, and are subjected to extensive post-translational 
modifications [67-68], further hinting to their functional relevance. 
Exonization of previously non-coding sequences, together with creation of novel domain 
combinations, has been directly related to the increase of organismal complexity [66, 69-
71]. Accordingly, we propose that MIR-b exonization during mammalian evolution 
determined the IGF-1 exon 5 gain and hence the addition of two new disordered tails to 
IGF-1: the Eb and Ec-tails. Thus, novel exon and E-peptide combinations may have 
created new layers of regulation to mature IGF-1 in mammalian species. Targeting these 
regulatory elements may represent a new strategy to control IGF-1 bioavailability in 
different physiological/pathological conditions, with particular attention to possible 
differences between species. 
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Supplementary Figure S1. Partial sequence alignment of IGF-1 genomic sequences among 23 
amniote vertebrates retrieved from Ensembl database (23 amniote vertebrates Pecan). (A) The 
nucleotide sequences surrounding the alternatively spliced exon 6 were shown. The exon 6 sequences are in 
upper case letters and highlighted in gray, the intron sequences are in lower case letters. Bold letters 
indicates the 3‘splice site of exon 6, dashed lines indicate sequence gaps. Human chromosomal 
location:GRCh38:12:102537063:102537363. (B) The nucleotide sequences surrounding the alternatively 
spliced exon 5 were shown. The exon 5 sequences are indicated in upper case letters and highlighted in 
black and gray: the black nucleotides designated a part of exon 5 common to IGF-1Eb and IGF-1Ec 
variants, while the grey region is included only in the IGF-1Eb isoform; the intron sequences are in lower 
case letters. The 3‘ splice site and the cryptic 5' splice site (c5‘ss) of exon 5 are shown in bold. Dashed lines 
indicate sequence gaps. Human chromosomal location:GRCh38: 12:102458404:102458924. Ensembl 
Genomes: Human (Homo sapiens) GRCh38.p5; Mouse (Mus musculus) GRCm38.p4; Rat (Rattus 
norvegicus) Rnor_6.0; Rabbit (Oryctolagus cuniculus) OryCun2.0; Chimpanzee (Pan troglodytes) 
CHIMP2.1.4 ; Gorilla (Gorilla gorilla gorilla) gorGor3.1; Orangutan (Pongo abelii) PPYG2; Macaque 
(Macaca mulatta ) MMUL 1.0 ; Marmoset (Callithrix jacchus) C_jacchus3.2.1; Cat (Felis catus) 
Felis_catus_6.2; Dog (Canis lupus familiaris) CanFam3.1; Horse (Equus caballus) Equ Cab 2; Cow (Bos 
taurus) UMD3.1; Sheep (Ovis aries) Oar_v3.1; Pig (Sus scrofa) Sscrofa10.2; Opossum (Monodelphis 
domestica ) monDom5 ; Platypus (Ornithorhynchus anatinus ) OANA5; Turkey (Meleagris gallopavo ) 
Turkey_2.01; Chicken (Gallus gallus ) Galgal4; Zebra Finch (Taeniopygia guttata ) taeGut3.2.4; Anole 
lizard (Anolis carolinensis ) AnoCar2.0. 
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Supplementary Figure S2. Analyses 
of the 3′ and the 5′ splice-site signals 
of the IGF-1 exon 5 among 58 
mammalian genomic sequence 
datasets available at the UCSC 
genome browser. Evolutionary tree of 
58 organisms and the reconstructed 
ancestral state was adapted from the 
UCSC Genome Browser. Strength of 
3‘ and 5‘ss in exon5 obtained using the 
Maximum Entropy scores is shown for 
each species [Yeo G. and Burge CB. 
Comput. Biol. (2004);11:377-394]. 
Species with relative strong exon 5 
5‘ss are boxed. n.d.= not determined. 
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Supplementary Figure S3. Species-Specific differences in expression pattern of the IGF-1 isoforms 
among mammals. (A, B and C) 3‘ RACE-PCR sequences obtained from liver tissues of mammalian 
species (see Figure 3B). 3‘ RACE-PCR products were sequenced and the nucleotide sequences 
corresponding to IGF-1Ea (A), IGF-1-1Eb (B) and IGF-1Ec (C) were aligned using Clustal W [Thompson 
J.D. et al. Curr Protoc Bioinformatics Chapter 2 (2002) Unit 23]. Poly(A) Signal Miner 
(http://dnafsminer.bic.nus.edu.sg/PolyA.html) was used to predict poly(A) signal and, if detected in the 
sequences, highlighted in bold. PCR product sizes (nucleotides) for each sequence are indicated in 
parentheses. The nucleotide sequences matched to the following NCBI Reference Sequence (RefSeq): IGF-
1Ea (Pig 350 and 283: NM_214256; Rabbit 537: XM_008256720/ XM_008256719; Macaque 537: 
NM_001260726; Human 627 and 534: NM_000618/ NM_001111284; Mouse 391: NM_001314010/ 
NM_001111275/ NM_001111276; Rat 381: NM_178866/ NM_001082479); IGF-1Eb (Pig 548 and 490: 
XM_005664196/ XM_005664195; Rabbit 725 and 678: XM_008256717/ XM_008256716; Macaque 685: 
NC_027903; Human 734, 688 and 491: NM_001111285); IGF-1Ec (Rabbit 589: XM_008256718; 
Macaque 589: XM_015152532/ XM_015152534; Pig 401: XM_005664197; Rat 466: NM_001082477/ 
NM_001082478; Mouse 539 and 450: NM_010512/ NM_001111274). (D) Amplification of IGF-1Eb and 
IGF-1Ec isoforms in liver tissue of goat, sheep, pig and cow with isoform-specific PCR strategy. Map of 
IGF-1 gene with the relative position of primers used to separately amplify IGF-1 isoforms is shown on the 
left. The IGF-1F forward primer is common to all mammals (5‘-CGTGGATGAGTGCTGCTTC-3‘); the 
IGF-1R1 reverse primer is specific for IGF-1Eb amplification in goat, sheep and cow (5‘-
TCCTTCTGTTCCCCTCCTGG-3‘); the IGF-1R2 reverse primer is specific for pig IGF-1Eb isoform (5‘-
CCCTCCTGGGTGTTTCTTTG-3‘); the IGF-1R3 reverse primer is specific for IGF-1Ec amplification in 
all mammals (5‘-CTTCAAATGTACTTCCTTTCC-3‘). The conventional PCR was carried out as 
described in Material and Methods. The PCR products were loaded on 4.0% agarose gel and DNA 
fragments were eluted from gel, subcloned and sequenced. The nucleotide sequences matched to the 
following NCBI Reference Sequence (RefSeq): IGF-1Eb (Goat: XM_013963970/ XM_013963971/ 
XM_005680531/ XM_005680532/ XM_005680533/ XM_005680534/ XM_005680535; Sheep: 
NC_019460; Cow; XM_015471061/ XM_015471062/ XM_015471063/ XM_015471064; Pig: 
XM_005664196/XM_005664195); IGF-1Ec (Goat: NC_022297; Sheep: NC_019460; Cow: 
XM_005206490; Pig: XM_005664197). 
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Supplementary Figure S4. The expression pattern of human and mouse IGF-1 minigenes in different 
human and mouse cell lines. RT-PCR analysis of splicing assay of human (hIGF-1; upper panel) and 
mouse (mIGF-1, lower panel) IGF-1 minigenes performed in the indicated human and mouse cell lines. 
Untransfected cells (-) or cells transfected with the empty vector (vect.) were used as a PCR control. L34 
was used as loading control. A diagram of primers position used for RT-PCR analysis is also shown. 
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Supplementary Figure S5. Cis-acting elements contribute to species-specific variation of IGF-1 
alternative splicing. (A,B) Representative Western-blot and RT-PCR analysis showing the expression 
level of hnRNP, SR and SR-like proteins in the splicing assay experiments. β-actin was used as loading 
control. C) RT-PCR analysis of splicing assay of human (hIGF-1) and mouse (mIGF-1) IGF-1 minigenes 
performed in HEK293T cells silenced with the indicated siRNAs. A representative western-blot showing 
the expression level of the silenced proteins is also shown. β-actin was used as loading control. D) RT-PCR 
analysis of splicing assay of endogenous human IGF-1 gene performed in LNCaP treated for 3hrs with 
100µM Sodium Arsenite (Na3AsO3). 
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Supplementary Figure S6. (A) RT-PCR analysis of splicing assay performed in HEK293T cell line of 
mouse and human wild-type (WT), hMUT (TGvsGA) (left panel) and mMUT (GAvsTG) (right panel) 
IGF-1 minigenes in presence or not of SRSF1. The ratio between IGF-1Ec/IGF-1Ea (left panel) and IGF-
1Eb/IGF-1tot (right panel) is also indicated. n.d.= not determined. A diagram of primers position used for 
RT-PCR analysis is also shown. (B) Representation of SRSF1 binding site (black box) in IGF-1 exon 5 
identified by Smith PJ. et al. [Endocrinology (2002) 143:146-154] and Cléry A. et al. [PNAS (2013) 
110:E2802-E2811]. Canonical cryptic 5' splice site (c5'ss) is also indicated. 
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Supplementary file S1. IGF-1 isoform nucleotide sequences of the 27 mammalian species used for 
IGF-1 evolutionary analysis. The ―CDS FASTA alignment from multiple alignments‖ data, derived from 
the ―multiz100way‖ alignment data prepared from 100 vertebrate genomes [Blanchette M. et al. Genome 
Res (2004), 14, 708-715], were downloaded using the Table Browser tool of the UCSC Genome Browser. 
Sequences were subsequently realigned using MUSCLE [Edgar R.C. Nucleic Acids Res (2004), 32, 1792-
1797] and protein-coding sequences from 27 mammalian species were extracted from these alignment 
datasets. The phylogenetic tree in Newick format was constructed using the IGF-1 core alignment of 
 
  
E1 E2 E3 E4 E5 E6
pA
c5'ss
pA
h/mIGF-1Ea_Fw h/mIGF-1Ea_Rv
h/mIGF-1Eb_Fw h/mIGF-1Eb_Rv
h/mIGF-1Ec_Fw h/mIGF-1Ec_Rv
Supplementary Table S1. List of the oligonucleotides used in this study. 
 Oligonucleotide name sequence 5’ 3’ Experiment Primer annealing positions 
/ hIGF1-Ea_Fw GACATGCCCAAGACCCAGAAGGA Real time RT-PCR (human and macaque)  
/ hIGF1-Ea_Rv CGGTGGCATGTCACTCTTCACTC Real time RT-PCR (human and macaque) 
/ hIGF1-Eb_Fw CTACCAACAAGAACACGAAGTCTCA Real time RT-PCR (human and macaque) 
/ hIGF1-Eb_Rv TCTGATCTGCAGACTTGCTTCTG Real time RT-PCR (human and macaque) 
/ hIGF1-Ec_Fw GCCCCCATCTACCAACAAGAACAC Real time RT-PCR (human and macaque) 
/ hIGF1-Ec_Rv TCCCTCTACTTGCGTTCTTCAAA Real time RT-PCR (human and macaque) 
/ mIGF1-Ea_Fw GCCCAAGACTCAGAAGGAAGTAC Real time RT-PCR (mouse) 
/ mIGF1-Ea_Rv CGGTGATGTGGCATTTTCTG Real time RT-PCR (mouse) 
/ mIGF1-Eb_Fw CACACTGACATGCCCAAGAC Real time RT-PCR (mouse) 
/ mIGF1-Eb_Rv AGTTGCCTCCGTTACCTCCT Real time RT-PCR (mouse) 
/ mIGF1-Ec_Fw GCTGCAAAGGAGAAGGAAAG Real time RT-PCR (mouse) 
/ mIGF1-Ec_Rv CGGTGATGTGGCATTTTCTG Real time RT-PCR (mouse) 
1 mIGF1-KPN1_Fw (P5) ACGGTACCACAAGCCCACAGG Mouse minigene (5’end)/splicing assay of endog. gene  
2 mIGF1-SalI_Rv ACGTCGACCCCGATGTTCTTTGG Mouse minigene (5’end) 
3 mIGF1-SalI_Fw ACGTCGACCCCGATGTTCTTTGG Mouse minigene (3’end) 
4 mIGF1-NotI_Rv ACGCGGCCGCTTGCACCCTCCTGGAAA Mouse minigene (3’end) 
5 hIGF1-EcoRI_Fw (P5) ACGAATTCACAAGCCCACAGGGTA Human minigene (5’end)/splicing assay of endog. gene 
6 hIGF1-SalI_Rv ACGTCGACCCTAAACCCTGGACT Human minigene (5’end) 
7 hIGF1-SalI_Fw ACGTCGACTCTAGAGGCCAGAAGGCTGGATT Human minigene (3’end) 
8 hIGF1-NotI_Rv ACGCGGCCGCTGTTGCACCCTTACAG Human minigene (3’end) 
9 mIGF1-GAvsTG_Fw AAGGAAAGGTTGGCCAAAGACA Mouse GAvsTG minigene (5’end) 
10 hIGF1-TGvsGA_Fw AAGGAAAGGTGAGCCAAAGACA Human TGvsGA minigene (5’end) 
11 PCI_Fw (P1) GGTGTCCACTCCCAGTTCAA Splicing assay  
12 m/hIGF1-Ex6_Rv (P3) CACTTCCTCTACTTGTGTTCTTCAAATGTAC Splicing assay 
13 mIGF1-Ex5_Rv (P2) TTTCCGAGTTGCCTCCGTTA Splicing assay 
14 hIGF1-Ex5_Rv (P2) TTCCCCTCCTGGATGTGTCT Splicing assay 
15 mIGF1-Ex4tot_Rv (P4) GATCCAGCTCCGGAAGCAA Splicing assay 
16 hIGF1-Ex4tot_Rv (P4) TTGAGGGGTGCGCAATACAT Splicing assay 
17 Tra2α_Fw AAGGAGCCGAAGCCATTCTC Expression level evaluation   
18 Tra2α_Rv GCCAAACACTCCAAGGCAAG Expression level evaluation  
19 Tra2β_Fw CCAGCAGTCTAGGCGTTCAA Expression level evaluation  
20 Tra2β_Rv TGATCCTACGCCCATCAAGC Expression level evaluation  
21 β-actin_Fw ATGATGATATCGCCGCGCTC Expression level evaluation  
22 β-actin_Rv AGGGTGAGGATGCCTCTCTT Expression level evaluation  
23 Control siRNA  AGACGAACAAGUCACCGAC-[dT] [dT] Protein depletion experiments  
24 SRSF1 siRNA CCAAGGACAUUGAGGACGT-[dT] [dT] Protein depletion experiments  
25 hnRNP A1 siRNA CAGCUGAGGAAGCTCTTCA-[dT] [dT] Protein depletion experiments  
26 TRA2 siRNA # 1 AAGCUAAAGAACGTGCCAA-[dT] [dT] Protein depletion experiments  
27 TRA2 siRNA # 2 GCCGAUGUGUCUAUUGUAU-[dT] [dT] Protein depletion experiments  
28 TRA2 siRNA # 3 CUGUUGUCUUGGAGUAUUU-[dT] [dT] Protein depletion experiments  
 
P3P2P4P1 pA
4 5 6
pA
E1 E2 E3 E4 E5 E6
pA
c5'ss
pA
#1;#5 #2;#6
#3;#7 #4;#8
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Abstract 
 
Background IGF1 is a key regulator of tissue growth and development and has been 
implicated in the initiation and progression of various cancers, including breast cancer. 
Through IGF1 mRNA splicing different precursor pro-peptides, i.e., the IGF1Ea, IGF1Eb 
and IGF1Ec pro-forms, are formed whose biological roles in the pathogenesis of breast 
cancer have not been established yet. The objective of this study was to assess the 
biological activity of the IGF1 pro-forms in human breast cancer-derived cells. 
Methods The different IGF1 pro-forms were generated through transient transfection of 
HEK293 cells with the respective vector constructs. The resulting conditioned media 
were applied in vitro to MCF7, T47D and ZR751 breast cancer-derived cell cultures. The 
recombinant human IGF1 pro-forms were also tested for their binding affinity to an anti-
IGF1 specific antibody by immunoprecipitation. To determine whether the IGF1 pro-
forms induce cell proliferation, mature IGF1 was neutralised in HEK293-derived 
conditioned media. 
Results We found that the IGF1 pro-forms were the only forms that were produced intra-
cellularly, whereas both mature IGF1 and the IGF1 pro-forms were detected extra-
cellularly. We also found that E peptides can impair the IGF1 pro-form binding affinity 
for the anti-IGF1 antibody and, thus, hamper an accurate measurement of the IGF1 pro-
forms. Additionally, we found that the IGF1 antibody can completely inhibit IGF1-
induced breast cancer cell proliferation and IGF1 receptor (IGF1R) phosphorylation, 
wheras the same antibody was found to only partially inhibit the biological activity of the 
pro-forms. Moreover, we found that the IGF1 pro-form activities can completely be 
inhibited by neutralising the IGF1R. Finally, we compared the bioactivity of the IGF1 
pro-forms to that of mature IGF1, and found that the IGF1 pro-forms were less capable of 
phosphorylating the IGF1R in the breast cancer-derived cells tested. 
Conclusions Our data indicate that IGF1 pro-forms can induce breast cancer cell 
proliferation via the IGF1R, independent from the mature IGF1 form. These results 
underline the importance of an accurate assessment of the presence of IGF1 pro-forms 
within the breast cancer microenvironment. 
 
Keywords: IGF1 pro-forms ∙ breast cancer ∙ IGF1 receptor 
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1. Introduction 
 
Insulin-like growth factor-1 (IGF1) plays an important role in normal tissue growth and 
development. In addition, several studies have shown associations between circulating 
IGF1 levels and the risk to develop breast cancer[1-3]. Since the IGF1 receptor (IGF1R) 
is over-expressed in about 90% of the breast cancer cases and since IGF1R levels are 
higher in breast cancer cells than in normal breast tissues [4], targeting the IGF1 system 
appears to be an attractive therapeutic option. 
IGF1 is synthesized as a precursor protein requiring proteolysis at both the N- and C- 
termini to produce mature IGF1 [5, 6]. The full-length IGF1 precursor, pre-pro-IGF1, 
contains an N-terminal signal peptide, a 70 amino acid mature IGF1 peptide and a C-
terminal E-peptide extension [7]. The signal peptide is cleaved off during translation in 
the endoplasmic reticulum, resulting in pro-IGF1. The E-peptide can subsequently be 
cleaved off from pro-IGF1 by proprotein convertases like furin, resulting in mature IGF1. 
The uncleaved pro-IGF1 has, however, also been detected in vitro in conditioned media 
and in vivo in sera [8-13]. 
The complexity of the IGF1 system is further enhanced by alternative splicing of the 
IGF1 mRNA, thereby producing multiple IGF1 isoforms (IGF1 pro-forms) that, while 
bearing the same mature IGF1 sequence, contain different N- and C-terminal extensions 
[5]. In humans, the alternative splicing that occurs at the 3‘ end of the IGF1 mRNA gives 
rise to three possible IGF1 pro-forms with different C-terminal extensions, called the Ea, 
Eb and Ec peptides (Fig. 1A). Another level of complexity results from glycosylation of 
the IGF1Ea pro-form, as the human Ea-peptide of IGF1 contains an N-linked 
glycosylation site at Asn92 [6]. 
Recent studies in humans have shown that the IGF1 splice variants can be differentially 
transcribed in response to varying conditions and pathologies, such as skeletal muscle 
damage [14, 15], endometriosis [16], or prostate [17], cervix [18] and colorectal cancer 
[19]. Moreover, although it is generally assumed that IGF1 exerts its biological actions 
predominantly through the mature peptide, different biological activities have been 
reported for the different IGF1 pro-forms and/or for their E-peptides, either exogenously 
administrated or over-expressed in various in vitro models [6, 14, 17, 20, 21].  
Even though circulating IGF1 levels are affected by physical activity and diet [22], the 
biological significance of the IGF1 pro-forms is currently unknown. Also, the 
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physiological and molecular mechanisms that regulate their expression and their 
circulating levels are unclear [6]. Despite the fact that the regenerative properties of the 
IGF1Ea pro-form in cardiac and skeletal muscles has extensively been documented [21, 
29, 30], little is known about the role of the various IGF1 pro-forms in cancer. 
Here we report the biological activity of IGF1 pro-forms on human breast cancer-derived 
cell lines. We analysed the intracellular and extracellular expression patterns of the IGF1 
pro-forms in transfected HEK293 cells and conditioned media. MCF7, T47D and ZR751 
breast cancer-derived cells were grown in conditioned media to assess whether the IGF1 
pro-forms induce cell proliferation and/or IGF1R phosphorylation. We further evaluated 
the bioactivities of the IGF1 pro-forms compared to the mature IGF1 form, in terms of 
cellular proliferation and IGF1R, AKT or ERK1/2 phosphorylation. 
 
 
2. Materials and Methods 
 
2.1 Cell cultures 
The MCF7, T47D, ZR751 and HEK293 cell lines were obtained from the American Type 
Culture Collection (ATCC, Rockville, MD, USA). The cells were cultured in DMEM 
(MCF7 and HEK293) or RPMI-1640 (T47D and ZR751) media supplemented with 10% 
fetal bovine serum, 10 mg/L insulin (MCF7 and T47D), 2 mmol/L L-glutamine, 1x MEM 
Non-essential Amino Acid Solution, 0.1 mg/ml streptomycin and 0.1 U/L penicillin 
(growth media). Cells were maintained in a humidified incubator (5 % CO2) at 37 °C 
during at maximum fifteen passages. 
For the experiments, the breast cancer-derived cells were starved overnight in red phenol-
free DMEM or RPMI-1640 media without FBS, after which the media were replaced by 
the same media with or without hormones. All cell culture materials were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). 
 
2.2 MTS cell proliferation assay 
Triplicate samples of 5×10
3
 MCF7, T47D and ZR751 cells in 96-well plates were treated 
for 4 days with mature IGF1 or IGF1 pro-forms. Cell viabilities were evaluated using a 
CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, 
WI, USA) based on the ability of viable cells to convert soluble tetrazolium salt (MTS) 
83 
 
into a formazan product, as reported before [23]. The results are expressed as the relative 
number of viable cells in treated samples relative to controls (untreated cells). 
 
2.3 Plasmid constructs 
Plasmid constructs containing sequences encoding human prepro-IGF1Ea, prepro-
IGF1Eb and prepro-IGF1Ec were kindly provided by Dr. Joanne Tonkin and Dr. 
Tommaso Nastasi, European Molecular Biology Laboratory (EMBL), Monterotondo 
(Rome, Italy). Each plasmid contained DNA encoding the class 1 IGF1 48-amino acid 
signal peptide, the mature 70-amino acid IGF1 peptide, the first 16 amino acids (aa) of 
the COOH-terminal peptide, and C-terminal sequences encoding either the Ea (19 aa), the 
Eb (61 aa) or the Ec (24 aa) peptide. 
 
2.4 Cell transfection assays 
HEK293 cells were cultured in DMEM without antibiotics at a density of 1x10
6
/well in 6 
well plates. After overnight incubation, the cells were transfected using a TransIT®-LT1 
Transfection Reagent (Mirus Bio, Madison, WI, USA) according the manufacturer‘s 
instructions. Briefly, 2.5 µg plasmid DNA was added to 250 µl growth medium without 
FBS and antibiotics and gently mixed, after which 7.5 µl TransIT®-LT1 Reagent was 
added. After a 30 min incubation at room temperature, the mixture was added drop-wise 
to the cells. After a 5 hour incubation, the culture medium was replaced by red phenol-
free DMEM without FBS. Next, the cells were incubated for another 24 hours, after 
which supernatants were collected, clarified by 1,000 rpm centrifugation for 5 min, and 
directly used or stored at -80° C for further experiments. Transfected HEK293 cells were 
lysed for Western blotting or real-time PCR analyses. To increase IGF1 pro-form 
production, a furin convertase inhibitor chloromethylketone (CMK) (Enzo Life Sciences 
Inc., Farmingdale, NY, USA) was added at a 2.5 µmol/L final concentration during 
transfection. For E peptide cleavage, supernatants without CMK were treated with 10 
nmol/L recombinant furin (R&D Systems Ltd, Minneapolis, MN, USA) overnight at 
room temperature with gently shaking [6]. 
 
2.5 ELISA assay 
For the quantitative determination of human IGF1 concentrations in transfected HEK293 
cell culture supernatants, a commercially available ELISA kit was used according to the 
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manufacturer‘s instructions (Quantikine® ELISA DG100, R&D Systems). Data were 
acquired in duplicate using a microplate reader (Multiskan EX, Thermo Fisher Scientific, 
Waltham, MA, USA) at 450 nm, after which the results were averaged. 
 
2.6 Western blot analysis 
MCF7, T47D, ZR751 and HEK293 cells were processed for Western blot analysis as 
previously reported [24]. Briefly, cells were lysed for 20 minutes on ice with 20 mmol/L 
HEPES (pH 7.9), 25 % v/v glycerol, 0.42 mol/L NaCl, 0.2 mmol/L EDTA, 1.5 mmol/L 
MgCl2, 0.5 % v/v Nonidet P-40, 1 mmol /L DTT, 1 mmol/L Naf, 1 mmol/L Na3VO4, and 
1× complete protease inhibitor cocktail (Roche Diagnostics Ltd, Mannheim, Germany). 
The cell lysates were frozen and thawed twice and clarified by centrifugation at 12,000 
rpm for 10 minutes at 4°C. The proteins from the HEK293 cell supernatants were 
concentrated using an Amicon Ultra 3K centrifugal filter unit (Merck Millipore, Billerica, 
MA, USA). Total cell lysates and concentrated supernatants were fractionated by SDS-
PAGE and electroblotted onto nitrocellulose membranes (0.2 μm pore size) (Bio-Rad 
Laboratories Inc., Hercules, CA, USA). The resulting blots were probed with the 
following primary antibodies: anti-phospho-IGF1 Receptor β (3024), anti-IGF1 Receptor 
β (3027), anti-phospho-p44/42 (ERK1/2) (9101), anti-p44/42 (ERK1/2) (9102), anti-
phospho-Akt (Ser473) (9271) and anti-Akt (9272), all purchased from Cell Signalling 
Technology (Beverly, MA, USA) and anti-IGF1 (I8773) purchased from Sigma-Aldrich. 
Protein bands were detected using a horseradish peroxidase-conjugated secondary 
antibody (Bio-Rad Laboratories Inc). The blots were treated with enhanced 
chemiluminescence reagents (ECL Kit, Amersham Bioscience, Arlington Heights, IL, 
USA), and the immunoreactive bands were detected and quantified using a Chemi-Doc 
System (Bio-Rad Laboratories Inc) equipped with Quantity One software. 
 
2.7 RNA extraction, cDNA synthesis and qRT-PCR 
Total RNA was extracted and purified using an Omega Bio-Tek E.Z.N.A.
TM
 Total RNA 
kit (Omega Bio-Tek, Norcross, GA, USA) according to the manufacturer‘s instructions. 
After digestion with DNase I (Qiagen, Hilden, Germany), cDNA was synthesized from 1 
μg of total RNA using Omniscript RT (Qiagen) and random hexamers. Subsequently, 
quantitative real-time PCR was performed using an Applied Biosystems StepOnePlus
TM
 
Real Time PCR System in conjunction with a TaqMan® Universal PCR Master Mix No 
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AmpErase® UNG and commercially available 6-carboxyfluorescein (FAM)-labeled 
TaqMan primers for human IGF1 (Hs01547656_m1) and GAPDH (Hs03929097_g1), 
respectively (Applied Biosystems, Foster City, CA, USA). mRNA expression data were 
generated using the 2
–ΔCT
 method. The real-time PCR conditions were: 95°C for 10 min 
followed by 40 cycles of two-steps at 95°C for 15 sec and 60°C for 1 min. The specificity 
of the amplification products was confirmed by thermal denaturation plots and by 
separation in 4% agarose gels. 
  
2.8 Immunoprecipitation assay 
To prepare magnetic beads for immunoprecipitation, Dynabeads® Protein G (Life 
Technologies, Monza, Italy) were washed twice with PBS/0.1% Tween-20 and incubated 
with 5 μg of IGF1 antibody (Sigma) for 1 hour at room temperature with end-over-end 
rotation. The bead-antibody complexes were washed with PBS/0.1% Tween-20 after 
which the IGF1 monoclonal antibody was covalently bound to the beads using BS
3
 as 
cross-linkers according to the manufacturer‘s instructions (Thermo Scientific, Milano, 
Italy). Subsequently, the beads were washed three times with PBS/0.1% Tween-20 to 
remove non-covalently bound antibodies and incubated with 1 ml of tissue culture 
supernatant for 1 hour at room temperature with end-over-end rotation. Finally, the beads 
were washed three times with washing buffer and the bound proteins were eluted by 
heating the beads for 10 minutes at 70°C in 20 μl elution buffer and 10 μl SDS-PAGE 
sample buffer. 
 
2.9 IGF1 and IGF1R neutralisation 
To neutralise IGF1 activity, culture medium containing IGF1 or IGF1 pro-forms was 
incubated with 3 µg/ml anti-IGF1 antibody (Sigma) for 1 hour at 37°C. Next, MCF7 and 
ZR751 cells were cultured in IGF1-neutralised media to evaluate their effects on cell 
proliferation and IGF1R phosphorylation. To neutralise IGF1R activity, cells were pre-
incubated with 5 µg/ml of anti-IGF1R antibody (R&D Systems) for 1 hour at 37°C and 
treated with IGF1 or IGF1 pro-forms to evaluate their effects on cell proliferation and 
IGF1R phosphorylation. 
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2.10 Statistical analyses 
Statistical analyses were performed using one-way or two-way ANOVA as appropriate, 
followed by Bonferroni‘s multiple comparison post hoc tests (GraphPad Software, Inc., 
La Jolla, CA, USA). 
 
 
3. Results 
 
3.1 Expression of IGF1 and its pro-forms in HEK293 transfected cells 
IGF1 pro-forms were generated through transient transfection of HEK293 cells with 
specific plasmid vector constructs for each pro-form. The resulting cell lysates and 
supernatants were analyzed by Western blotting using an antibody directed against the 
mature region of IGF1. The amount of IGF1 and its pro-forms in the supernatants were 
quantified by ELISA and concentrated using filter columns, after which 50 ng was loaded 
on gel. By doing so, we found that the IGF1 pro-forms were the only forms produced 
intra-cellularly by the transfected HEK293 cells, whereas both mature IGF1 and the IGF1 
pro-forms were detected extra-cellularly (Fig. 1b). Notably, both glycosylated and non-
glycosilated IGF1Ea were detected in the cell lysates, whereas only the glycosylated 
IGF1Ea pro-form (gly-IGF1Ea) was secreted. Moreover, we found that both IGF1Eb and 
IGF1Ec showed additional higher molecular weight bands, suggesting that also these pro-
forms are subject to extensive post-translational modification. 
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Fig. 1. Human IGF1 pro-forms. (a) Schematic presentation of mature IGF1 and IGF1 pro-forms. (b) 
Western blot analysis of HEK293 cells transfected with specific constructs. Cell lysates and supernatants 
(SN) were analysed 24 hours post-transfection using an anti-IGF1 antibody. Images are representative of 
three replicates giving similar results. 
 
 
3.2 E peptides impair an accurate quantification of the IGF1 pool 
As previously reported [13], the quantity of the gly-IGF1Ea pro-form may be 
underestimated in non-denaturating conditions such as ELISA assays, suggesting that the 
E peptide could impair the binding affinity between IGF1 and anti-IGF1 antibodies. In 
order to evaluate whether the ELISA assay provides an accurate measure of the IGF pool, 
HEK293 cells were transfected with IGF1Ea, IGF1Eb and IGF1Ec expression vectors 
with or without the furin inhibitor CMK. In doing so, the same IGF1 mRNA expression 
efficiencies were obtained in CMK treated and untreated cells (Supplementary Fig. S1). 
Next, the supernatants were analysed by both ELISA and Western blotting after filter 
column concentration for IGF1 quantification. As shown in Fig. 2a, Western blot analysis 
of conditioned media from the CMK treated or untreated HEK293 cells did not show any 
significant variation in the total IGF1 pool (i.e., mature IGF1 and pro-forms). IGF1 
quantification by ELISA of gly-IGF1Ea enriched medium did not show any change after 
CMK treatment, whereas a significant reduction of IGF1 was observed, after CMK 
treatment, in IGF1Eb and IGF1Ec enriched media (Fig. 2b). Therefore, we conclude that 
the E peptides in the IGF1 pro-forms may impair their affinity to the anti-IGF1 antibody 
under non-denaturating conditions and, hence, hamper the accuracy of the ELISA assay. 
To further confirm this notion, conditioned media obtained from HEK293 cells 
transfected with the IGF1 pro-form vectors were immunoprecipitated with Dynabeads 
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coupled to an anti-IGF1 antibody. The proteins bound to the bead-antibody complex were 
subsequently recovered and analysed by Western blotting. As shown in Fig. 2c, the gly-
IGF1Ea pro-form was, at least partially, recognized by the anti-IGF1 antibody, whereas 
the IGF1Eb and IGF1Ec pro-forms were only weakly recognized by the anti-IGF1 
antibody in the immunoprecipitates. These results confirm that E peptides, in the IGF1 
pro-forms, hamper an accurate measurement of the IGF1 pool. 
 
 
 
   
 
 
3.3 Biological activity of IGF1Ea, IGF1Eb and IGF1Ec enriched media 
Next, the activity of each IGF1 pool in the MCF7 and ZR751 human breast cancer-
derived cells was evaluated in terms of cell proliferation and IGF1R phosphorylation. 
Cell proliferation was evaluated using a MTS cell proliferation assay, an indirect assay 
Fig. 2. Mature IGF1 and IGF1 pro-form affinities 
to anti-IGF1 antibody. Quantification of mature 
IGF1 and IGF1 pro-forms from a representative 
set (n = 3) of transfected HEK293 cells using (a) 
Western blot analysis and (b) ELISA. The furin 
convertase inhibitor chloromethylketone (CMK) 
was used to increase the IGF1 pro-form 
production. c Representative Western blot after 
immunoprecipitation of mature IGF1 and 
HEK293 supernatants containing IGF1 pro-forms 
using Dynabeads-anti-IGF1 complexes. Arrows 
indicate IGF1 pro-forms. 
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that evaluates the cellular metabolic activity. First, MCF7 cells were grown in the 
presence of increasing concentrations of mature IGF1. After 4 days of culture, the cellular 
proliferation was evaluated by both the MTS assay and by cell counting. As shown in 
supplementary Fig. 2S, both methods yielded similar results. Subsequently, the cells were 
cultured in IGF1 pro-form-enriched media, previously normalised to 10 ng/ml using an 
ELISA assay. Since it was not possible to accurately quantify the total IGF1 pool (i.e., 
mature IGF1 and pro-forms) in IGF1 pro-form-enriched media using an ELISA assay 
(see above), we were unable to directly compare the effects between each IGF1 pool. We 
found, however, that the IGF1 pro-form-enriched media significantly induced both MCF7 
and ZR751 cell proliferation compared to the control (unstimulated) cells (Fig. 3a and b). 
It was not possible to evaluate the proliferation response in T47D cells due to their poor 
growth in serum free medium (not shown). Supernatants of un-transfected HEK293 cells 
or HEK293 cells transfected with an empty vector did not affect cell proliferation (not 
shown). Next, the anti-IGF1 antibody was used to neutralize the activity of mature IGF1. 
As shown in Fig. 3a and b, we found that the anti-IGF1 antibody completely inhibited the 
IGF1-induced cell proliferation, whereas the same antibody only partially inhibited 
MCF7 (Fig. 3a) and ZR751 (Fig. 3b) cell proliferation induced by HEK293 supernatants 
containing the IGF1 pro-forms. Moreover, we found that the anti-IGF1 antibody 
markedly inhibited the IGF1R phosphorylation induced by mature IGF1, but not the 
phosphorylation induced by the IGF1 pro-forms (Fig. 3c and d). These results suggest 
that the IGF1 pro-forms can induce breast cancer cell proliferation and IGF1R 
phosphorylation. The activity of the IGF1 pro-forms is IGF1R dependent. In fact, by 
inhibiting IGF1R activation with an anti-IGF1R antibody, neither cell proliferation nor 
IGF1R phosphorylation, induced by either mature IGF1 or the IGF1 pro-forms, were 
detected (Fig. 3). 
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Fig. 3. IGF1 pro-forms induce cell proliferation via the IGF1R. (a) MCF7 and (b) ZR751 cells were 
cultured 4 days with mature IGF1 (10 ng/ml) or HEK293 supernatants containing IGF1 pro-forms (means ± 
SEM; n = 3). Cell proliferation was evaluated by MTS assay. Data are expressed as relative proliferation vs. 
unstimulated cells. *** Significantly different, P < 0.001; ns: not significantly different; 1-way ANOVA 
followed by Bonferroni's multiple comparison test. Representative Western blot (n = 3) of phospho-IGF-R 
levels in (c) MCF7 and (d) ZR751 cells stimulated for 10 minutes with mature IGF1 or HEK293 
supernatants containing IGF1 pro-forms. IGF1R was used as a loading control. Densitometry values for 
specific proteins relative to unstimulated cells (set as one-fold) are included below the lanes. An anti-IGF1 
antibody was used to neutralise the biological activity of IGF1. An anti-IGF1R antibody was used to inhibit 
IGF1R phosphorylation/activation. 
 
 
3.4 Biological activity of mature IGF1 versus the IGF1 pro-forms 
To evaluate the activity of the IGF1 pro-forms compared to mature IGF1, supernatants 
containing different ratios of mature IGF1 and pro-forms were produced. Recombinant 
furine was used to induce E peptide cleavage and to increase the amount of mature IGF1. 
The furin convertase inhibitor CMK was used to inhibit E peptide cleavage and to 
increase the IGF1 pro-form amounts during transfection. The supernatants were 
concentrated using filter columns and analysed by Western blotting using an anti-IGF1 
antibody. We found that CMK markedly increased the IGF1 pro-form amounts, while in 
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the furine-treated supernatants the IGF1 pro-forms were not detectable (Fig. 4a, 4b and 
4c). 
 
 
Fig. 4. IGF1 pro-form production and E peptides cleavage. Representative Western blots are shown for 
supernatants of HEK293 cells transfected with specific constructs for the (a) IGF1Ea, (b) IGF1Eb and (c) 
IGF1Ec pro-forms. Mature IGF1 and IGF1 pro-forms were detected using an anti-IGF1 antibody. The furin 
convertase inhibitor CMK was used to increase IGF1 pro-form production. Recombinant furin was used to 
induce E peptides cleavage. 
 
 
Next, MCF7 cells were cultured in two-fold diluted conditioned media (from 1:4 to 1:32) 
containing different ratios of mature IGF1 and the IGF1 pro-forms, after which cellular 
proliferation and IGF1R, AKT and ERK1/2 phosphorylation were evaluated at the 
indicated time points. No significant differences in MCF7 cell proliferation were detected 
(supplementary Fig. S3a-b-c), but by increasing the amount of the gly-IGF1Ea pro-form 
in the cell culture medium, IGF1R phosphorylation was found to be markedly reduced 
(Fig. 5a), suggesting a minor binding affinity of gly-IGF1Ea for the IGF1R. While 
increasing the amount of gly-IGF1Ea also reduced AKT phosphorylation in MCF7 cells, 
no effect on ERK1/2 phosphorylation was observed (Fig. 5a). Decreased levels of IGF1R 
phosphorylation were also observed in MCF7 cells cultured with higher amounts of 
IGF1Ec and, partially, IGF1Eb, whereas no differences in AKT and ERK1/2 
phosphorylation were observed (Fig. 5b and 5c). 
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Fig. 5. Phosphorylation of 
IGF1R, AKT and ERK1/2 in 
MCF7 cells. Representative 
Western blot (n = 3) 
showing phospho-IGFR, 
phospho-AKT and phospho-
ERK1/2 levels in MCF7 
cells stimulated for the 
indicated times with 
HEK293 supernatants 
containing mature IGF1 and 
the (a) IGF1Ea, (b) IGF1Eb 
and (c) IGF1Ec pro-forms. 
IGF1R, AKT and ERK1/2 
were used as loading 
controls. Densitometry 
values for specific proteins 
relative to unstimulated cells 
(set as one-fold) are 
included below the lanes. 
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The activity of the IGF1 pro-forms compared to mature IGF1 was also evaluated in T47D 
and ZR751 breast cancer-derived cells (Fig. 6). In conformity with the results obtained 
with MCF7 cells, we found that the glycosylated IGF1Ea and IGF1Ec pro-forms were 
less potent in phosphorylating IGF1R in both the T47D (Fig. 6a) and ZR751 (Fig. 6b) 
cells. Additionally, we found that furin and its inhibitor CMK did not alter the 
phosphorylation status of IGF1R, AKT and ERK1/2 when induced by mature IGF1 
(supplementary Fig. S3d). 
 
  
Fig. 6. Phosphorylation of IGF1R, AKT and ERK1/2 in (a) T47D and (b) ZR751 cells. Representative 
Western blot (n = 3) showing phospho-IGF1R, phospho-AKT and phospho-ERK1/2 levels in cells 
stimulated for 60 minutes with HEK293 supernatants containing mature IGF1 and the IGF1Ea, IGF1Eb and 
IGF1Ec pro-forms. IGF1R, AKT and ERK1/2 were used as loading controls. Densitometry values for 
specific proteins relative to unstimulated cells (set as one-fold) are included below the lanes. 
 
 
4. Discussion 
The IGF1 pathway plays a well-documented role in the development and/or progression 
of breast carcinomas [2]. IGF1 mRNA splicing events generate different precursor IGF1 
polypeptides, namely the IGF1Ea, IGF1Eb and IGF1Ec pro-forms in humans, that share 
the mature peptide, but differ by the structure of their extension peptides, or E-peptides, 
in the C-terminus [5, 6]. The IGF1 pro-forms also undergo posttranslational 
modifications, such as glycosylation and proteolytic processing by proprotein convertases 
such as furin [6]. Convertase-mediated cleavage generally occurs intra-cellularly [25], but 
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it has also been reported that there are potential proprotein convertases that may process 
pro-IGF1 extra-cellularly, resulting in the secretion of unprocessed IGF1 pro-forms [10, 
13]. Our data confirm this latter notion by revealing that the IGF1 pro-forms are the 
predominant forms inside the transfected HEK293 cells, and that they are also abundantly 
secreted in the cell culture media. Our results also showed that the non-glycosylated 
IGF1Ea form was detectable in the cell lysates only, whereas only the glycosylated form 
was secreted. The Ea-peptide of human IGF1 is a unique E peptide that contains an N-
linked glycosylation site, and it has been hypothesized that its glycosylation may play a 
role in IGF1 biological activity modulation, such as bioavailability [26]. Interestingly, our 
data revealed that both IGF1Eb and IGF1Ec are subject to posttranslational 
modifications. These modifications still require detailed characterization. 
As reported by Durzyńska et al. [13], ELISA measurements are more sensitive to mature 
IGF1 than to the IGF1 pro-forms, suggesting that the presence of the E-peptide may 
impair the ability of the anti-IGF1 antibody to recognize the native protein. Our results 
support this hypothesis, showing that the anti-IGF1 antibody has a higher affinity for 
mature IGF1 compared to the IGF1 pro-forms, especially IGF1Eb and IGF1Ec. 
Moreover, according to the literature [13], the ELISA quantification appears to be 
impaired in supernatants with large amounts of pro-forms after CMK treatment during 
the transfections, even though our Western blotting results did not show a decrease in 
total IGF1. Thus, it is difficult to compare the bioactivities of the different pro-forms, as 
the E-peptide in pro-IGF1 hamper the ability to accurately measure and subsequently 
normalize the IGF1 content under non-denaturing conditions. 
Since it was unclear whether pro-IGF1 is bioactive or simply an inactive precursor or 
source for mature IGF1 [7], we cultured MCF7 and ZR751 cells in IGF1-neutralised 
conditioned media. As expected, the anti-IGF1 antibody was able to completely 
neutralise the activity of mature IGF1 in terms of the induction of cell proliferation and 
IGF1R phosphorylation. On the contrary, the anti-IGF1 antibody was found to be 
ineffective in inhibiting the proliferation and IGF1R phosphorylation in cells cultured in 
conditioned media containing the IGF1 pro-forms (Fig. 7). These results suggest that the 
IGF1 pro-forms are able to induce breast cancer cell proliferation. In vitro studies have 
suggested that the E-peptides of the human IGF1 precursors may act as independent 
growth factors, inducing mitosis independently from IGF1R [6]. In contrast, we found 
that by neutralising the IGF1R, the induction of cell proliferation by mature IGF1 or the 
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IGF1 pro-forms was completely inhibited, suggesting that IGF1 pro-forms induce cell 
proliferation via IGF1R activation (Fig. 7). 
Despite the vast amount of evidence regarding the biological activity of E peptides, little 
is known about the biological activities of the IGF1 pro-forms [6, 13, 21, 27]. Here, we 
evaluated the biological activities of the IGF1 pro-forms compared to those of mature 
IGF1. To this end, we generated a set of conditioned media containing different ratios of 
mature IGF1 and IGF2 pro-forms by using the proprotein convertase furin to induce pro-
form cleavage and to increase the mature IGF1 amounts and, on the other hand, by using 
the convertase inhibitor CMK during transfection to inhibit pro-form cleavage and to 
increase the IGF1 pro-form amounts. We found that after culturing MCF7, T47D and 
ZR751 cells with increasing amounts of the GF1 pro-forms, phosphorylation of the 
IGF1R markedly decreased. This result correlates with recent data showing that 
glycosylated pro-IGF1Ea is less efficient in receptor activation than pro-IGF1 and mature 
IGF1 [13]. Despite the finding that the pro-forms decreased the activation of the IGF1R, 
no significant differences were observed in cellular proliferation and ERK1/2 
phosphorylation compared to mature IGF1. Interestingly, AKT phosphorylation in MCF7 
cells seems to be affected by gly-IGF1Ea. It has previously been suggested that IGF1Ea 
may activate alternative IGF1R downstream pathways [6], as the canonical 
PI3K/AKT/mTOR signaling pathway was not induced in transgenic mice over-expressing 
IGF1Ea [28, 29]. The effect of gly-IGF1Ea on AKT phosphorylation in breast cancer 
cells requires, however, independent confirmation. 
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In conclusion, we found that IGF1 pro-forms can induce breast cancer cell proliferation 
via IGF1R phosphorylation. There are other data supporting a role of the IGF1 pro-forms 
in cancer, such as prostate [17], cervical [18] and colorectal cancer [19]. As yet, however, 
the biological activity of IGF1 variants in breast cancer development has not been 
established, and no analytical methods are available to correctly detect and quantify the 
IGF1 pro-forms. In fact, the available methods rely on the use of antibodies that primarily 
recognise the mature IGF1 peptide, thereby underestimating the pro-forms. The low 
specificity of anti-IGF1 antibodies to the pro-forms could also have implications for the 
design of breast cancer therapies, since current targeted strategies include anti-IGF1 
antibodies to neutralise the IGF system [31]. The low affinities of pro-IGF1s for IGF1R, 
together with the poor prognosis associated with high IGF1R expression, make the search 
Fig. 7. Schematic presentation of IGF1 pro-
form biological activity in breast cancer cells. 
(a) IGF1 induces IGF1R phosphorylation that 
is completely inhibited by neutralizing IGF1 
or IGF1R. (b) E peptide decreases IGF1R 
phosphorylation induced by IGF1. IGF1 
neutralisation is ineffective in inhibiting 
IGF1R phosphorylation that, on the other 
hand, is completely inhibited by IGF1R 
neutralization. 
97 
 
for regulatory mechanism(s) and potentially specific bioactivities of the various IGF1 
peptides an area of particular interest, and further studies will focus on the identification 
of the pro-IGF1s as candidate prognostic factors. 
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Supplementary data 
 
Supplementary Fig. S1. Relative expression of IGF1 in transfected HEK293 cells with CMK relative to 
control (no CMK). CMK did not significantly alters the IGF1 expression. 
 
 
 
Supplementary Fig. S2. MCF7 cells were grown with increasing concentration of mature IGF1, and after 
4 days of culture, cell proliferation was evaluated with both MTS assay and cell count (means ± SEM. 
n=3). Both methods given similar results. Insulin (INS, 10 µg/ml) was used as positive control. 
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Supplementary Fig. S3. Proliferative activity of mature IGF1 vs. IGF1 pro-forms: relative cell 
proliferation MCF7 cultured 4 day with HEK293 supernatants containing mature IGF1 and (A) IGF1Ea, 
(B) IGF1Eb and (C) IGF1Ec pro-forms (means ± SEM; n=3). HEK293 supernatants were two-fold diluted 
from 1:4 to 1:32. Black triangles indicate changes in mature IGF1 and IGF1 pro-forms amounts. Furin 
convertase inhibitor CMK and recombinant furin were used to change mature IGF1/IGF1 pro-form ratios. 
Cell proliferation was evaluated by MTS assay. Data are expressed as relative proliferation vs. unstimulated 
cells. ns: not significantly different; 2-way ANOVA. 
(D) Western blot analysis of phospho-IGF-R, phospho-AKT and phospho-ERK1/2 levels in MCF7 cells 
stimulated for 10 minutes with mature IGF1 with or without CMK and furin. IGF1R, AKT and ERK1/2 
were used as a loading controls. 
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Graphical Abstract 
 
 
 
 
 
Proposed mechanism of actions for disordered E-domain on pro-IGF-1Ea (A) and pro-
IGF-1Eb and pro-IGF-1Ec secretion (B). ER lumen in the upper panel, ER membrane in 
red and the cytosol in the lower panel. (A) The pro-IGF-1Ea nascent peptide is 
synthesized and released into the lumen of the ER. Here, the newly created polypeptide is 
subjected to glycosylation and hence secreted. N-linked glycosylation inhibitors 
determined the exit of unglycosylated pro-IGF-1Ea from the ER and its degradation by 
the cytosolic proteasome. (B) The pro-IGF-1Eb and pro-IGF-1Ec nascent peptides are 
synthesized and released into the ER. Then the occurrence of Eb- or Ec-domain regulates 
the subcellular localizations of pro-IGF-1Eb and pro-IGF-1Ec, promoting their partial 
nuclear accumulation.  
B A B 
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1. Introduction 
Insulin-like growth factor-1 (IGF-1) is a growth factor with multiple roles in various 
aspects of normal and pathological growth and differentiation [1-2]. The translation of the 
igf-1 gene gives rise to an immature IGF-1 peptide, which has a signal peptide at the 5‘ 
end of the gene, a core region and a C-terminal E-domain extension. The passage of the 
polypeptide into the endoplasmic reticulum (ER) removes the signal peptide while the 
nascent IGF-1 pro-hormone (pro-IGF-1) is emerging, retaining the E-domain. Conversion 
of pro-IGF-1 to mature peptide requires the endoproteolytic cleavage of the E-domain by 
proprotein convertases, such as furin, which processes proproteins at highly conserved, 
unique pentabasic motif [3].  
Due to alternative splicing of terminal exon 5 of the igf-1 gene, three distinct pro-IGF-1s 
might exist: pro-IGF-1Ea, pro-IGF-1Eb and pro-IGF-1Ec [3-4]. These pro-hormones 
have the same IGF-1 mature sequence of 70 amino acids (aa) but different E-domains. In 
particular, the human Ea-domain is composed of 35 aa; the first 16 aa of Ea-domain are 
common in all E-domains, while 19 aa are unique to this isoform. The human Ea-domain 
contains a potential N-glycosylation site, N92, which follows the consensus sequence 
motif for N-glycosylation, NX(S/T) (where X can be any amino acid except proline). 
Accordingly, two bands corresponding to unglycosylated pro-IGF-1Ea (11.7 kDa) and 
glycosylated pro-IGF-1Ea (~17-22 kDa) were found in normal and IGF-1-overexpressing 
cells [5-6]. The human Eb and Ec-domains contain the 16 common aa and 61 and 24 
additional isoform-specific aa respectively, with a predicted molecular weight of 16.5 
kDa for pro-IGF-1Eb and 12.5 kDa for pro-IGF-1Ec. The human Eb and Ec-domains lack 
potential N-linked glycosylation consensus sequences [3].  
Current evidence suggests that pro-IGF-1s are not a simple inactive precursor of mature 
IGF-1, but are stable intermediates of posttranslational processing. For example, normal, 
unstimulated mammalian tissues mainly produced the glycosylated pro-IGF-1Ea [5]. 
Moreover, in mouse skeletal muscle, viral delivery of IGF-1Ea or IGF-1Eb, but not 
mature IGF-1, increase muscle mass, suggesting that E-domains may be necessary to 
promote functional hypertrophy [7].  
Bioinformatic analysis of pro-IGF-1 structures showed that the E-domains are putative 
intrinsically disordered regions (IDRs) [4, 8]. Moreover, we recently demonstrated that 
the structure of pro-IGF-1s has been strongly conserved to maintain both the folded 
structure of mature IGF-1 and its intrinsically disordered E-domain tails [4]. IDRs are 
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regions within proteins that exhibit high flexibility and may lack a secondary or tertiary 
structure [9]. IDRs may facilitate the regulation of protein function through various 
mechanisms. For example, owing to their conformational flexibility, IDRs have a high 
propensity to undergo posttranslational modifications, such as acetylation, glycosylation, 
methylation, or phosphorylation [10]. IDRs might also control protein half-life by 
efficiently engaging proteins to the proteasome [11-12]. Moreover, studies have 
identified IDRs as enriched in the alternatively spliced protein segments, indicating that 
protein isoforms may display functional diversity due to the alteration of tissue-specific 
and species-specific modules within these regions [13].  
In this study, we analyzed the structural propriety of mature IGF-1 and pro-IGF-1Es, and 
we investigated the role of alternative E-domains on IGF-1 stability, localization and 
secretion. 
 
 
2. Materials and Methods 
 
2.1 Tissue sampling and cell cultures 
Tissue sampling and cell cultures were carried out by standard methods as previously 
described [4]. Briefly, human and animal tissues, about 30 mg, were immediately 
submerged in liquid nitrogen and stored at -80°C prior to protein extraction. The 
HEK293, K562, HeLa, LoVo and MCF7 cell lines were obtained from the American 
Type Culture Collection (ATCC, Rockville, MD, USA). The cells lines were cultured in 
DMEM (HEK293, MCF7, LoVo) or RPMI-1640 (K562 and HeLa) media supplemented 
with 10% fetal bovine serum, 2 mmol/L L-glutamine, 1x MEM Non-essential Amino 
Acid Solution, 0.1 mg/ml streptomycin and 0.1 U/L penicillin. Cells were maintained in a 
humidified incubator (5% CO2) at 37 °C. All cell culture materials were purchased from 
Sigma-Aldrich (St. Louis, MO, USA).  
 
2.2 Protein extraction and Western blotting analysis 
Tissues and cells were processed for Western blot analysis as previously reported [6]. 
Briefly, protein extracts were prepared by homogenizing with a Polytron homogenizer 
(KINEMATICA AG, Switzerland) in lysis buffer containing: 20 mmol/L HEPES (pH 
7.9), 25% v/v glycerol, 0.42 mol/L NaCl, 0.2 mmol/L EDTA, 1.5 mmol/L MgCl2, 0.5% 
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v/v Nonidet P-40, 1 mmol /L DTT, 1 mmol/L Naf, 1 mmol/L Na3VO4, and 1× complete 
protease inhibitor cocktail (Roche Diagnostics Ltd, Mannheim, Germany). The lysates 
were frozen and thawed twice and clarified by centrifugation at 12,000 rpm for 10 
minutes at 4°C. Total protein concentrations were determined using the Bradford 
colorimetric assay. Equal amount of total proteins were fractionated by SDS-PAGE on a 
15% polyacrylamide gel and then transferred on PVDF membranes (GE Healthcare). The 
membranes were incubated overnight at 4°C with the primary antibodies directed 
towards: IGF-1 (1:2,000; no. 500P11), purchased from Peprotech (Rocky Hill, New 
Jersey, USA), pro-IGF-1s (1:2000; no. PA5-19382) purchased from Invitrogen (Carlsbad, 
California, USA), β-tubulin (1:2000; no. 2146), Lamin A/C (1:2000; no. 4777), Calnexin 
(1:2000; no. 2679) phospho-IGF-1 Receptor β (1:2000; no. 3024), IGF-1 Receptor β 
(1:2000; no. 3027), phospho-p44/42 (ERK1/2) (1:2000; no. 9101), p44/42 (ERK1/2) 
(1:2000; no. 9102), phospho-Akt (Ser473) (1:2000; no. 9271) and Akt (1:2000; no. 9272) 
were purchased from Cell Signaling Technology (Beverly, MA, USA). Membranes were 
washed and incubated with appropriate secondary HRP-conjugated antibodies (Bio-Rad 
Laboratories Inc). Protein bands were visualized using Clarity Western ECL Substrate 
(Bio-Rad) and the immunoreactive bands were quantified using Fluor-S MAX System 
(Bio-Rad Laboratories Inc) equipped with Quantity One software. β-tubulin was used for 
normalization. 
 
2.3 Cell culture transfection assays  
Transient cell transfection was carried out with TransIT-X2® Transfection Reagent 
(Mirus Bio, Madison, WI, USA) with plasmid constructs containing sequences encoding 
pro-IGF-1s as previously described [6]. Each plasmid contained DNA encoding the class 
1 IGF-1 48-amino acid signal peptide, the mature 70-amino acid IGF-1 peptide, the first 
16 aa common in all E-domains, and C-terminal sequences encoding either the Ea (19 
aa), the Eb (61 aa) or the Ec (24 aa) domain. Where indicated, to inhibits N-
glycosylation, cells were growth in glucose-depleted medium or treated with 0.1 µg/ml of 
Tunicamycin (Tun) (Sigma-Aldrich, St. Louis, MO, USA) for 24h. The supernatants of 
HEK293-transfected cells growth in glucose depleted media or Tun were also used to 
treated the MCF7 cells for 1h in order to evaluate their effects on IGF-1R, AKT and 
ERK1/2 phosphorylation. Afterwards the MCF7 cells were washed with PBS and lysed 
for western blotting analysis. Were indicated, the protein synthesis inhibitor 
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cycloheximide (CHX) (Sigma-Aldrich) and the proteasome inhibitor MG132 (Sigma-
Aldrich) were added to HEK293 cells cultured with a final concentration of 25μg/ml and 
10μM respectively in a time-course experiment. The cells were then collected at indicated 
time points, lysed and prepared to western blotting analysis. Deglycosylation of pro-IGF-
1Ea was performed by incubation of pro-IGF-1Ea enriched media with 2500 U of 
PNGase F (NewEngland Biolabs) for 3 hours at 37°C, according to manufacturer‘s 
recommendations. Aliquot of pro-IGF-1Ea supernatant incubated with equal volume of 
PNGase assay reaction buffer without the enzyme PNGase F was used as control. 
 
2.4 Limited proteolysis 
Supernatants of IGF-1Ea-, IGF-1Eb- or IGF-1Ec-transfected HEK293 cells were 
concentrated using an Amicon Ultra 3K centrifugal filter unit (Merck Millipore, Billerica, 
MA, USA) and subjected to limited proteolysis. Enzymatic digestion was performed at 
37°C adding bovine trypsin (Sigma-Aldrich) and proteinase K (Sigma-Aldrich) to protein 
extract at a 1:100 enzyme/substrate ratio (wt/wt). Reactions were removed over a time-
course and the digested products were quenched with SDS sample buffer prior to SDS-
PAGE and analyzed by Western blotting. The quantification of bands intensity were 
normalized to the ―no trypsin‖ samples of each set.  
 
2.5 Subcellular localization analysis 
The cytosol, ER and nucleus isolations were performed as described in [14]. Briefly, cells 
were treated with permeabilization buffer for 5 minutes and were centrifuged at 3,000 g 
for 5 min to collect the cytosol fraction in the soluble fraction. The pellet was then 
washed, subjected to lysis buffer for 5 minutes and centrifuged again at 3,000 g for 5 min 
to collect the ER in the soluble fraction, whereas the pellet represent the nucleus fraction. 
Finally all the samples were clarified at 7,500 g for 10 minutes to remove cell debris and 
transferred to clean tubes for further analysis. 
The HEK-293 cells subjected to immunofluorescence were seeded in 4-well chamber 
slide at a density of 5x104 cells/well, incubated overnight and transfected for IGF-1 
isoforms expression as previously described. After overnight incubation, cells were fixed 
with 4% paraformaldehyde for 15 minutes, permeabilized with 0.2% TritonX-100, 
blocked with 5% of goat serum and incubated overnight at 4°C with the anti-mature IGF-
1 antibody (Prepotech). Next, cells were incubated 1 hour with an anti-rabbit-PE 
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conjugated antibody, stained with DAPI, mounted with Fluoreshield (Sigma) and 
photographed with a fluorescence microscope (ZEISS AxioVert A.1). 
 
2.6 Conservation of Ea-domain N-glycosylation site 
BLASTP was used to align protein sequence of human Ea-domain 
(EVHLKNASRGSAGNKNYRM) against the entire UniProt database using E-threshold 
of 0.01 [15]. The obtained UniProt hits (250 sequences with a minimal sequence identity 
of ∼60%) were aligned using MUSCLE [16] and WebLogo 
(http://weblogo.berkeley.edu/logo.cgi) was used to create relative frequency plots. 
 
2.7 Statistical analysis 
Data are represented as mean ± SEM af at least three independent experiments. Statistical 
analyses were performed using repeated measures ANOVA or one-way ANOVA as 
appropriate, followed by Bonferroni‘s multiple comparison post hoc tests. A p value 
<0.05 was considered statistically significant. 
 
 
3. Results 
 
3.1 Disorder propensity of Human IGF-1 isoforms 
We used the D
2
P
2
 platform (http://d2p2.pro/) and limited proteolysis to predict 
intrinsically disordered regions of human IGF-1Ea (ENSP00000416811), IGF-1Eb 
(ENSP00000302665) and IGF-1Ec (ENSP00000376638) isoforms [17]. Figure 1 shows 
the plot generated by the D
2
P
2
 platform. This analysis showed that the mature IGF-1 is 
mostly ordered while all the predictors predict the E-domains as disordered. The Eb-
domain also contains two predicted molecular recognition features (MoRFs) and two 
phosphorylation sites.  
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Figure 1. Evaluation of the intrinsic disorder propensity of human IGF-1 isoforms predicted using the D
2
P
2
 
platform (http://d2p2.pro/). The red box correspond to the insulin-like domain; the green-and-white bar in 
the middle of the plot shows the predicted disorder agreement between nine predictors, with green parts 
corresponding to portions of sequence where at least 75% of the predictors agreed. Yellow bars show the 
location of the predicted disorder-based binding sites (molecular recognition features, MoRFs), whereas red 
circles at the bottom of the plot show the location of putative phosphorylation sites.  
 
 
Subsequently, we used limited proteolysis to identify the regions of the polypeptide chain 
most prone to proteolysis and thus the sites of high flexibility or local unfolding [18]. The 
supernatant of HEK293 cells enriched of pro-IGF-1Ea, pro-IGF-1Eb, pro-IGF-1Ec and 
mature IGF-1 recombinant proteins were digested with trypsin, loaded on SDS-PAGE 
gels and probed with an anti-mature IGF-1 antibody. As shown in Figure 2, all pro-IGF-
1s were sensitive to trypsin digestion while mature IGF-1 was significantly more 
resistant. Same results were obtained by proteinase K digestion of pro-IGF-1Ea 
(Supplementary Figure 1). These data show that pro-IGF-1s are composed of both protein 
structural domains, i.e. the mature IGF-1, and intrinsically disordered regions, i.e. the C-
terminal E-domains. 
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Figure 2. Limited proteolysis of IGF-
1 isoforms following incubation with 
0.2 μM trypsin at 37°C for different 
times. The IGF-1 isoforms were 
partially digested with trypsin. 
Reactions were removed over a time-
course and the digested products were 
load on 12% SDS-PAGE and analysed 
by Western blotting with anti-IGF-1 
antibody. Repeated measures 
ANOVA, # significantly different 
compared to pro-IGF-1Ea, pro-IGF-
1Eb and pro-IGF-1Ec (p<0.05); * 
significantly different compared to 0 
minute time point (p<0.05). 
 
3.2 Intracellular IGF-1 are mainly expressed as pro-hormones, not mature IGF-1 
Using RT-PCR analyses, we previously demonstrated that skeletal muscle, adipose 
tissues and liver of several mammalian species mainly expressed the IGF-1Ea isoform, 
which represents about 90% of IGF-1 transcripts [4]. The first goal of the present study 
was to examine the protein forms endogenously produced in these tissues. 
Immunoblotting of protein lysates using the anti-mature IGF-1 antibody showed a 
distinct ~17 kDa band, most likely representing glycosylated pro-IGF-1Ea, in all samples 
analyzed (Figure 3A). Notably, the band corresponding to mature IGF-1 (~7kDa) was not 
found in naïve tissues, in agreement with [5].  
 
Figure 3. Immonoblotting of several mammalian tissues using an antibody directed against mature IGF-1 
sequence (A) or common region of E-peptides (B). (A) Protein lysates (80 μg) were subjected to 12% SDS-
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PAGE and immunoblotted with anti-mature IGF-1 antibody. A band at a molecular weight around 17 kDa, 
most likely representing glycosylated pro-IGF-1Ea, was detected in all the tissue samples tested. A cell 
lysate of HEK293T overexpressing IGF-1Ea was used has a positive control. The band corresponding to 
mature IGF-1 (~7kDa) was not found in tissues and is detectable in HEK293T overexpressing IGF-1Ea 
only after long exposure of the blots; (B) Immonoblotting of liver and muscle pig lysate using an antibody 
directed against E-domains (right). Two bands at a molecular weight around 12 kDa and 17 kDa were 
detected in all the tissue samples tested, most likely representing the unglycosilated and glycosylated pro-
IGF-1Ea respectively. No band at a molecular weight of Ea peptide (around 4 kDa ) was detected. A cell 
lysate of HEK293T overexpressing IGF-1Ea and synthetic human Ea peptide were used has a positive 
controls. 
 
 
To further confirm the presence of pro-IGF-1s, we used an antibody directed against the 
common E-domain region of pro-IGF-1s (RSVRAQRHTD). The antibody specificity 
towards E-domain region was checked using HEK293 cells overexpressing IGF-1 
isoforms (data not shown). As shown in Figure 3B, two bands of ~12kDa and ~17 kDa 
were detectable with the anti E-domain antibody, corresponding respectively to the 
molecular weight of unglycosylated and glycosylated pro-IGF-1Ea. As expected, no band 
corresponding to the molecular size of Ea-domain (~4kDa) was detected in the lysate of 
HEK293 cells overexpressing IGF-1Ea or tissues confirming that intracellularly, the E 
domain was not cleaved from the IGF-1 mature protein. Subsequently, we moved to a 
cell-based system to improve IGF-1 detection and to control the IGF-1 isoforms 
produced. We recently demonstrated that after over-expression of IGF-1 isoforms in 
HEK293 cells the pro-IGF-1s are the main forms produced intracellularly, and for pro-
IGF-1Ea both unglycosylated (~12kDa) and glycosylated (~17kDa) forms were detected 
[6]. Hence the IGF-1 expression pattern of different tissues analyzed was recapitulated in 
our HEK293 cell-based transient gene expression system. Notably, the results were not 
cell-type dependent, since the same results were obtained by transfection of others cell 
lines including HeLa, K562 and LoVo (Supplementary Figure 2). HEK293 cell-based 
system was used for the next experiments due to their relatively high transfection 
efficiency. We next examined the effects of E-domains on pro-IGF-1s stability and 
secretion, starting with the predominant isoform produced in normal tissues, i.e. the pro-
IGF-1Ea. 
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3.3 Glycosylation is necessary to stabilize pro-IGF-1Ea and regulate mature IGF-1 
secretion 
Multiple sequence alignment of vertebrate Ea domain showed that the N-glycosylation 
site of pro-IGF-1Ea had been conserved in mammals, birds, amphibians, and teleosts 
(Figure 4A).  
This strong evolutionary conservation suggested that glycosylation plays an important 
role in the regulation of pro-IGF-1Ea.  
Figure 4. WebLogo of Ea-domain sequences obtained from UniProt database. The relative frequency plots 
of amino acids of 250 E-domain sequences obtained from UniProt database is shown. The consensus 
sequence motif for N-glycosylation NX(S/T) (where X can be any amino acid except proline) is underline. 
The WebLogo was produced using the web server at http://weblogo.berkeley.edu/logo.cgi.  
 
 
Subsequently, we wondered whether glucose withdrawal or direct inhibition of N-
glycosylation by Tun might interfere with WT IGF-1Ea production. In this regard, we 
overexpressed pro-IGF-1Ea in HEK293 cells cultured in glucose-depleted medium or 
treated with Tun (Figure 5A). Notably, the band, corresponding to glycosylated pro-IGF-
1Ea, completely disappeared in the absence of glucose or after treatment with Tun. 
Moreover, the analysis of culture media of IGF-1Ea-transfected HEK293 cells showed 
that the inhibition of glycosylation by glucose deprivation or Tun completely abrogated 
the glycosylated pro-IGF-1Ea secretion and markedly reduced the mature IGF-1 secretion 
(Figure 5B). Accordingly, the phosphorylation of IGF-1 receptor, ERK1/2 and AKT was 
inhibited when MCF-7 breast cancer cells were treated with conditioned media from IGF-
1Ea-transfected HEK293 cells grown in glucose-depleted medium or treated with Tun 
(Figure 6). The marked reduction of pro-IGF-1Ea after glucose deprivation or Tun was 
not due to general suppression of transcription, as shown by IGF-1Ea mRNA 
quantification (Supplementary Figure 3A), or general protein synthesis inhibition, as 
shown by cotransfection of GFP (Supplementary Figure 3B). 
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Figure 5. N-glycosilation is required for proper pro-IGF-1Ea secretion. IGF-1Ea was transiently expressed 
in HEK293 cells in glucose depleted medium or in the presence of 0.1 µg/ml of tunicamycin (Tun). After 
24 h the cell lysates (A) and conditioned media (B) were analyzed by Western blot and relative expression 
level of glycosylatyed pro-IGF-1Ea, unglycosylated pro-IGF-1Ea and mature IGF-1 was calculated. The 
band at a molecular weight around 17 kDa, corresponding to glycosylated pro-IGF-1Ea, disappeared in 
absence of glucose or in presence of Tun in cell lysates (A) and in the secreted media (B). The band 
corresponding to mature IGF-1 (~7kDa) was markedly reduced in conditioned media after both treatments 
(B). Error bars represent the mean ± SEM; a one-way ANOVA was used to evaluate statistical significance 
(* p < 0.05). β-tubulin was used as a loading control for the cell lysates. 
 
 
Figure 6. Phosphorylation of IGF-1R, AKT and 
ERK1/2 after treatment of MCF7 cells with 
conditioned media from IGF-1Ea-transfected 
HEK293 cells grown in glucose-depleted medium 
or treated with Tunicamycin (Tun). The 
phosphorylation of the IGFR pathway was 
markedly reduced after glycosylation inhibitor 
treatments. Error bars represent the mean ± SEM; 
a one-way ANOVA was used to evaluate 
statistical significance (* p < 0.05).  
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We then tested whether the modulation of pro-IGF-1Ea production by glucose was dose-
dependent. Therefore, IGF-1Ea-transfected HEK293 cells were growth in medium with 
concentrations of glucose ranging from 0.65g/L (3.6mM) to 5g/L (27.8mM). As shown in 
figure 7 the expression level of pro-IGF-1Ea dose-dependently increased by glucose 
concentrations. 
Collectively, these results document that the interference with Ea-domain glycosylation 
resulted in a dramatic decrease of intracellular pro-IGF-1Ea level and hence pro-IGF-1Ea 
and mature IGF-1 secretion. 
 
Figure 7. Influence of glucose concentration on pro-IGF-
1Ea production. IGF-1Ea was transiently expressed in 
HEK293 cells grown in culture medium with different 
glucose concentration. After 24 h the cell lysates were 
analyzed by Western blot and relative expression level of 
glycosylatyed pro-IGF-1Ea was calculated. Error bars 
represent the mean ± SEM; a one-way ANOVA was used to 
evaluate statistical significance (* p < 0.05). β-tubulin was 
used as a loading control for the cell lysates.  
 
 
 
3.4 The turnover of unglycosylated pro-IGF-1Ea is faster than glycosylated pro-
IGF-1Ea and depends on proteasome activity 
Inhibition of pro-IGF-1Ea glycosylation by glucose starvation or Tun treatment, did not 
determine a concomitant increase of unglycosylated pro-IGF-1Ea (Figure 5A). One 
possibility is that the unglycosylated pro-IGF-1Ea was rapidly degraded. Thus, we next 
sought to examine the role of glycosylation in the stability of pro-IGF-1Ea. In the 
presence of protein synthesis inhibitor cycloheximide (CHX), the turnover rate for 
unglycosylated pro-IGF-1Ea was faster than glycosylated pro-IGF-1Ea (Figure 8A). To 
test the involvement of 26S proteasome machinery on unglycosylated pro-IGF-1Ea 
degradation, we subsequently treated IGF-1Ea-transfected HEK293T cells with 
proteasome inhibitor MG132. As shown in Figure 8B, we found an increase of 
unglycosylated pro-IGF-1Ea while glycosylated pro-IGF-1Ea was only marginally 
affected by the proteasome inhibitor. These results demonstrated that unglycosylated pro-
IGF-1Ea was unstable and degraded faster than glycosylated pro-IGF-1-Ea.  
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Figure 8. Analysis of pro-IGF-1Ea stability. IGF-1Ea was transiently expressed in HEK293 cells in the 
presence of 25μg/ml of protein synthesis inhibitor cycloheximide (CHX) (A) or 10μM of the proteasome 
inhibitor MG132 (B) in a time-course experiment. Cells were collected at different time points, and relative 
expression level of glycosylated and unglycosylated pro-IGF-1Ea was calculated. After MG132 treatment 
intracellular accumulation of a ~23kDa band was found (indicated with an asterisk in figure 8B), probably 
representing unglycosylated pro-IGF-1Ea dimer. Cytosol, endoplasmic reticulum (ER) and nucleus 
isolations of the conditioned media treatment with MG132 (C). Two bands at a molecular weight around 12 
kDa and 17 kDa, representing the unglycosylated and glycosylated pro-IGF-1Ea respectively, were 
detected in the cytosol fraction, whereas the band at a molecular weight around 23 kDa was detected only 
in the cytosolic fraction. Deglycosylation of pro-IGF-1Ea enriched media using the N-Glycosidase F 
(PNGase F) (D). The PNGase treatment determined an accumulation of two bands: the unglycosylated pro-
IGF-1Ea and the band at a molecular weight around 23 kDa probably corresponding to unglycosylated pro-
IGF-Ea dimer. Repeated measures ANOVA, # significantly different compared to glyc_pro-IGF-1Ea 
(p<0.05); * significantly different compared to 0 minute time point (p<0.05). β-tubulin was used as a 
loading control for the cell lysates and the cytosol separation; Calnexin was used as a control for the ER 
separation. 
 
 
Besides the increase of unglycosylated pro-IGF-1Ea, treatment with MG132 promoted a 
high accumulation of a band of approximately 23kDa (Figure 8B). We hypothesize that 
the 23kDa band corresponds to the dimer of unglycosylated pro-IGF-1Ea. In support of 
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this hypothesis we demonstrated that after MG132 treatment, the 23kDa band 
accumulated only in the cytoplasmic fraction and not in the ER fraction (Figure 8C). 
Moreover, enzymatic deglycosylation of the pro-IGF-1Ea enriched media determines the 
accumulation of both unglycosylated pro-IGF-1Ea and the putative 23kDa dimer (Figure 
8D). These results demonstrated that addition of N-glycan on N92 of Ea-domain prevent 
the degradation of pro-IGF-1Ea by the proteasome, probably overcoming the folding 
limitation of Ea-domain and its tendency to self-aggregate. 
 
3.5 The alternative Eb- and Ec-domains made the pro-IGF-Eb and pro-IGF-Ec 
isoforms insensitive to glucose starvation or Tun treatment and determined nuclear 
accumulation of pro-hormones  
The pro-IGF-1Eb and pro-IGF-1Ec ran at the expected molecular weight of 16.5 kDa and 
12.5 kDa in SDS-PAGE gels respectively, suggesting that these pro-hormones do not 
harbor any posttranslational modifications [6]. Accordingly, unlikely pro-IGF-1Ea, pro-
IGF-1Eb do not contains any potential glycosylation sites, and migrated at the same 
molecular weight in standard or glucose depleted media or after treatment of HEK239 
cells with Tun (Figure 9). Noteworthy, unlikely pro-IGF-1Ea, also the quantity of pro-
IGF-1Eb were unaffected by glucose deprivation or Tun treatment (Figure 9). Same 
results were obtained with the Ec-domain (data not shown). Hence, modulation of pro-
IGF-1s stability and secretion were differentially regulated by E-domain tail and the 
presence of the Eb or Ec-domain, instead of Ea-domain, completely abrogates the 
response of pro-IGF-1s to glycosylation status of the HEK293 cells. 
 
Figure 9. Effect of N-glycosylation inhibitors on IGF-1Eb 
production. IGF-1Eb was transiently expressed in HEK293 
cells in glucose-depleted medium or in the presence with 0.1 
µg /ml of Tunicamycin (Tun). After 24 h the cell lysates were 
analyzed by Western blot and relative expression level of IGF-
1Eb was calculated. The bands of the two pro-hormones were 
unaffected by either of the treatment and migrated at the same 
level. β-tubulin was used as a loading control for the cell 
lysates.  
 
Previous studies demonstrated that Eb- or Ec-
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domains contain nuclear localization signal [19]. Accordingly, we found that pro-IGF-
1Eb and pro-IGF-1Ec partially accumulated in the nucleus of HEK293-transfected cells 
(Figure 10). On the contrary, the pro-IGF-1Ea was mainly localized to the ER (Figure 
10). These data suggested that pro-IGF-1Eb and pro-IGF-1Ec were less efficiently 
secreted. In addition, we previously demonstrated that lower amount of pro-IGF-1Eb, 
pro-IGF-1Ec and mature IGF-1 was detected in cell culture media of HEK293 cells 
overexpressing IGF-1Eb or IGF-1Ec isoforms compared to IGF-1Ea-transfected HEK293 
cells [6]. These data showed that Eb- and Ec-domains control subcellular localization of 
pro-IGF-1s and hence the bioavailability of IGF-1. 
 
 
Figure 10. Subcellular localization of IGF-1 isoforms analyzed by cytosol, ER and nucleus isolations (A) 
or immunofluorescence (B). (A) pro-IGF-1Ea is present in the cytosol fraction (unglycosylated pro-IGF-
1Ea) and the ER fraction (unglycosilated and glycosylated pro-IGF-1Ea), IGF-1Eb and IGF-1Ec are present 
in the ER and nucleus fraction. β-tubulin was used as a control for the cytosol separation, Calnexin as a 
control for the ER separation and Lamin as a control for the nucleus separation. (B) Immunofluorescence 
staining of pro-IGF-1Ea, pro-IGF-1Eb and pro-IGF-1Ec in transfected HEK293 cells. DAPI nuclear 
staining (blue).  
 
 
4. Discussion 
It is now well established that most peptide hormones and growth factors are initially 
synthesized as pro-hormones that are converted to active forms by endoproteolysis at 
specific sites [20]. Accordingly, the growth factor IGF-1 is produced as pro-hormone 
which contains a C-terminal domain, i.e. the E-domain, cleaved by furin convertase [3].  
Evidence has been provided that only a small portion of pro-IGF-1 cleavage occurs 
intracellularly; hence most pro-IGF-1 might be converted to mature forms at the cell 
surface membrane or extracellularly [5-6]. The results of our study confirm these findings 
121 
 
showing that intracellular IGF-1 is mainly expressed as pro-IGF-1, not mature IGF-1, 
both in vitro and in vivo [Figure 3].  
The amino acid composition of mature IGF-1 markedly differs compared to E-domains 
[4, 21]. In particular, the E-domains are enriched in disorder-promoting amino acids, and 
by bioinformatic analysis, we demonstrated that the E-domains are IDRs, which was also 
confirmed by limited proteolysis [Figure 1 and 2]. Therefore, the pro-IGF-1s consist of 
two different parts: the mature IGF-1, with a well-organized structure, and the flexible C-
terminal E-domains. Notably, the disorder features of E-domains are conserved both 
across species and for all the three E-domains generated by alternative splicing [4].  
Many studies showed that the conformational plasticity associated with intrinsic disorder 
provides IDRs with a complementary functional repertoire of ordered domains [10], 
especially if these IDRs are at the protein termini [22]. Therefore, we next focused on the 
functional role of C-terminal Ea-, Eb- and Ec-domains.  
The Ea-domain contains a highly conserved N-glycosylation site (N92) [Figure 4], which 
is heavily glycosylated with sugar comprising over 30% of the total mass of the pro-IGF-
1Ea both in human and mouse [Figure 3] [5-6]. Here we demonstrated that abrogation of 
N-glycosylation by glucose starvation or Tun treatment blocked the production of 
glycosylated pro-IGF-1Ea [Figure 5A]. Unexpectedly, the unglycosylated pro-IGF-1 did 
not accumulate in glucose-depleted media or after treatment with Tun. Hence, the 
secretion of pro-IGF-1Ea and mature IGF-1 was also substantially affected by glucose 
starvation or Tun treatment [Figure 5B]. More interestingly, conditioned media from 
IGF-1Ea-transfected cells grown in glucose-depleted medium or treated with Tun were 
unable to activate the IGF-1 receptor pathway in human breast cancer cell line MCF7 
[Figure 6]. Noteworthy, the IGF-1Ea mRNA quantity and GFP expression were 
unaffected by N-linked glycosylation inhibitors, ruling out general inhibition of 
transcription or translation efficiencies [Supplementary Figure 3]. The effect of glucose 
on pro-IGF-1Ea production was dose-dependent, and maximum pro-IGF-Ea expression 
was observed in high glucose cultures (2.5 and 5 g/L) (Figure 7). 
Subsequently, we demonstrated that unglycosylated pro-IGF-1 has a rapid turnover 
compared with glycosylated pro-IGF-1 [Figure 8A]. The proteasome inhibitors MG132 
partially rescued the accumulation defect of unglycosylated pro-IGF-1Ea, but also 
markedly increased the production of a 23kDa band, probably representing 
unglycosylated pro-IGF-1Ea dimer [Figure 8B]. N-glycosylation is important for the 
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folding and trafficking of many glycoproteins [23]. Indeed glycosylation is a common 
mechanism to prevent the degradation of many secreted proteins [24]. Accordingly, our 
work indicates that addition of N-glycan on Ea-domain prevent the degradation of pro-
IGF-1Ea by the proteasome, probably overcoming the folding limitation of 
unglycosylated pro-IGF-1Ea and its entry into the ER-associated degradation (ERAD) 
pathway.  
In mammalian, in addition to Ea-domain, two alternative C-terminal tails can be 
produced by alternative splicing: the Eb- and Ec-domains [3-4]. The IGF-1Eb and IGF-
1Ec isoforms are not so wide expressed as IGF-1Ea, although their level increased under 
specific conditions/stimuli (e.g. cancer [25-26] or exercise [27]) and are also expressed in 
a species-specific manner [4] suggesting isoform-specific functions. Accordingly, in the 
present study, we demonstrated that the behavior of pro-IGF-1Eb and pro-IGF-1Ec 
entirely differed compared to pro-IGF-1Ea. In particular, since both Eb- and Ec-domains 
lacking N-glycosylation sites, the intracellular and secreted level of pro-IGF-1Eb and 
pro-IGF-1Ec were unaffected by glucose starvation or Tun treatment [Figure 9]. 
Moreover, the Eb- and Ec-domains determined the partial nuclear localization of pro-
IGF-1Eb and pro-IGF-1Ec [Figure 10]. Hence, the final location of pro-IGF-1Eb and pro-
IGF-1Ec represent a balance of the competition between secretory and nuclear 
localization signals of Eb- and Ec-domains. 
 
5. Conclusions 
Despite the fact that IGF-1 has been implicated as a potential therapy in many 
pathological processes, its biogenesis is yet to be elucidated. Our data suggested that 
alternative E-domains act as flexible tails controlling pro-IGF-1s and mature IGF-1 
bioavailability. In particular, we demonstrated that N-linked glycosylation regulates the 
stability and secretion of pro-IGF-1Ea, probably ensuring proper pro-hormone folding 
and favoring its passage through the secretory pathway.  
The alternative Eb-a nd Ec-domains lack N-terminal glycosylation sites hence pro-IGF-
1Eb and pro-IGF-1Ec isoforms were insensitive to glycosylation status of the cells. 
Moreover, the Eb- and Ec-domains regulate the subcellular localizations of pro-IGF-1Eb 
and pro-IGF-1Ec, promoting their nuclear accumulation. 
Thus, disordered E-domains play an important role in the structure, regulation and 
functioning of IGF-1.   
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Supplementary data 
 
 
Supplementary Figure 1. Limited proteolysis of pro-IGF-1Ea with proteinase K at 37°C for different 
times. pro-IGF-1Ea were partially digested with proteinase K for indicated times. The digested products 
were load on 12% SDS-PAGE and and analysed by Western blotting with anti-IGF-1 antibody. Repeated 
measures ANOVA, # significantly different compared to pro-IGF-1Ea (p<0.05); * significantly different 
compared to 0 minute time point (p<0.05). 
 
 
Supplementary Figure 2. Immunoblotting using the anti-mature IGF-1 antibody to HEK293T, Hela, K562 
and LoVo cells transfected with plasmid constructs containing sequences encoding for IGF-1Ea. A band at 
a molecular weight around 17 kDa, most likely representing glycosylated pro-IGF-1Ea, was detected in all 
mammalian cells transfected tested. Two bands at a molecular weight around 12 kDa and 17 kDa were 
detected in the HEK293T cell lysate, most likely representing the unglycosilated and glycosylated pro-IGF-
1Ea respectively. 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3. IGF-1Ea mRNA quantification (A) 
and GFP expression (B) in IGF-1Ea-transcted HEK293 cells 
grown in glucose depleted medium or in the presence of 0.1 
µg/ml of tunicamycin (Tun). The mRNA expression of IGF-
1Ea (A) and GFP expression (B) were unaffected treatments 
with glucose depleted media or Tun.  
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THE INSULIN-LIKE GROWTH FACTOR POOL IN 
BREAST CANCER AND THE EFFECT OF EXERCISE 
AND LIFESTYLE 
 
1. Introduction 
 
Insulin-like growth factors (IGFs) are strong mitogens involved in regulating cell 
proliferation in breast cancer (BC) and targeting IGF-1R was one of the most investigated 
areas in anticancer drug development [1]. The human igf-1 gene contains six exons that 
can be differentially spliced to create multiple transcript variants as deeply described in 
the first chapter. Exon 1 and exon 2 are mutually exclusive first exons and generate 
different signal peptides with local or circulating functions that have not yet been 
clarified [2]. At the 3’ end of the gene, alternative splicing gives rise to three mRNAs, 
each encoding a unique E-terminal peptide [3]. We have previously demonstrated that 
these IGF-1 isoforms induce BC cells proliferation via IGF-1R as also described in the 
second chapter [4], and we revealed that they are enriched in regulatory elements at the 
mRNA and protein level further hinting for their functional relevance (See Chapter 1, 
[5]). Numerous studies have focused mostly on circulating IGF-1 showing a cross-talk 
between IGF-1, circulating estrogen and ER stimulation, leading to increased IGF-1 
expression [6]. Nowadays, there are few data about the activation of IGF-1/IGF-1R 
signaling in tumor microenvironment [7, 8]. Moreover there are no data about the 
expression of IGF-1 isoforms in luminal BC and their association with clinical-
histopathological features and lifestyle habits of BC patients.  
Indeed, the host exposure to regular exercise significantly reduces the risk of 
development and recurrence of several cancers and might improve clinical outcomes 
following a diagnosis of a primary disease. However, the molecular mechanisms that 
establish the apparent anticancer effects of physical exercise on tissues that are distant 
from those directly implicated in the exercise response are poorly understood [8, 9]. 
Recently the remodeling of integrity and composition of the cancer microenvironment 
(TME) in response to specific signals derived from lifestyle factors such as exercise have 
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been described by Lee W. Jones and collaborator in an elegant review in Nature Reviews 
Cancer 17, 620–632 (2017) (Figure 1).  
 
 
Figure. 1. Exercise-dependent regulation of the tumor microenvironment. Prolonged exposure to 
physical inactivity is associated with elevated circulating concentrations of numerous growth factors and 
hormones—a pro‐tumorigenic milieu (blue boxes). By contrast, host exposure to acute bouts of exercise 
stimulates inter‐organ signaling achieved by the secretion of hormones, cytokines and growth factors into 
the host systemic milieu from various tissues and organs (for example, skeletal muscle, heart, bone, liver 
and adipose tissue), which can subsequently regulate multiple highly integrated homeostatic control circuits 
that operate at the cellular, tissue and whole‐organismal levels (purple boxes). Over time, chronic exercise‐
induced perturbation of inter‐organ signaling promotes physiological adaptation across homeostatic control 
circuits (establishment of a higher homeostatic ‗set point‘) that, in concert, stimulates the reprogramming of 
the systemic milieu, potentially characterized by alterations in the specific cell types and/or molecules 
(green boxes), potentially altering their availability and composition in ‗distant‘ tumor microenvironments 
(TMEs). Exercise‐induced alterations in the systemic milieu influence key regulatory mechanisms in the 
TME, such as angiogenesis, immune regulation and metabolism, thus having a cumulative antitumorigenic 
effect (ochre box). In addition to activating the secretion of numerous factors from skeletal muscle, during 
acute exercise, blood flow is redirected to the metabolically active skeletal muscle that paradoxically occurs 
in conjunction with increased tumor blood perfusion and reduced tumor hypoxia. As such, this represents 
an alternative mechanism of exercise regulation of the TME (red box). CRP, C‐reactive protein; IGF-1, 
insulin‐like growth factor 1; IL‐6, interleukin 6; MCT1, monocarboxylate transporter 1; NK cell, natural 
killer cell; TAM, tumor‐associated macrophage [8]. 
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A recent grant of Italian Ministry of Health (RF-2009-1532789) allowed us to study and 
evaluate the biological activity of IGF-1 isoforms in BC cells showing an induction of 
cell proliferation [4]. This study underlines the importance of an accurate assessment of 
the presence of IGF-1 pro-forms within the BC microenvironment in order to select a 
patient's course of treatment, since these pro-forms promote BC progression 
independently of the mature IGF-1. The paper highlights the plasticity of cancer cells and 
the need for a different long-term approach in the battle against BC. In this regard and in 
collaboration with Dr. Franco Berrino and Dr. Anna Villarini from the National Cancer 
Institute in Milan, it was possible to analyze modification in lifestyle, including dietary 
change-associated with moderate physical activity for the BC prevention [10]. 
In particular, in this study data obtained from the Italian DIANA-5 clinical trial 
(randomized trial of diet, physical activity and BC recurrences: the DIANA-5 study in 
progress since 2008, funded by AIRC and Health Department), to assess whether 
Mediterranean diet and moderate physical activity influence circulating levels of unbound 
IGF-1, were analyzed. The DIANA-5 study focus on the effectiveness of a diet based on 
Mediterranean and macrobiotic recipes and principles, associated with moderate physical 
activity, in reducing additional BC events (prevention of BC recurrence) in women with 
early-stage invasive BC. The patients involved in this project are aged between 35 and 70 
years diagnosed with BC over the past five years without BC recurrences or other 
cancers. The control group receives routine care for diet and physical activity based on 
international recommendations (WCRF/AICR 2007); scientists assisted the intervention 
group with regards to eating habits and to the acquisition of a more active lifestyle. The 
main aim of the study is to evaluate the impact of moderate intensity exercise 
intervention combined with a controlled diet on serum IGF-1 levels in the BC survivors 
of DIANA 5, as a response dependent on diet and/or dependent on physical activity and 
to assess whether the risk of BC recurrence may be related to specific IGF-1 isoform or 
the overall IGF-1s pool.  
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2. Materials and Methods 
 
2.1 DIANA-5 study design  
The overview of DIANA-5 study design is described in Villarini et al., 2012 [10]. 
Between 2008 and 2012, the study randomly assigned 1675 patients to an intensive diet 
and exercise intervention (841 patients) or to a control group (834 patients) to be 
followed-up after 5 years. General lifestyle recommendations for the prevention of cancer 
are given to both groups, and the intervention group is being offered a comprehensive 
lifestyle intervention, including cooking classes, conferences, common meals and 
exercise sessions. Adherence assessments occurred at baseline and at 12 months and are 
planned at 36 and 60 months. They include recall 24 h, anthropometric measures, body 
fat distribution assessed with impedance scale, one week registration of physical activity 
with a multisensor arm-band monitor, metabolic and endocrine blood parameters. 
Outcome BC events are assessed through self report at semi-annual meetings or 
telephone interview and are validated through medical record verification. At baseline 
and after 12 months, blood was drawn, separated in aliquots of red blood cells, buffy 
coat, plasma and serum, and stored at -80 °C. The collection of further blood samples is 
planned at 36 and 60 months.  
 
2.2 Intervention 
Before randomization into intervention or control group, all women received a leaflet 
illustrating the WCRF/AICR recommendations for cancer prevention (Table 1). After 
randomization, only the intervention group was offered a counselling program supported 
by cooking classes, physical activity sessions, conferences and print materials. The 
counselling program purposes to increase physical activity, control weight, promotes a 
healthy and low calorie diet.  
The physical activity aims were primarily based on achieving and maintaining regular 
participation in a moderate intensity physical activity (approximately 3 to 5 metabolic 
equivalents) program of 210 min/week (30 min on the average per day) over at least 3 
days/week, and decreasing sedentary behaviour by 30 min/day on at least 5 days/week. 
During the first 12 months, one group of exercise session per month is offered to improve 
program adoption. The focus is on maintaining moderate intensity activities, such as 
walking. In addiction women are encouraged to progress in more vigorous activity. 
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Participants have been provided with a pedometer for self-monitoring and compliance 
enhancement. 
The dietary goals were based on reducing glycaemic and insulinemic response through 
moderate caloric restriction, reduce consumption of high glycaemic index foods, reduce 
protein intake, particular animal protein, and preferring consumption of satiating foods. 
 
Table 1. WCRF/AICR 2007 recommendations  
1. Be as lean as possible within the normal range of body weight  
2. Be physically active as part of everyday life  
3. Limit consumption of energy-dense food & avoid sugary drinks  
4. Eat mostly food of plant origin, with a variety of non-starchy vegetables and fruit 
every day and unprocessed cereals and/or pulses within every meal  
5. Limit intake of red meat & avoid processed meat  
6. Limit alcoholic drinks  
7. Limit consumption of salt & avoid mouldy cereals or pulses  
8. Aim to meet nutritional needs through diet alone  
9. Mothers to breastfeed; children to be breastfed  
10. Cancer survivors: follow the recommendations for cancer prevention WCRF, World 
Cancer Research Fund; AICR, American Institute of Cancer Research.  
 
 
2.3 Level of Physical Activity 
In 563 DIANA-5 BC survivors was collected metabolic physical activity information 
using a metabolic holter (SenseWear® armband device). The SenseWear® armband was 
wear on the back of the upper arm for a full week to evaluate physical activity duration, 
total energy expenditure, active and resting energy expenditure in metabolic equivalents 
(METs), total number of steps, sleep duration and lying down. Data were analyzed 
through Software Cronolife. The patients of the intervention group were asked to 
maintain regular participation in a moderate intensity physical activity (approximately 3 
to 5 METs) program of 210 minutes/week (30 min on average per day) over at least 3 
days/week. The analyses were conducted with intervals of 12 months from the beginning 
of the intervention. To provide motivational feedbacks the patients will be provided with 
a pedometer to collect daily walking information. In addition, agreements with some 
public gyms, fitness centers, yoga or martial arts centers, and dance schools were draw 
up, to give the opportunity to the patients to attend (once a month) theoretical and 
practical lessons. Women wishing to take up vigorous sports were encouraged to do it. 
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During the study, to monitor the patients compliance, recall 24-hour of physical activity 
and nutrition were delivered to high risk women. For diary compilation the patients were 
contacted by telephone and requested to information regarding the previous day. Patients 
were follow-up for a longer period (5 years) to repeat the IGF-1 analysis. 
 
2.4 Radioimmunoassay (RIA) for IGF-1 
The radioimmunoassay was performed according to the protocol with the Insulin-like 
growth factor-1 reagent pack provided by Amersham (code IM 1721). The reaction 
mixture contained 100 µL of assay buffer, unlabeled IGF-1 (0.05–3.2 ng) or serum 
samples and 100 µL of diluted antibody 1:4000 with assay buffer. Samples were 
incubated for 30 min at room temperature and then 100 µL of 125I-IGF-1 was added and 
incubated for 48 h at 4° C. After the incubation 500 µL of second antibody reagent was 
added. The mixture was incubated for 10 min at room temperature and centrifuged at 
25,000 g for 10 min. The radioactivity of the sediment was determined. A standard 
competition curve was established using 0.05–3.2 ng of unlabeled IGF-1 per tube. The 
radioactivity of control samples was subtracted from the radioactivity of the test samples 
to correct for non-specific binding. 
 
2.5 Statistical Analysis 
Statistical analysis approach to estimate the likely effect of the proposed lifestyle 
intervention, data from epidemiological studies of prognosis and lifestyle were used and 
described in [10]. All variables are summarized with descriptive statistics: total count, 
mean, standard deviation, median, gamma and IQR for continuous variables, and 
cumulative frequency (count and percentage) for categorical variables. The continuous 
variables will be subjected to verification of normal or gaussian distribution and the 
comparative statistics pre-post exercise will be performed with Friedman test if the 
outcome measures won’t result normally distributed; on the other hand, the two-way 
repeated measures ANOVA test will be applied to measure the post-treatment outcome 
results variations. The categorical variables will be compared using the Chi-square test. 
Logistic regression equation will be used to search predictive factors of the slowing down 
of tumor cellular growth. Calculation of the statistical power has been performed 
according to the variation of IGF-1 measured after the lifestyle intervention and for this 
calculation we hypothesized that a comprehensive dietary intervention plus physical 
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activity will reduce BC recurrence rate by 33% or more, but we also considered a more 
conservative estimate of a 25% reduction.  
 
3. Results 
 
In order to determine whether nutrition and physical activity can affect circulating IGF-1 
levels, radioimmunoassay was used to quantify the circulating IGF-1 levels in the serum 
of 600 DIANA-5 BC survivors.  
In addition, the volunteers worn a metabolic holter for 6 consecutive days to monitor 
physical activity, assess energy expenditure, METs. METs and indicate of food 
consumption frequencies through a 24h recall. Compared to the 600 women, 563 were 
included in the statistical analysis since in 37 women the holter was not properly worn 
and physical activity data were incomplete. The anthropometric and clinical 
characteristics of the population in the study are given in Table 2. 
 
Variables  Mean ( SD) 
 
Age 52.16 ( 8.29) 
Waist circumference (cm) 86.62 ( 12.06) 
Weight (Kg) 68.86 ( 12.85) 
Height (m) 160. 56 ( 6.44) 
BMI (kg/m
2
) 26.83 ( 5.12) 
Diastolic pressure (mmHg) 82.34 (11.51) 
Systolic pressure (mmHg) 126.26 (18.27) 
Glycaemia (mg/dl) 95.44 (18.77) 
Total cholesterol (mg/dl) 209.16 (36.88) 
HDL cholesterol (mg/dl) 60.07 (15.36) 
LDL cholesterol (mg/dl) 126.33 (36.63) 
Triglycerides (mg/dl) 116.73 ( 85.08) 
IGF-1 (ng/ml) 161.77 ( 61.41) 
Education  
        Primary school 23.68% 
        High school 43.80% 
        University degree 32.52% 
Current smokers  
         YES 11.01% 
         NO 88.99% 
  
Table 2. Characteristics of DIANA-5 study population at baseline by this study group.  
 
 
In the study group, the median of circulating IGF-1 levels was 151.32 ng/ml. The average 
of circulating IGF-1 levels in those with an IGF-1<151.32 ng/ml results to be 117.38 
ng/ml, whereas those with IGF-1≥151.32 ng/ml are 206.01 ng/ml.  
The data show a statistically significant relationship between the circulation levels of 
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IGF-1 and the consumption of milk and dairy foods, total consumption of predominantly 
protein foods (meats, eggs, milk, dairy products, yogurt, cheeses, fish, shellfish, 
crustaceans, legumes, soy) as well as the consumption of predominantly protein animal 
foods, the consumption of protein animal foods without meats and the total consumption 
of sugars added to foods and beverages. The significance for protein foods is not 
confirmed when they are excluded from the pattern of milk consumption and dairy 
products.  
There is also a significant increase in the levels of IGF-1 in relation to the METs of 
physical activity and the daily minutes doing moderate physical activity, but there is no 
significant relation with for average walking steps in one day.  
Additionally, IGF-1 levels resulted influenced by BMI (with a growing trend up to the 
3rd quintile) and age (with a gradual and constant drop aging related). 
Table 3 presents data obtained by evaluating the all population through the t-test and the 
Wilcoxon test in relation to the frequency of consumed foods and physical activity 
expressed as average of METs, minutes of moderate daily physical activity and the 
average of daily steps.  
 
 IGF-1<151.32 ng/ml 
n.281 
IGF-1≥151.32 ng/ml 
n.282  
P 
(t-test) 
P 
(wilcoxon test) 
Milk and dairy 
products  
1.34 (±0.97) 1.56 (±1.05) 0.013 0.02 
Total protein foods 2.91 (±1.56) 3.26 (±1.8) 0.01 0.01 
Animal protein 2.66 (±1.48) 2.97 (±1.73) 0.02 0.04 
Animal protein foods 
without milk and dairy 
products 
1.56 (±1.09) 1.70 (±1.3) 0.15 0.21 
Vegetable protein  0.24 (±0.5) 0.29 (±0.5) 0.29 0.18 
Protein animal foods 
without meats 
1.85 (±1.21) 2.12 (±1.4) 0.016 0.02 
Total added sugar 
foods 
1.58 (±1.52) 1.82 (±1.51) 0.06 0.03 
Physical activity 
(METs)  
1.39 (± 0.23) 1.45 (± 0.21) 0.002 
 
Daily minutes doing 
moderate physical 
activity 
79.81 (± 46.03) 93.50 (± 53.10) 0.001 
 
Daily walking steps  
10342 (± 3555) 10815 (± 3326) 0.1 
 
Table 3. Frequency of consumed foods and physical activity in relation to IGF-1 levels. 
 
In Table 4 is notable that less active or sedentary subjects (METs<1.4) have IGF-1 levels 
significantly lower than more active subjects, excluded by the number of daily average 
steps. 
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Less active or sedentary 
subjects 
n.275 
Active subjects 
n.288 
P 
(t-test) 
± 10,000 steps 158.03 (± 56.04) 165.14 (± 65.79) 0.17 
Daily minutes doing moderate 
physical activity above and 
below the median (81.34) 
153.096 (± 56.62) 169.5 (± 65.01) 0.002 
METs above and below the 
median (1.4) 
154.04 (± 55.64) 169.15 (± 65.7) 0.003 
Table 4. IGF-1 levels in active and sedentary subjects. 
 
 
The relationship between IGF-1 levels of age and BMI was assessed and in agreement 
with Pasanisi et al. 2011 [11], it emerges that IGF-1 levels are affected by BMI, with a 
growing trend up to the 3rd quintile and by aging, with a gradual and constant drop in the 
age (Figure 2). 
 
  
Figure 2. Relationship between IGF-1 levels and BMI and age.  
 
 
In accord with these, the relationship between the circulation levels of IGF-1, age and 
BMI was evaluated. In women aged <52.1 years (Table 5), data show a statistically 
significant relationship with the consumption of predominantly protein foods (meats, 
salami, eggs, milk, dairy products, yoghurt, cheeses, fish, molluscs, crustaceans, legumes, 
soya) with the consumption of predominantly protein animals, and with the total 
consumption of sugars added to food and drink. In addition, a positive trend with the 
consumption of milk and dairy products was revealed. Significance for protein foods is 
not confirmed when they are excluded from the pattern of milk consumption and dairy 
products. There is, however, no significant increase in IGF-1 levels in relation to the 
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METs of physical activity, to the daily minutes of doing moderate physical activity and to 
the daily walking average. 
 
 
IGF-1<151.32 ng/ml 
n.115 
IGF-1≥151.32 ng/ml 
n.167 
P 
(t-test) 
P 
(wilcoxon test) 
Milk and dairy 
products 
1.33 (±0.92) 1.55 (±1.05) 0.08 0.14 
Total protein foods 2.88 (±1.57) 3.32 (±1.82) 0.04 0.05 
Animal protein 2.59 (±1.49) 3.00 (±1.85) 0.04 0.09 
Animal protein foods 
without milk and dairy 
products 
1.55 (±1.09) 1.77 (±1.3) 0.17 0.11 
Vegetable protein 0.29 (±0.59) 0.31 (±0.53) 0.74 0.5 
Protein animal foods 
without meats 
1.83 (±1.19) 2.09 (±1.5) 0.12 0.19 
Total added sugar 
foods 
0.92 (±0.94) 1.06 (±1.03) 0.04 0.04 
Physical activity 
(METs) 
1.43 (± 0.22) 1.47 (± 0.21) 0.13 
 
Daily minutes doing 
moderate physical 
activity 
87.5 (± 49.01) 94.2 (± 57) 0.3 
 
Daily walking steps 10759 (±3572) 10893 (± 3477) 0.75 
 
Table 5. Relationship between IGF-1 levels and nutrient consumption in women aged<52.1 years. 
 
 
Table 6 show the comparison with less active or sedentary subjects (METs <1.4) and the 
most active subjects, but no significant data emerge. 
 
 
Less active or sedentary 
subjects 
n.117 
Active subjects 
n.165 
P 
(t-test) 
± 10,000 steps 169.63 (± 58.33) 176.24 (± 68.3) 0.39 
Daily minutes doing moderate 
physical activity above and below 
the median (81.34) 
169.62 (± 59.41) 176.51 (± 67.59) 0.36 
METs above and below the 
median (1.4) 
170.15 (± 57.78) 175.67 (± 68.13) 0.47 
Table 6. IGF-1 levels in active and sedentary subjects in women aged<52.1 years. 
 
 
In women with age>=52.1 years (Table 7) the data show a statistically significant 
relationship only to the consumption of predominantly protein without meat and a 
positive trend with the consumption of milk and dairy products is confirmed. Significance 
for protein foods is not confirmed when they are excluded from the pattern of milk 
consumption and dairy products. There is also a significant increase in the levels of IGF-1 
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in relation to the METs of physical activity and the daily minutes of doing moderate 
physical activity, but there is no significant significance for daily walk averaged. 
 
 
IGF-1<151.32 ng/ml 
n.166 
IGF-1≥151.32 ng/ml 
n.115 
P 
(t-test) 
P 
(wilcoxon test) 
Milk and dairy 
products 
1.36 (±1.0) 1.57 (±0.98) 0.07 0.08 
Total protein foods 2.93 (±1.55) 3.19 (±1.63) 0.18 0.17 
Animal protein 2.72 (±1.47) 2.93 (±1.55) 0.23 0.22 
Animal protein foods 
without milk and dairy 
products 
1.57 (±1.02) 1.61 (±1.1) 0.73 0.89 
Vegetable protein 0.21 (±0.43) 0.25 (±0.45) 0.44 0.38 
Protein animal foods 
without meats 
1.86 (±1.23) 2.15 (±1.25) 0.05 0.04 
Total added sugar 
foods 
0.9 (±0.96) 1.13 (±0.96) 0.1 0.1 
Physical activity 
(METs) 
1.36 (± 0.24) 1.41 (± 0.2) 0.07 
 
Daily minutes doing 
moderate physical 
activity 
74.43 (± 43.12) 92.4 (± 47) 0.001 
 
Daily walking steps 10053 (±3524) 10702 (± 3150) 0.1 
 
Table 7. Relationship between IGF-1 levels and nutrient consumption in women age>=52.1 years. 
 
 
It is noted that less active or sedentary subjects (METs <1.4) have IGF-1 levels 
significantly lower in relation to daily minutes doing moderate physical activity and to 
the METs, whereas this is excluded by the number of daily steps average (Table 8). 
 
 
Less active or sedentary 
subjects 
n.158 
Active subjects 
n.123 
P 
(t-test) 
± 10,000 steps 148.27 (± 52.26) 152.08 (± 60.75) 0.57 
Daily minutes doing moderate 
physical activity above and below the 
median (81.34) 
140.86 (± 50.77) 161.18 (± 60.96) 0.002 
METs above and below the median 
(1.4) 
142.10 (± 50.98) 160.41 (± 61.49) 0.006 
Table 8. IGF-1 levels in active and sedentary subjects in women age>=52.1 years. 
 
 
In women with BMI<26.7 (Table 9), the data show a statistically significant relationship 
with the consumption of milk and dairy products, predominantly protein foods, with the 
consumption of predominantly protein animals, with the consumption of the total protein 
foods excluding the meat, and with the total consumption of sugars added to foods and 
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beverages. Significance for protein foods is not confirmed when they are excluded from 
the pattern of milk consumption and dairy products. There is, however, no significant 
increase in IGF-1 levels in relation to the METs of physical activity, to the daily minutes 
of doing moderate physical activity and to daily walking on average. 
 
 
IGF-1<151.32 ng/ml 
n.127 
IGF-1≥151.32 ng/ml 
n.179 
P 
(t-test) 
P 
(wilcoxon test) 
Milk and dairy 
products 
1.25 (±0.96) 1.56 (±0.77) 0.008 0.01 
Total protein foods 2.77 (±1.53) 3.3 (±1.78) 0.008 0.006 
Animal protein 2.51 (±1.48) 2.99 (±1.68) 0.01 0.01 
Animal protein foods 
without milk and dairy 
products 
1.51 (±1.11) 1.73 (±1.27) 0.13 0.11 
Vegetable protein 0.26 (±0.55) 0.3 (±0.53) 0.52 0.36 
Protein animal foods 
without meats 
1.86 (±1.24) 2.15 (±1.38) 0.06 0.05 
Total added sugar 
foods 
0.9 (±0.92) 1.17 (±1.03) 0.02 0.02 
Physical activity 
(METs) 
1.52 (± 0.21) 1.53 (± 0.18) 0.8 
 
Daily minutes doing 
moderate physical 
activity 
94.37 (± 52.07) 102.30 (± 55.02) 0.17 
 
Daily walking steps 11260 (±3614) 11276 (± 3362) 0.98 
 
Table 9. Relationship between IGF-1 levels and nutrient consumption in women with BMI<26.7. 
 
 
By comparing less active or sedentary subjects (METs <1.4) with the most active, no 
significant data emerged (Table 10). 
 
 
Less active or sedentary 
subjects 
n.83 
Active subjects 
n.223 
P 
(t-test) 
± 10,000 steps 175.50 (± 58.99) 175.88 (± 71.41) 0.96 
Daily minutes doing moderate 
physical activity above and below 
the median (81.34) 
169.81 (± 60.0) 179.51 (± 70.6) 0.21 
METs above and below the median 
(1.4) 
176.44 (± 65.25) 175.47 (± 67.44) 0.91 
Table 10. IGF-1 levels in active and sedentary subjects in women with BMI<26.7. 
 
 
In women with BMI>=26.7 (Table 11), the data show no statistically significant 
relationship the circulating IGF-1 levels, with dietary consumption and physical activity. 
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IGF-1<151.32 ng/ml 
n.154 
IGF-1≥151.32 ng/ml 
n.103 
P 
(t-test) 
P 
(wilcoxon test) 
Milk and dairy 
products 
1.42 (±0.96) 1.54 (±1.1) 0.35 0.48 
Total protein foods 3.02 (±1.57) 3.21 (±1.85) 0.3 0.57 
Animal protein 2.79 (±1.46) 2.95 (±1.82) 0.45 0.73 
Animal protein foods 
without milk and dairy 
products 
1.60 (±1.08) 1.66 (±1.34) 0.66 0.87 
Vegetable protein 0.22 (±0.46) 0.26 (±0.46) 0.55 0.43 
Protein animal foods 
without meats 
1.84 (±1.19) 2.06 (±1.43) 0.17 0.31 
Total added sugar 
foods 
0.91 (±0.98) 0.95 (±0.94) 0.77 0.63 
Physical activity 
(METs) 
1.28 (± 0.19) 1.30 (± 0.17) 0.32 
 
Daily minutes doing 
moderate physical 
activity 
67.81 (± 36.39) 77.36 (± 45.5) 0.06 
 
Daily walking steps 9579 (±3327) 10014 (± 3120) 0.29 
 
Table 11. Relationship between IGF-1 levels and nutrient consumption in women with BMI>=26.7. 
 
 
Even comparing less active or sedentary (METs <1.4) subjects with the most active no 
significant data emerges (Table 12). 
 
 
Less active or sedentary 
subjects 
n.192 
Active subjects 
n.65 
P 
(t-test) 
± 10,000 steps 143.98 (± 49.42) 146.72 (± 65.7) 0.6 
Daily minutes doing moderate 
physical activity above and below the 
median (81.34) 
142.32 (± 51.12) 149.96 (± 50.0) 0.23 
METs above and below the median 
(1.4) 
144.35 (± 47.96) 147.47 (± 54.45 0.6 
Table 12. IGF-1 levels in active and sedentary subjects in women with BMI>=26.7. 
 
 
4. Discussions 
 
The DIANA multicenter randomized controlled trials from 1 to 5 Diana Projects carried 
out in Milan analyzed if changes on lifestyle, such as a diet based on Mediterranean and 
macrobiotic principles associated with moderate physical activity, influence the incidence 
of BC. In particular, data deriving from healthy postmenopausal women (DIANA-1) [12, 
13] and from BC patients (DIANA-2) [14] showed that highly satiating and insulin-
lowering diet, based on traditional Mediterranean and macrobiotic recipes, significantly 
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decreases body weight, serum testosterone, and the bioavailability of both estrogens and 
IGF-1.  
It is well documented that hormonal and micro-environmental factors can influence 
growth and progression of cancer disease [15] and exercise might affect both of them. 
Numerous studies have investigated the relation between lifestyle factors and BC [16, 
17]. Sedentary lifestyle and alcohol intake have been documented to be associated with 
higher levels of estrogens and androgens [18, 19], insulin [20] and C-peptide [21]. 
Nutrition and in particular hyper-caloric diet, high protein intake, high glycemic index 
food and high-fat diet are major determinants of metabolic syndrome, insulin resistance 
and increased androgenic synthesis and activity. The relationship between a high-fat diet 
and BC has been attributed to overweight and body adiposity [22], which is associated 
with altered hormonal environment. On the contrary, moderate calorie restriction and 
high intake of satiating foods have been associated with low levels of circulating 
hormones, including thyroid, insulin, testosterone, and estrogen [23].  
Post-menopausal overweight is associated with increased concentrations of total and free 
androgens, estrogens, insulin levels and decreased SHBG which all promote cancer 
development [24]. The role of insulin in the BC development has been demonstrated. 
Insulin stimulates the synthesis of androgens in the ovary, the expression of growth 
hormone receptors, increase levels of bioavailable estrogen via aromatase activity in 
adipose tissue and through reductions in concentrations of sex hormone-binding globulin 
(SHBG), a protein that binds to estrogen to decrease sex hormones bioavailability [25]. In 
addition, insulin inhibits the liver production of and IGFBP-1 and 2, thus increasing the 
bioavailability of IGF-1 and stimulating the mitogenic and antiapoptotic actions of IGF-1 
in BC [26].  
The importance of IGF-1 axis in the development and progression of BC has been 
demonstrated [27]. The over-expression of IGF-1R in BC has been reported and its high 
expression has been related to poorer survival [28]. However, the direct relationship 
between circulating IGF-1 as a result of dietary intake and its effect on IGF-1 axis 
signaling and cancer progression is not well establish.  
The levels of circulating IGF-1 increasing by a diet rich in protein, in particular in milk 
protein [29]. It was postulated that high intake of satiating foods could reduce the risk of 
cancer development, in particular through phytonutrient, which may regulate cell growth 
and differentiation and induce apoptosis [30]. In addition, it was shown that moderate 
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calorie restriction could reduce cancer incidence in rodents due to its inhibitory effect on 
IGF-1 synthesis [31]. However, this was not revealed in humans because the caloric 
restriction was insufficient to decrease the IGF-1 concentration [32]. Thus the relation 
between diet intervention and BC risk in the modulation of circulating IGF-1 levels have 
yet to be conducted.  
Physical activity, including both aerobic and resistance exercise, may affect the 
prevention and the progression of BC [33] and has been also proposed to promote 
psychological well-being during and following cancer treatment [34, 35]. Numerous 
studies have demonstrated that exercise can improve insulin sensitivity, reduces 
circulating insulin and sex hormones levels [36]. In particular in a randomized controlled 
trial in postmenopausal women of 12-month diet and exercise interventions showed that 
sex hormones levels, in particular estradiol levels decreased significantly with a 
combined diet and exercise intervention [37].  
The role of physical exercise in the modulation of the IGF system at both cellular and 
systemic level, remains poorly understood. Numerous studies on BC lifestyle have 
investigated the relation between exercise and circulating IGF-1 levels, but with 
discordant results. Some studies have reported an increase or no difference or even a 
decrease in circulating IGF-1 levels associated with physical activity [38]. In particular 
the Yale Exercise and Survivorship trial showed significant reductions in IGF-1 and 
IGFBP-3 in postmenopausal women compared to non-active after a 6-month walking 
intervention [39]. Moreover, randomized trials in postmenopausal women based on 
chronic exercise intervention indicate that exercise confer similar effects in patients with 
primary BC [39, 40]. On the contrary, another study reported no significant changes in 
IGFBP-1 and IGFPB-3 after a 12-week intervention [41]. Although there is a lack of 
consensus in the literature on the effects of physical exercise in the modulation of 
circulating IGF-1 and BC development at both cellular and systemic levels, it is emerging 
the need of specification on exercise protocol management (for example acute vs chronic 
or aerobic vs resistance exercise), and also in terms of modalities, intensity, frequency 
and duration for a corrected determination of exercise dose–response.  
The physiological muscle adaptations to exercise induce tissue-relevant biological 
processes (including metabolic, angiogenic and immune responses). In these light, the 
acute exercise activates a diverse network of transcription factors, kinases and co-
regulatory proteins that culminate in gene expression changes that may induce local and 
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systemic catabolic or anabolic response depending on type of exercise and muscle 
recruited. In agreement, we demonstrated that a single isoinertial exercise session, which 
emphasize the eccentric overload, at the maximum strength induces muscle damage with 
an early muscular adaptation, showing a local decrease of all IGF-1 muscle transcript 
variants and a significant increase of circulating IGF-1 within the 24h post-exercise 
(Contarelli et al., In preparation). These results reveled different responses induced by 
acute exercise on cellular and circulating IGF-1. By contrast, chronic exercise, both 
aerobic and resistance, significantly increases glucose uptake in skeletal muscle via 
insulin-independent mechanisms, leading to decreased basal circulating levels of insulin, 
IGF-1 and glucose [42]. In this line, the physiological adaptations to exercise acute and 
chronic, lead early relevant biological processes in skeletal muscle tissue and induce 
systemic responses in the whole-body homeostasis, which might act on reprogramming 
‗distant‘ cancer tissue microenvironments.  
Exercise-induced effects are involved on the maintenance of whole organism metabolic 
control and might alter homeostatic control signals that regulate nutrient and growth 
factor uptake and availability at both tissue and cancer cell level, causing downstream 
effects on metabolism and bioenergetics. In a model of mammary carcinogenesis, 
physical activity caused a delay in carcinogenesis [43], with a concomitant reductions of 
insulin, IGF-1 and leptin levels in circulation [44]. These decreases at the systemic level 
concurrent with alterations in metabolic intracellular signaling, indicated by increased 
activation of AMPK and reductions of activated AKT and mTOR [43]. 
 
5. Conclusions 
The data show within DIANA-5 clinical trial a statistically significant relationship with 
the IGF-1 levels, the consumption of milk and dairy food-free diet, with total 
consumption of predominantly protein foods (meats, meats, eggs, milk, dairy products, 
yogurt, cheeses, fish, shellfish, crustaceans, legumes, soy) as well as with the 
consumption of predominantly protein animal foods, the consumption of protein animal 
foods without meats and the total consumption of sugars added to foods and beverages. 
The significance for protein foods is not confirmed, when they are excluded from the 
pattern of milk consumption and dairy products. There is also a significant increase in the 
levels of IGF-1 in relation to the METs of physical activity and the daily minutes doing 
143 
 
moderate physical activity, but there is no significant significance for daily average 
walking steps. The IGF-1 levels resulted influenced by BMI and age.  
We propose that the transient increases in exercise factors during exercise appear to be 
mediating the positive effect of regular exercise on BC survivors. Interesting, based on 
recent evidence, exercise might induce either pro-tumorigenic or anti-tumorigenic effects, 
depending on the context. However, when the known effects are considered in their 
global view, we assume that exercise infer an overall cancer-suppressive effect in the 
most of oncology scenarios. If appropriately prescribed and dosed, exercise might 
regulate the host-tumor microenvironment interaction preventing cancer recurrence and 
improving overall survival. 
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Breast Cancer (BC) is the most common type of cancer for women worldwide and is the 
second leading cause of cancer death in women. Numerous studies have linked high 
serum levels of IGF-1 and BC, although the mechanisms of action of this growth factor 
are not yet fully known.  
In contrast to the IGF-1 circulating level little is known about the local role of IGF-1. 
Growing evidence has shown that tissue production of IGF-1 is controlled by complex 
transcriptional and post-translational modifications. Indeed, distinct IGF-1 isoforms may 
arise via the use of different promoters, alternative splicing, proteolytic processing and 
glycosylation events. 
We demonstrated that igf-1 isoforms are differentially expressed across tissues and 
species and using an igf-1 minigene approach we showed that several cis-acting elements 
(e.g. 5‘ splice site strength and exonic splice enhancer) finely regulated the splicing 
pattern of igf-1. These results prompt us to get more insights into IGF-1 isoforms native 
regulation. 
We highlighted that the IGF-1 protein retaining C-terminal E-domains (i.e. IGF-1 pro-
hormones) are the predominant forms produced intracellularly, instead of mature IGF-1, 
and are subjected to extensive post-translational modifications, further hinting to their 
functional relevance. 
The characterization of IGF-1 pro-hormone structures showed that the E-domains contain 
disorder-promoting amino acids and that there is substantial evolutionary pressure to keep 
the different E-domains as intrinsically disordered regions (IDRs). We also demonstrated 
that the E-domains are regulatory elements for the modulation of IGF-1 isoforms 
stability, intracellular localization and efficient secretion. 
Moreover, the results of our experiments indicate that IGF-1 pro-hormones possess 
biological roles per se, i.e. independently from the mature IGF-1, and that pro-hormones 
can activate IGF-1 receptor signaling pathways and BC cell proliferation. This study 
underlines the importance of an accurate assessment of the IGF-1 pool to select a patient's 
course of treatment. 
The level of circulating IGF-1 can be influenced both by diet and physical activity. In this 
regard, preliminary results obtained from Italian DIANA-5 clinical trial, show a 
significant relationship between IGF-1 level and protein foods as well as the total 
consumption of sugars added to foods and beverages. There is also a significant increase 
in the levels of IGF-1 in relation to physical activity and the daily minutes doing 
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moderate physical activity. Further analyses are still ongoing to detect and characterize 
the IGF-1 isoforms in serum and tissues and identify association with BC recurrence, 
metastasis or second tumor.  
IGF-1 is a point of convergence for major signaling pathways involved in BC growth. 
This Thesis work highlights the importance of assessing the IGF-1 isoforms, i.e. splice 
variants, pro-hormones and mature IGF-1, and their association with IGF-1R signaling in 
BC. 
A better comprehension of the complexity of IGF-1 isoforms regulation and function, 
alongside their accurate detection, quantification and occurrence at a local and systemic 
level, will be useful for the National Health Service in developing strategies for primary 
and secondary prevention of BC.  
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